[
  {
    "spl_product_data_elements": [
      "Duke Cannon Supply Co. Daily Defense Face Mineral Sunscreen Broad Spectrum SPF 32 Zinc Oxide TETRASODIUM GLUTAMATE DIACETATE SODIUM BENZOATE GLYCERIN PEG-20 SORBITAN ISOSTEARATE CETOSTEARYL ALCOHOL ZINC OXIDE ZINC OXIDE .ALPHA.-TOCOPHEROL, DL- ASIAN GINSENG ALOE VERA LEAF BUTYLOCTYL SALICYLATE CAFFEINE ASCORBIC ACID CAPRYLIC/CAPRIC ACID WATER POLYSORBATE 60 POLYSORBATE 80 BISABOLOL OXIDE A ISOHEXADECANE GLUCONOLACTONE VINYLPYRROLIDONE/HEXADECENE COPOLYMER SUNFLOWER OIL XANTHAN GUM ETHYL FERULATE HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER (45000 MPA.S AT 1%) PHENOXYETHANOL OLIVE OIL POLYGLYCERYL-6 ESTERS SODIUM STEAROYL LACTYLATE TRIETHOXYCAPRYLYLSILANE"
    ],
    "active_ingredient": [
      "Actrive Ingredients Zinc Oxide 15.0%"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses \u2022 Helps prevent sunburn \u2022 if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"
    ],
    "warnings": [
      "Warnings For external use only"
    ],
    "do_not_use": [
      "Do not use \u2022 on damaged or broken skin"
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove"
    ],
    "stop_use": [
      "Stop use and ask a doctor \u2022 if rash occurs"
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "dosage_and_administration": [
      "Directions \u2022 Apply liberally 15 minutes before sun exposure \u2022 Reapply: \u2022 after 80 minutes of swimming or sweating \u2022 immediately after towel drying \u2022 at least every 2 hours Children under 6 months of age: Ask a doctor \u2022 Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: \u2022 limit time in the sun, especially from 10 a.m. \u2013 2 p.m. \u2022 wear long-sleeved shirts, pants, hats and sunglasses"
    ],
    "storage_and_handling": [
      "Other information \u2022 Protect the product in this container from excessive heat and direct sun May stain or damage some fabrics, materials or surfaces"
    ],
    "inactive_ingredient": [
      "Inactrive Ingredients aloe barbadensis leaf juice, ascorbic acid, bisabolol, butyloctyl salicylate, caffeine, caprylic/capric triglyceride, cetearyl alcohol, dimethicone, ethyl ferulate, farnesol, fragrance, gluconolactone, glycerin, glyceryl stearate, helianthus annuus (sunflower) seed oil, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, isohexadecane, olive oil polyglyceryl-6 esters, panax ginsing root extract, phenoxyethanol, polysorbate 60, polysorbate 80, sodium benzoate, sodium stearoyl lactylate, sorbitan isostearate, tetrasodium glutamate diacetate, tocopherol, triethoxycaprylylsilane, VP/hexadecene copolymer, water, xanthan gum"
    ],
    "package_label_principal_display_panel": [
      "Label Duke Cannon Face Lotion SPF 32 Duke Cannon Face Lotion SPF 32"
    ],
    "set_id": "0c47278b-2ec2-81ab-e063-6294a90ac937",
    "id": "43f71ea6-cd8c-f744-e063-6294a90a5a45",
    "effective_time": "20251119",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "Duke Cannon Supply Co. Daily Defense Face Mineral Sunscreen Broad Spectrum SPF 32"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "DUKE CANNON SUPPLY CO."
      ],
      "product_ndc": [
        "71782-201"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "43f71ea6-cd8c-f744-e063-6294a90a5a45"
      ],
      "spl_set_id": [
        "0c47278b-2ec2-81ab-e063-6294a90ac937"
      ],
      "package_ndc": [
        "71782-201-03"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "1912 Herb Co Vital Air Herb Honeysuckle, Bellflower, Ginseng LONICERA CAPRIFOLIUM FLOWER LONICERA CAPRIFOLIUM FLOWER PLATYCODON GRANDIFLORUS WHOLE PLATYCODON GRANDIFLORUS WHOLE MINT PANAX GINSENG ROOT OIL PANAX GINSENG ROOT OIL"
    ],
    "active_ingredient": [
      "Honeysuckle(20%), Bellflower(15%) Ginseng(5%)"
    ],
    "inactive_ingredient": [
      "Burdock(5%), Mint(5%), Lilyturf(5%), Goji Berry(5%), Heartleaf(5%), Schisandra Berry(5%), Ginger(5%), Green Tea(5%), Prickly ash(5%), Dried Tangerine Peel(5%), Perilla Leaf(5%), Barley Flour(5%)"
    ],
    "purpose": [
      "relief of allergic rhinitis, improvement of bronchial function, cough relief"
    ],
    "keep_out_of_reach_of_children": [
      "keep out of reach of the children"
    ],
    "indications_and_usage": [
      "Take 1 pouch (3g) three time a day after a meal"
    ],
    "warnings": [
      "If you have an unusual or allergic constitution, check the ingredients before consuming."
    ],
    "dosage_and_administration": [
      "for oral use only"
    ],
    "package_label_principal_display_panel": [
      "label"
    ],
    "set_id": "0e0370a8-3ecf-1afc-e063-6394a90a9c0a",
    "id": "0e0348ea-d272-59fd-e063-6294a90a0030",
    "effective_time": "20240102",
    "version": "1",
    "openfda": {
      "brand_name": [
        "1912 Herb Co Vital Air Herb"
      ],
      "generic_name": [
        "HONEYSUCKLE, BELLFLOWER, GINSENG"
      ],
      "manufacturer_name": [
        "Agricultural Corporation YUBIMUHUAN CO Ltd"
      ],
      "product_ndc": [
        "83933-0001"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "LONICERA CAPRIFOLIUM FLOWER",
        "PANAX GINSENG ROOT OIL",
        "PLATYCODON GRANDIFLORUS WHOLE"
      ],
      "spl_id": [
        "0e0348ea-d272-59fd-e063-6294a90a0030"
      ],
      "spl_set_id": [
        "0e0370a8-3ecf-1afc-e063-6394a90a9c0a"
      ],
      "package_ndc": [
        "83933-0001-1"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "5N1WD9784U",
        "P9T4K47OM0",
        "WC73QE9274"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "1912 Herb Co Easy Stomach Herb Malt, Hawthorn HAWTHORN LEAF WITH FLOWER HAWTHORN LEAF WITH FLOWER PAEONIA LACTIFLORA ROOT"
    ],
    "active_ingredient": [
      "Malt(20%), Hawthorn(20%)"
    ],
    "inactive_ingredient": [
      "Peony Root(10%), Citrus Peel(10%), Agastache(10%), Gardenia Fruit(5%), Turmeric(5%), Ginger(5%), Jujube(5%), Cabbage(5%), Fructooligosaccharides(5%)"
    ],
    "purpose": [
      "digestive enhancement, relief of stomach pain, improvement of digestive function"
    ],
    "keep_out_of_reach_of_children": [
      "keep out of reach of the children"
    ],
    "indications_and_usage": [
      "Take 1 pouch (3g) three time a day after a meal"
    ],
    "warnings": [
      "If you have an unusual or allergic constitution, check the ingredients before consuming."
    ],
    "dosage_and_administration": [
      "for oral use only"
    ],
    "package_label_principal_display_panel": [
      "label"
    ],
    "set_id": "0e043a48-d128-3d89-e063-6294a90a3c6c",
    "id": "0e03da21-01e9-954d-e063-6294a90a0ce4",
    "effective_time": "20240102",
    "version": "1",
    "openfda": {
      "brand_name": [
        "1912 Herb Co Easy Stomach Herb"
      ],
      "generic_name": [
        "MALT, HAWTHORN"
      ],
      "manufacturer_name": [
        "Agricultural Corporation YUBIMUHUAN CO Ltd"
      ],
      "product_ndc": [
        "83933-0002"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "HAWTHORN LEAF WITH FLOWER"
      ],
      "spl_id": [
        "0e03da21-01e9-954d-e063-6294a90a0ce4"
      ],
      "spl_set_id": [
        "0e043a48-d128-3d89-e063-6294a90a3c6c"
      ],
      "package_ndc": [
        "83933-0002-1"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "6OM09RPY36"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "REPAIRWEAR LASER FOCUS SPF 15 LINE SMOOTHING CO/O Octinoxate, Titanium Dioxide DISODIUM NICOTINAMIDE ADENINE DINUCLEOTIDE CAPRYLYL GLYCOL BUTYL ACRYLATE/METHYL METHACRYLATE/METHACRYLIC ACID COPOLYMER (18000 MW) METHICONE (20 CST) HEXYLENE GLYCOL POTASSIUM SORBATE LINOLEIC ACID CAFFEINE DIPALMITOYL HYDROXYPROLINE HYALURONATE SODIUM DOCOSANOL EDETATE DISODIUM ANHYDROUS HYDROXYPROLINE GLYCINE HIGH DENSITY POLYETHYLENE TANGERINE PEEL SACCHAROMYCES LYSATE POLYGONUM CUSPIDATUM ROOT BUTYLENE GLYCOL GLYCERIN PADINA PAVONICA CREATINE PEG-100 STEARATE GLYCERYL MONOSTEARATE ADENOSINE PHOSPHATE COLEUS BARBATUS ROOT PHYTOSPHINGOSINE CETYL ETHYLHEXANOATE HYDROGENATED SOYBEAN LECITHIN PORPHYRIDIUM PURPUREUM WHEAT BRAN BETULA PUBESCENS BARK BLACK OLIVE SIGESBECKIA ORIENTALIS FLOWERING TOP ACETYL HEXAPEPTIDE-8 CHOLESTEROL ETHYLHEXYL STEARATE ETHYLHEXYL PALMITATE DECARBOXY CARNOSINE HYDROCHLORIDE PROLINE POTASSIUM HYDROXIDE POTASSIUM SULFATE CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE SILICON DIOXIDE ROBUSTA COFFEE BEAN ASTROCARYUM MURUMURU SEED BUTTER OCTYLDODECYL NEOPENTANOATE PENTYLENE GLYCOL OCTINOXATE OCTINOXATE TITANIUM DIOXIDE TITANIUM DIOXIDE WATER PROPYLENE GLYCOL DICAPRATE TREHALOSE AMINOPROPYL ASCORBYL PHOSPHATE ALUMINUM HYDROXIDE PHENOXYETHANOL SOYBEAN SORBITOL CETYL ALCOHOL XANTHAN GUM"
    ],
    "active_ingredient": [
      "Active Ingredients Octinoxate 7.5% Titanium Dioxide 1.5%"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Use helps prevent sunburn"
    ],
    "warnings": [
      "Warnings Do not use on damaged or broken skin When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin"
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor if rash occurs"
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions For sunscreen use: apply liberally 15 minutes before sun exposure reapply at least every two hours use a water resistant sunscreen if swimming or sweating Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.\u20132 p.m. wear long-sleeved shirts, pants, hats and sunglasses children under 6 months of age: ask a doctor"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients water\\aqua\\eau,cetyl ethylhexanoate,butylene glycol,octyldodecyl neopentanoate,peg-100 stearate,glyceryl stearate,glycerin,hydrogenated lecithin,polyethylene,pentylene glycol,silica,citrus reticulata (tangerine) peel extract,saccharomyces lysate extract,polygonum cuspidatum root extract,algae extract,triticum vulgare (wheat) bran extract,coffea robusta seed extract,astrocaryum murumuru seed butter,padina pavonica thallus extract,betula alba (birch) bark extract,creatine,adenosine phosphate,laurdimonium hydroxypropyl hydrolyzed soy protein,linoleic acid,hydrolyzed rice extract,hydroxyproline,olea europaea (olive) fruit extract,sigesbeckia orientalis (st. paul's wort) extract,coleus barbatus extract,acetyl hexapeptide-8,sodium dna,caffeine,cholesterol,ethylhexyl stearate,sorbitol,ethylhexyl palmitate,decarboxy carnosine hcl,phytosphingosine,propylene glycol dicaprate,disodium nadh,caprylyl glycol,acrylates copolymer,trehalose,sodium rna,cetyl alcohol,dipalmitoyl hydroxyproline,proline,aminopropyl ascorbyl phosphate,behenyl alcohol,methicone,hexylene glycol,xanthan gum,sodium hyaluronate,potassium hydroxide,potassium sulfate,glycine,potassium sorbate,aluminum hydroxide,lecithin,carbomer,disodium edta,phenoxyethanol <iln41741>"
    ],
    "storage_and_handling": [
      "Other information protect the product in this container from excessive heat and direct sun"
    ],
    "package_label_principal_display_panel": [
      "CLINIQUE repairwear laser focus line smoothing cream braod spectrum SPF 15 COMBINATION OILY TO OILY POIDS NET WT. 1.7 OZ/50 ml e Principal Display Panel"
    ],
    "set_id": "10f7ec01-541b-a15a-e063-6294a90aa9df",
    "id": "10f7ec01-541c-a15a-e063-6294a90aa9df",
    "effective_time": "20240209",
    "version": "1",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "REPAIRWEAR LASER FOCUS SPF 15 LINE SMOOTHING CO/O"
      ],
      "generic_name": [
        "OCTINOXATE, TITANIUM DIOXIDE"
      ],
      "manufacturer_name": [
        "CLINIQUE LABORATORIES LLC"
      ],
      "product_ndc": [
        "49527-118"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "OCTINOXATE",
        "TITANIUM DIOXIDE"
      ],
      "spl_id": [
        "10f7ec01-541c-a15a-e063-6294a90aa9df"
      ],
      "spl_set_id": [
        "10f7ec01-541b-a15a-e063-6294a90aa9df"
      ],
      "package_ndc": [
        "49527-118-01"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "4Y5P7MUD51",
        "15FIX9V2JP"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "co-HYPERT Sodium Tetrachloroaurate, Barium Carbonate, Anamirta cocculus seed, Iberis amara Seed, Magnesium chloride, Ferula Sumbul Root, Melilotus officinalis Top, and Viscum album Fruiting Top SODIUM TETRACHLOROAURATE TETRACHLOROAURATE ION BARIUM CARBONATE BARIUM CATION ANAMIRTA COCCULUS SEED ANAMIRTA COCCULUS SEED IBERIS AMARA SEED IBERIS AMARA SEED MAGNESIUM CHLORIDE MAGNESIUM CATION CHLORIDE ION FERULA SUMBUL ROOT FERULA SUMBUL ROOT MELILOTUS OFFICINALIS TOP MELILOTUS OFFICINALIS TOP VISCUM ALBUM FRUITING TOP VISCUM ALBUM FRUITING TOP WATER ALCOHOL"
    ],
    "active_ingredient": [
      "Ingredients: Anamirta cocculus (Cocculus) 4X Natrium tetrachloroauratum (Aurum chloratum natronatum) 6X Barium carbonicum 8X Iberis amara 4X Magnesium chloratum 6X Ferula moschata (Sumbulus moschatus) 6X Meliotus officinalis 3X Viscum album 3X Selected ingredients prepared by spagyric processes."
    ],
    "active_ingredient_table": [
      "<table width=\"65%\"><col width=\"60%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"right\" valign=\"bottom\"/><thead><tr><th>Ingredients:</th><th/></tr></thead><tbody><tr><td>Anamirta cocculus (Cocculus)</td><td>4X</td></tr><tr><td>Natrium tetrachloroauratum  (Aurum chloratum natronatum)</td><td>6X</td></tr><tr><td>Barium carbonicum</td><td>8X</td></tr><tr><td>Iberis amara</td><td>4X</td></tr><tr><td>Magnesium chloratum</td><td>6X</td></tr><tr><td>Ferula moschata (Sumbulus moschatus)</td><td>6X</td></tr><tr><td>Meliotus officinalis</td><td>3X</td></tr><tr><td>Viscum album</td><td>3X</td></tr></tbody></table>"
    ],
    "inactive_ingredient": [
      "Contains 17% alcohol by volume."
    ],
    "indications_and_usage": [
      "Indications For relief of occasional nervous tension. Application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. With severe forms of this disease, a clinically proven therapy is indicated."
    ],
    "purpose": [
      "For relief of occasional nervous tension. Application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. With severe forms of this disease, a clinically proven therapy is indicated."
    ],
    "dosage_and_administration": [
      "Dosage Unless otherwise prescribed, adults take 15-20 drops, 3 times per day. For pediatric dosages, consult your practitioner."
    ],
    "warnings": [
      "Warning If symptoms persist, contact a licensed practitioner. If you have known sensitivity to any of the ingredients, please consult your licensed practitioner before use. If you are pregnant or nursing a baby, seek the advice of a health care professional before use. Keep out of the reach of children."
    ],
    "ask_doctor": [
      "If symptoms persist, contact a licensed practitioner. If you have known sensitivity to any of the ingredients, please consult your licensed practitioner before use. If you are pregnant or nursing a baby, seek the advice of a health care professional before use."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of the reach of children."
    ],
    "storage_and_handling": [
      "Protect from light and heat."
    ],
    "spl_unclassified_section": [
      "Tamper Evident Do not use this product if tamper evident strip is broken or removed from base of cap.",
      "Distributed by: BioResource Inc. Cotati, CA 94931 Manufactured by: PEKANA \u00ae GmbH D-88353 Kisslegg"
    ],
    "questions": [
      "To report adverse events, contact BioResource at 321B Blodgett Street, Cotati, CA 94931"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - 50 ml Bottle Box co-HYPERT\u2122 Oral Drops Homeopathic Medicine For relief of occasional nervous tension 1.7 FL OZ (50 ml) PEKANA \u00ae PRINCIPAL DISPLAY PANEL - 50 ml Bottle Box"
    ],
    "set_id": "19ba62c0-2c49-47c4-9406-0e637df04b75",
    "id": "a68d96c9-c25c-48db-b807-9628b9721117",
    "effective_time": "20230111",
    "version": "2",
    "openfda": {
      "brand_name": [
        "co-HYPERT"
      ],
      "generic_name": [
        "SODIUM TETRACHLOROAURATE, BARIUM CARBONATE, ANAMIRTA COCCULUS SEED, IBERIS AMARA SEED, MAGNESIUM CHLORIDE, FERULA SUMBUL ROOT, MELILOTUS OFFICINALIS TOP, AND VISCUM ALBUM FRUITING TOP"
      ],
      "manufacturer_name": [
        "PEKANA Naturheilmittel Gmbh"
      ],
      "product_ndc": [
        "59469-304"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ANAMIRTA COCCULUS SEED",
        "BARIUM CARBONATE",
        "FERULA SUMBUL ROOT",
        "IBERIS AMARA SEED",
        "MAGNESIUM CHLORIDE",
        "MELILOTUS OFFICINALIS TOP",
        "SODIUM TETRACHLOROAURATE",
        "VISCUM ALBUM FRUITING TOP"
      ],
      "spl_id": [
        "a68d96c9-c25c-48db-b807-9628b9721117"
      ],
      "spl_set_id": [
        "19ba62c0-2c49-47c4-9406-0e637df04b75"
      ],
      "package_ndc": [
        "59469-304-10"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "810258W28U",
        "6P669D8HQ8",
        "GLA4808EHQ",
        "T90A7M66YF",
        "02F3473H9O",
        "GM6P02J2DX",
        "7FT6QUT299",
        "BK9092J5MP"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "DALLAS JAMES SKINCARE CO. SPF 50 Sunscreen DALLAS JAMES SKINCARE CO. SPF 50 Sunscreen CENTELLA ASIATICA TRITERPENOIDS COCONUT OIL POLYGLYCERYL-4 ISOSTEARATE LEMON CETYL DIMETHICONE 25 TOCOPHEROL HYALURONATE SODIUM POTASSIUM SORBATE WATER ALOE VERA LEAF MEDIUM-CHAIN TRIGLYCERIDES SORBITAN MONOSTEARATE HEXYL LAURATE ZINC OXIDE ZINC OXIDE CERAMIDE NS JOJOBA OIL WATERMELON NIACINAMIDE"
    ],
    "active_ingredient": [
      "Zinc Oxide 24%"
    ],
    "purpose": [
      "sunscreen"
    ],
    "indications_and_usage": [
      "Uses uses helps prevent sunburn. if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun."
    ],
    "warnings": [
      "Warnings \u2460 For external use only. \u2461 When using this product keep out of eyes."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions apply liberally 15 minutes before sun exposure & reapply: \u25a0after 40 minutes of swimming or sweating \u25a0immediately after towel drying \u25a0at least every 2 hours"
    ],
    "storage_and_handling": [
      "Other information sun protection measures: spending time in the sun increases your risk of skin cancer and early skin aging. to decrease this risk, regularly use a sunscreen with a broad spectrum spf value of 15 or higher and other sun protection measures including: \u25a0 limit time in the sun, especially from 10 a.m.-2 p.m. \u25a0 wear long-sleeve shirts, pants, hats, and sunglasses. \u25a0children under 6 n mornths: ask a doctor."
    ],
    "inactive_ingredient": [
      "Inactive Ingredients aqua, aloe barbadensis leaf juice, caprylic/ capric triglycerides, sorbitan stearate, polyglyceryl-4 isostearate, hexyl laurate, cetyl dimethicone, helianthus annuus (sunflower) seed oil, simmondsia chinensis (jojoba) seed oil, citrullus lanatus (watermelon) fruit extract, rubus chamaemorus (cloudberry) fruit extract, niacinamide, centella asiatica extract, ceramide NP, tocopherol (vitamin e), citrus limon (lemon) fruit extract, sodium hyaluronate, watermelon essential oil, potassium sorbate."
    ],
    "recent_major_changes": [
      ""
    ],
    "package_label_principal_display_panel": [
      "label label"
    ],
    "set_id": "225faeec-4f96-e082-e063-6394a90a9a31",
    "id": "479ede96-3c89-57cd-e063-6394a90afcb3",
    "effective_time": "20260105",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "DALLAS JAMES SKINCARE CO. SPF 50 Sunscreen"
      ],
      "generic_name": [
        "DALLAS JAMES SKINCARE CO. SPF 50 SUNSCREEN"
      ],
      "manufacturer_name": [
        "Guangzhou Fantesy Biotechnology Co.,Ltd"
      ],
      "product_ndc": [
        "83447-010"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "479ede96-3c89-57cd-e063-6394a90afcb3"
      ],
      "spl_set_id": [
        "225faeec-4f96-e082-e063-6394a90a9a31"
      ],
      "package_ndc": [
        "83447-010-01"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Noorish Foot Co. Anti-Fungal Pen Anti-Fungal Pen ALPHA-TOCOPHEROL WATER SALICYLIC ACID GLYCERIN LACTIC ACID SORBITOL CHITIN UREA RETINOL PROPYLENE GLYCOL EDETATE DISODIUM ACETALDEHYDE CALCIUM PCA BIOTIN UNDECYLENIC ACID UNDECYLENIC ACID KERATIN, TYPE I CYTOSKELETAL 18"
    ],
    "active_ingredient": [
      "Active Ingredient(s) Undecylenic Acid 10%........ Anti-Fungal"
    ],
    "purpose": [
      "Purpose Anti-Fungal"
    ],
    "indications_and_usage": [
      "Use Cures most athlete's foot (dermatophytosis). Relieves itching, scaling and"
    ],
    "warnings": [
      "Warnings For external use only Do not use on \u2022 children under 2 years \u2022 for diaper rash When using this product \u2022 Avoid contact with the eyes Stop use and consult a doctor if \u2022 irritation occurs \u2022 if there is no improvement within 4 weeks"
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions \u2022 Wash the affected area and dry thoroughly. \u2022 Apply a thin layer of the product over the affected area twice daily (morning and night) or as directed by a doctor. \u2022 Supervise children in the use of this product. \u2022 For athlete's foot: Pay special attention to spaces between the toes; wear well-fitting, ventilated shoes, and change shoes and socks at least once daily \u2022 For athlete's foot and ringworm, use daily for 4 weeks. If the condition persists longer, consult a doctor."
    ],
    "storage_and_handling": [
      "Other information Store at room temperature 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F)."
    ],
    "inactive_ingredient": [
      "Inactive ingredients Biotin, Deacetylated Chitin, Disodium EDTA, Ethanol, Glycerol, Keratin, Lactic Acid, PCA Calcium, Propylene Glycol, Retinol, Salicylic Acid, Sorbitol, Urea, Vitamin E, Water."
    ],
    "package_label_principal_display_panel": [
      "Package Label - Principal Display Panel 5 mL: NDC: 84841-111-11 5-mL Pen"
    ],
    "set_id": "24ffeb92-2c9f-ac96-e063-6394a90a7416",
    "id": "43d691b2-8a5d-aacf-e063-6294a90a5ddb",
    "effective_time": "20251117",
    "version": "2",
    "openfda": {
      "application_number": [
        "M005"
      ],
      "brand_name": [
        "Noorish Foot Co. Anti-Fungal Pen"
      ],
      "generic_name": [
        "ANTI-FUNGAL PEN"
      ],
      "manufacturer_name": [
        "Noorish Foot Co. LLC"
      ],
      "product_ndc": [
        "84841-111"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "UNDECYLENIC ACID"
      ],
      "spl_id": [
        "43d691b2-8a5d-aacf-e063-6294a90a5ddb"
      ],
      "spl_set_id": [
        "24ffeb92-2c9f-ac96-e063-6394a90a7416"
      ],
      "package_ndc": [
        "84841-111-11"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0198715311969"
      ],
      "unii": [
        "K3D86KJ24N"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Noorish Foot Co. Anti-Fungal Pen Anti-Fungal Pen WATER SALICYLIC ACID GLYCERIN LACTIC ACID SORBITOL CHITIN UREA RETINOL PROPYLENE GLYCOL EDETATE DISODIUM ACETALDEHYDE CALCIUM PCA BIOTIN UNDECYLENIC ACID UNDECYLENIC ACID KERATIN, TYPE I CYTOSKELETAL 18 ALPHA-TOCOPHEROL"
    ],
    "active_ingredient": [
      "Active Ingredient(s) Undecylenic Acid 10%........ Anti-Fungal"
    ],
    "purpose": [
      "Purpose Anti-Fungal"
    ],
    "indications_and_usage": [
      "Use Cures most athlete's foot (dermatophytosis). Relieves itching, scaling and"
    ],
    "warnings": [
      "Warnings For external use only Do not use on \u2022 children under 2 years \u2022 for diaper rash When using this product \u2022 Avoid contact with the eyes Stop use and consult a doctor if \u2022 irritation occurs \u2022 if there is no improvement within 4 weeks"
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions \u2022 Wash the affected area and dry thoroughly. \u2022 Apply a thin layer of the product over the affected area twice daily (morning and night) or as directed by a doctor. \u2022 Supervise children in the use of this product. \u2022 For athlete's foot: Pay special attention to spaces between the toes; wear well-fitting, ventilated shoes, and change shoes and socks at least once daily \u2022 For athlete's foot and ringworm, use daily for 4 weeks. If the condition persists longer, consult a doctor."
    ],
    "storage_and_handling": [
      "Other information Store at room temperature 15\u00b0-30\u00b0C (59\u00b0-86\u00b0F)."
    ],
    "inactive_ingredient": [
      "Inactive ingredients Biotin, Deacetylated Chitin, Disodium EDTA, Ethanol, Glycerol, Keratin, Lactic Acid, PCA Calcium, Propylene Glycol, Retinol, Salicylic Acid, Sorbitol, Urea, Vitamin E, Water."
    ],
    "package_label_principal_display_panel": [
      "Package Label - Principal Display Panel 5 mL: NDC:84896-111-11 5-mL Pen"
    ],
    "set_id": "26404b5b-ea61-efa0-e063-6394a90a8b99",
    "id": "43d692a9-154e-0389-e063-6394a90a8eb4",
    "effective_time": "20251117",
    "version": "2",
    "openfda": {
      "application_number": [
        "M005"
      ],
      "brand_name": [
        "Noorish Foot Co. Anti-Fungal Pen"
      ],
      "generic_name": [
        "ANTI-FUNGAL PEN"
      ],
      "manufacturer_name": [
        "Guangzhou Mizi Biotechnology Co., Ltd."
      ],
      "product_ndc": [
        "84896-111"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "UNDECYLENIC ACID"
      ],
      "spl_id": [
        "43d692a9-154e-0389-e063-6394a90a8eb4"
      ],
      "spl_set_id": [
        "26404b5b-ea61-efa0-e063-6394a90a8b99"
      ],
      "package_ndc": [
        "84896-111-11"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0198715311969"
      ],
      "unii": [
        "K3D86KJ24N"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "1912Herb Co Heart Well Herb Agrimony, Gogi Berry, Angelica gigas root , Licorice , Lilyturf AGRIMONIA EUPATORIA AGRIMONIA EUPATORIA PAEONIA LACTIFLORA ROOT"
    ],
    "active_ingredient": [
      "Agrimony 20%, Gogi Berry 8%, Angelica gigas root 8%, Licorice 8%, Lilyturf 8%"
    ],
    "inactive_ingredient": [
      "Poria Cocos 8%, Cnidium 8%, Turmeric 8%, Paeoniae Radix Alba 8%, Jujube 8%, Ginger 8%"
    ],
    "purpose": [
      "digestive enhancement, relief of stomach pain, improvement of digestive function"
    ],
    "keep_out_of_reach_of_children": [
      "keep out of reach of the children"
    ],
    "indications_and_usage": [
      "Take 1 pouch (3g) three time a day after a meal"
    ],
    "warnings": [
      "If you have an unusual or allergic constitution, check the ingredients before consuming."
    ],
    "dosage_and_administration": [
      "for oral use only"
    ],
    "package_label_principal_display_panel": [
      "label"
    ],
    "set_id": "268c5fe9-b0e6-bd80-e063-6394a90a6521",
    "id": "268c5e7a-31cd-c250-e063-6394a90ad3b5",
    "effective_time": "20241110",
    "version": "1",
    "openfda": {
      "brand_name": [
        "1912Herb Co Heart Well Herb"
      ],
      "generic_name": [
        "AGRIMONY, GOGI BERRY, ANGELICA GIGAS ROOT , LICORICE , LILYTURF"
      ],
      "manufacturer_name": [
        "Agricultural Corporation YUBIMUHUAN CO Ltd"
      ],
      "product_ndc": [
        "83933-0003"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "AGRIMONIA EUPATORIA"
      ],
      "spl_id": [
        "268c5e7a-31cd-c250-e063-6394a90ad3b5"
      ],
      "spl_set_id": [
        "268c5fe9-b0e6-bd80-e063-6394a90a6521"
      ],
      "package_ndc": [
        "83933-0003-1"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "EBU0U94820"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "1912Herb Co Herbal Sugar Guard Yam, Margose, Taraxacum herb, Agastache TARAXACUM PALUSTRE ROOT TARAXACUM PALUSTRE ROOT PAEONIA LACTIFLORA ROOT"
    ],
    "active_ingredient": [
      "Yam 15%, Margose 15%, Taraxacum herb 10%, Agastache 10%"
    ],
    "inactive_ingredient": [
      "Hawthorn 15%, Poria Cocos 10%, Citrus Pee )10%, Weed 5%, Licorice 5%, Ginger 5%"
    ],
    "purpose": [
      "digestive enhancement, relief of stomach pain, improvement of digestive function"
    ],
    "keep_out_of_reach_of_children": [
      "keep out of reach of the children"
    ],
    "indications_and_usage": [
      "Take 1 pouch (3g) three time a day after a meal"
    ],
    "warnings": [
      "If you have an unusual or allergic constitution, check the ingredients before consuming."
    ],
    "dosage_and_administration": [
      "for oral use only"
    ],
    "package_label_principal_display_panel": [
      "label"
    ],
    "set_id": "268efcae-b53d-bac7-e063-6394a90ac6bc",
    "id": "268f0aca-5201-aff9-e063-6394a90a1b2b",
    "effective_time": "20241110",
    "version": "1",
    "openfda": {
      "brand_name": [
        "1912Herb Co Herbal Sugar Guard"
      ],
      "generic_name": [
        "YAM, MARGOSE, TARAXACUM HERB, AGASTACHE"
      ],
      "manufacturer_name": [
        "Agricultural Corporation YUBIMUHUAN CO Ltd"
      ],
      "product_ndc": [
        "83933-0004"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "TARAXACUM PALUSTRE ROOT"
      ],
      "spl_id": [
        "268f0aca-5201-aff9-e063-6394a90a1b2b"
      ],
      "spl_set_id": [
        "268efcae-b53d-bac7-e063-6394a90ac6bc"
      ],
      "package_ndc": [
        "83933-0004-1"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "GCZ4W7077C"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Dimples Bath Co - Sunstick New Kid On The Block Zinc Oxide BISABOLOL TOCOPHEROL COCOS NUCIFERA (COCONUT) OIL OLEA EUROPAEA (OLIVE) FRUIT OIL EUPHORBIA CERIFERA (CANDELILLA) WAX HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL COPERNICIA CERIFERA (CARNAUBA) WAX THEOBROMA CACAO (COCOA) SEED BUTTER ORYZANOL BUTYROSPERMUM PARKII (SHEA) BUTTER BUTYLOCTYL SALICYLATE SQUALENE ZINC OXIDE ZINC OXIDE BETA-SITOSTEROL"
    ],
    "active_ingredient": [
      "Zinc Oxide 20.6%"
    ],
    "purpose": [
      "Sunscreen"
    ],
    "indications_and_usage": [
      "Uses Helps prevent sunburn. If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun."
    ],
    "warnings": [
      "For external use only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs"
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center immediately"
    ],
    "dosage_and_administration": [
      "Directions \u2022 Apply liberally 15 minutes before sun exposure \u2022 Reapply after 80 minutes of swimming or sweating \u2022 Immediately after towel drying at least every 2 hours \u2022 Sun Protection Measures Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protecting measures including \u2022 Limit time in the sun, especially from 1Oam - 2pm Wear long-sleeved shirts, pants, hats, and sunglasses \u2022 Children under 6 months Ask a doctor"
    ],
    "inactive_ingredient": [
      "Bisabolol, Butyloctyl Salicylate, Butyrospermum Parkii (Shea) Butter, Cocos Nucifera (Coconut) OiI, Copernicia Cerifera (Carnauba) Wax, Euphorbia Cerifera (Candelilla) Wax, Helianthus Annuus (Sunflower) Seed Oil, Olea Europaea (Olive) Fruit Oil, Oryzanol, Theobroma Cacao (Cocoa) Seed Butter, Tocopherol"
    ],
    "other_safety_information": [
      "Protect this product from excessive hear and direct sun"
    ],
    "questions": [
      "Come say hi at helloblissbaby.com"
    ],
    "package_label_principal_display_panel": [
      "Dimples Bath Co Mineral Stick Stick Carton"
    ],
    "set_id": "26f682f4-2440-f111-e063-6294a90ab4b7",
    "id": "2b0c7812-f14b-ca0e-e063-6294a90acfb2",
    "effective_time": "20250106",
    "version": "3",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "Dimples Bath Co - Sunstick New Kid On The Block"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "Dimples Bath Co. LLC"
      ],
      "product_ndc": [
        "84568-550"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "2b0c7812-f14b-ca0e-e063-6294a90acfb2"
      ],
      "spl_set_id": [
        "26f682f4-2440-f111-e063-6294a90ab4b7"
      ],
      "package_ndc": [
        "84568-550-58",
        "84568-550-01"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tattoo Numbing Cream Co LIDOCAINE HYDROCHLORIDE ARNICA MONTANA FLOWER C13-14 ISOPARAFFIN DIMETHYL SULFONE EMU OIL DIETHYLENE GLYCOL MONOETHYL ETHER ETHYLHEXYLGLYCERIN GLUCOSAMINE SULFATE ISOPROPYL PALMITATE LAURETH-7 TEA TREE OIL PHENOXYETHANOL POLYACRYLAMIDE (10000 MW) PROPYLENE GLYCOL CHONDROITIN SULFATE (PORCINE; 5500 MW) STEARIC ACID TROLAMINE WATER LIDOCAINE HYDROCHLORIDE LIDOCAINE LIDOCAINE HYDROCHLORIDE"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other information Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active ingredient Lidocaine HCL 4.0% w/w"
    ],
    "purpose": [
      "Purpose External Analgesic"
    ],
    "indications_and_usage": [
      "Uses For temporary relief of pain and itching."
    ],
    "warnings": [
      "Warnings For external use only . Do not use on wounds or damaged skin, in large quantities, or if you are allergic to any ingredients of this product. When using this product use only as directed. Avoid contact with the eyes, rashes, or mucous membranes. Stop use and ask doctor if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days. Keep out of reach of children and pets If swallowed get medical help or contact a Poison Control Center right away."
    ],
    "keep_out_of_reach_of_children": [
      ""
    ],
    "dosage_and_administration": [
      "Directions Adults and children 12 years of age and over: Clean and dry affected area, apply to affected area not more than 3 to 4 times daily. Children 12 years of age or younger : ask a doctor."
    ],
    "inactive_ingredient": [
      "Inactive ingredients Aqua (Deionized Water), Arnica Montana Flower Extract, C13-14 Isoparaffin, Chondroitin Sulfate, Emu Oil, Ethoxydiglycol, Ethylhexylglycerin, Glucosamine Sulfate, Isopropyl Palmitate, Laureth-7, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Methylsulfonylmethane (MSM), Phenoxyethanol, Polyacrylamide, Propylene Glycol, Stearic Acid, Triethanolamine"
    ],
    "package_label_principal_display_panel": [
      "Product label die cut Tube"
    ],
    "set_id": "2a64b3ef-ed2d-49db-996d-f63ffecb5a1e",
    "id": "436c1752-2f0a-b7e0-e063-6394a90aa7a1",
    "effective_time": "20251112",
    "version": "3",
    "openfda": {
      "application_number": [
        "M017"
      ],
      "brand_name": [
        "Tattoo Numbing Cream Co"
      ],
      "generic_name": [
        "LIDOCAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Sambria Pharmaceuticals, LLC"
      ],
      "product_ndc": [
        "54723-023"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "LIDOCAINE HYDROCHLORIDE"
      ],
      "spl_id": [
        "436c1752-2f0a-b7e0-e063-6394a90aa7a1"
      ],
      "spl_set_id": [
        "2a64b3ef-ed2d-49db-996d-f63ffecb5a1e"
      ],
      "package_ndc": [
        "54723-023-01"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "V13007Z41A"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "LY-CO Angelica Archangelica, Kali Muriaticum, Yucca Filamentosa, Cartilago Suis, Phytolacca Decandra, Hydrastis Canadensis, Rhus Tox, Causticum, Magnesia Phosphorica, Manganum Metallicum, Oxalicum Acidum, Arnica Montana, Borrelia Burgdorferi Nosode, Latrodectus Mactans, Citricum Acidum, Cytomegalovirus Nosode, Rickettsia Nosode (rickettsia prowazekii), Chlamydia Trachomatis, Ledum Palustre ANGELICA ARCHANGELICA ROOT ANGELICA ARCHANGELICA ROOT POTASSIUM CHLORIDE POTASSIUM CATION YUCCA FILAMENTOSA WHOLE YUCCA FILAMENTOSA SUS SCROFA CARTILAGE SUS SCROFA CARTILAGE PHYTOLACCA AMERICANA ROOT PHYTOLACCA AMERICANA ROOT GOLDENSEAL GOLDENSEAL TOXICODENDRON PUBESCENS LEAF TOXICODENDRON PUBESCENS LEAF CAUSTICUM CAUSTICUM MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE MAGNESIUM CATION MANGANESE MANGANESE OXALIC ACID DIHYDRATE OXALIC ACID ARNICA MONTANA WHOLE ARNICA MONTANA BORRELIA BURGDORFERI BORRELIA BURGDORFERI LATRODECTUS MACTANS LATRODECTUS MACTANS ANHYDROUS CITRIC ACID ANHYDROUS CITRIC ACID HUMAN HERPESVIRUS 5 HUMAN HERPESVIRUS 5 RICKETTSIA PROWAZEKII RICKETTSIA PROWAZEKII CHLAMYDIA TRACHOMATIS CHLAMYDIA TRACHOMATIS RHODODENDRON TOMENTOSUM LEAFY TWIG LEDUM PALUSTRE TWIG WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENTS: Angelica Archangelica 2X, Kali Muriaticum 3X, Yucca Filamentosa 3X, Cartilago Suis 4X, 6X, 12X, Phytolacca Decandra 4X, 12X, 30X, Hydrastis Canadensis 5X, Rhus Tox 6X, Causticum 6X, 12X, 30X, Magnesia Phosphorica 8X, Manganum Metallicum 8X, Oxalicum Acidum 8X, 12X, Arnica Montana 8X, 100X, 1000X, Borrelia Burgdorferi Nosode 12X, 30X, 60X, Latrodectus Mactans 12X, 30X, 60X, Citricum Acidum 6C, Cytomegalovirus Nosode 6C, Rickettsia Nosode (Rickettsia prowazekii) 8C, Chlamydia Trachomatis 12C, Ledum Palustre 30C."
    ],
    "purpose": [
      "PURPOSE: Supports the immune system. Formulated and produced under the guidelines of the Homeopathic Pharmacopoeia of the United States."
    ],
    "warnings": [
      "WARNINGS: If pregnant or nursing ask your health Care Practitioner before use. Keep out of reach of children. Store in a cool, dry and dark place. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use if tamper evident seal is broken or missing."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: Take 10 drops 1 to 3 times per day under the tongue 30 minutes before meal or as directed by a Health Care Practitioner. Consult your physician for use in children under 12 years of age."
    ],
    "indications_and_usage": [
      "INDICATIONS: Supports the immune system. Formulated and produced under the guidelines of the Homeopathic Pharmacopoeia of the United States."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized Water and Organic Alcohol (Ethanol) 20%."
    ],
    "questions": [
      "QUESTIONS: Manufactured for: BHP Holdings, Inc. Woodinville, WA 98072 Phone: 425-462-8414 www.biopureus.com info@biopureus.com"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: 58048-0006-1 BioPure\u00ae LY-CO HOMEOPATHIC 2 fl.oz (60mL) LY-CO"
    ],
    "set_id": "47140966-5b49-432d-bf35-bcae14f42082",
    "id": "53dad825-4744-4b41-8974-831a37af78f5",
    "effective_time": "20230601",
    "version": "1",
    "openfda": {
      "brand_name": [
        "LY-CO"
      ],
      "generic_name": [
        "ANGELICA ARCHANGELICA, KALI MURIATICUM, YUCCA FILAMENTOSA, CARTILAGO SUIS, PHYTOLACCA DECANDRA, HYDRASTIS CANADENSIS, RHUS TOX, CAUSTICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, OXALICUM ACIDUM, ARNICA MONTANA, BORRELIA BURGDORFERI NOSODE, LATRODECTUS MACTANS, CITRICUM ACIDUM, CYTOMEGALOVIRUS NOSODE, RICKETTSIA NOSODE (RICKETTSIA PROWAZEKII), CHLAMYDIA TRACHOMATIS, LEDUM PALUSTRE"
      ],
      "manufacturer_name": [
        "Bhp Holdings, Inc."
      ],
      "product_ndc": [
        "58048-0006"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ANGELICA ARCHANGELICA ROOT",
        "ANHYDROUS CITRIC ACID",
        "ARNICA MONTANA WHOLE",
        "BORRELIA BURGDORFERI",
        "CAUSTICUM",
        "CHLAMYDIA TRACHOMATIS",
        "GOLDENSEAL",
        "HUMAN HERPESVIRUS 5",
        "LATRODECTUS MACTANS",
        "MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE",
        "MANGANESE",
        "OXALIC ACID DIHYDRATE",
        "PHYTOLACCA AMERICANA ROOT",
        "POTASSIUM CHLORIDE",
        "RHODODENDRON TOMENTOSUM LEAFY TWIG",
        "RICKETTSIA PROWAZEKII",
        "SUS SCROFA CARTILAGE",
        "TOXICODENDRON PUBESCENS LEAF",
        "YUCCA FILAMENTOSA WHOLE"
      ],
      "spl_id": [
        "53dad825-4744-4b41-8974-831a37af78f5"
      ],
      "spl_set_id": [
        "47140966-5b49-432d-bf35-bcae14f42082"
      ],
      "package_ndc": [
        "58048-0006-1"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175833",
        "N0000175835",
        "N0000175980",
        "N0000008556",
        "N0000175089"
      ],
      "pharm_class_moa": [
        "Acidifying Activity [MoA]",
        "Calcium Chelating Activity [MoA]"
      ],
      "pharm_class_epc": [
        "Calculi Dissolution Agent [EPC]",
        "Anti-coagulant [EPC]"
      ],
      "pharm_class_pe": [
        "Decreased Coagulation Factor Activity [PE]"
      ],
      "unii": [
        "DTN01M69SN",
        "XF417D3PSL",
        "O80TY208ZW",
        "0J8NV9V5Q8",
        "DD5FO1WKFU",
        "T6NI39QU44",
        "ZW3Z11D0JV",
        "7COI029E6K",
        "XJJ7QA858R",
        "HF539G9L3Q",
        "42Z2K6ZL8P",
        "0K2L2IJ59O",
        "11E6VI8VEG",
        "660YQ98I10",
        "877L01IZ0P",
        "TVS414L9M5",
        "73ECW5WG2F",
        "6IO182RP7A",
        "T6VR38UJ9I"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Abbasi co Minoxidil Abbasi co Minoxidil shampoo WATER MINOXIDIL MINOXIDIL"
    ],
    "keep_out_of_reach_of_children": [
      "Eye protection: Avoid getting shampoo foam into your baby's eyes during washing. If it accidentally gets into their eyes, gently rinse with clean water until the irritation subsides. Skin reaction: If persistent redness, itching, or blistering occurs, discontinue use and consult a pediatrician. Storage and handling: Keep out of reach of children, store in a cool, dark place, and avoid direct sunlight and high temperatures. Use within the expiration date indicated on the packaging after opening."
    ],
    "indications_and_usage": [
      "Shampoo is used to cleanse the hair and scalp, while also providing a foundation for styling, making hair smooth and nourished, and preventing split ends."
    ],
    "warnings": [
      "(I) Shampoo 1. Warning: If it accidentally gets into your eyes, rinse immediately with plenty of water. If irritation persists, seek medical attention. 2. Note: Everyone's hair type is different, and the results may vary. If you experience scalp discomfort or other issues, you may want to switch to a different product. 3. Tip: Use the shampoo correctly according to the instructions. Avoid frequent washing to prevent damage to your scalp and hair."
    ],
    "inactive_ingredient": [
      "Water Sodium Laureth Sulfate Ammonium Lauryl Sulfate Disodium Laureth Sulfosuccinate Cocamidopropyl Betaine Glycerin Polyquaternium-7 Cocamide MEA Collagen Keratin Niacinamide Rosmarinus Officinalis (Rosemary) Leaf Oil Bergamot Oil Melaleuca Alternifolia (Tea Tree) Leaf Oil Biotin Tripeptide-1 Sodium Chloride Panthenol Hydroxyacetophenone 1,2-Hexanediol Citric Acid Disodium EDTA Panax Ginseng Extract Aloe Barbadensis Extract CI 19140 CI 15985 CI 16035 Parfum"
    ],
    "recent_major_changes": [
      ""
    ],
    "purpose": [
      "It cleanses the hair and scalp, removing oil, dirt, dust, and styling product residue, thus maintaining a clean and healthy scalp environment."
    ],
    "dosage_and_administration": [
      "These highlights do not include all the information needed to use see full prescribing information for initial U.S. Approver Apply or spray onto the scalp in the areas of hair loss, not on the hair itself."
    ],
    "package_label_principal_display_panel": [
      "1"
    ],
    "set_id": "485a7777-f20f-351d-e063-6294a90af1cb",
    "id": "485a777f-c5c4-3732-e063-6294a90a624a",
    "effective_time": "20260114",
    "version": "1",
    "openfda": {
      "application_number": [
        "M032"
      ],
      "brand_name": [
        "Abbasi co Minoxidil"
      ],
      "generic_name": [
        "ABBASI CO MINOXIDIL SHAMPOO"
      ],
      "manufacturer_name": [
        "Guangzhou Yilong Cosmetics.,Ltd"
      ],
      "product_ndc": [
        "74458-131"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "MINOXIDIL"
      ],
      "spl_id": [
        "485a777f-c5c4-3732-e063-6294a90a624a"
      ],
      "spl_set_id": [
        "485a7777-f20f-351d-e063-6294a90af1cb"
      ],
      "package_ndc": [
        "74458-131-01"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175379",
        "N0000175564"
      ],
      "pharm_class_pe": [
        "Arteriolar Vasodilation [PE]"
      ],
      "pharm_class_epc": [
        "Arteriolar Vasodilator [EPC]"
      ],
      "unii": [
        "5965120SH1"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Abbasi and co Minoxidil Abbasi co Minoxidil shampoo WATER MINOXIDIL MINOXIDIL"
    ],
    "keep_out_of_reach_of_children": [
      "Eye protection: Avoid getting shampoo foam into your baby's eyes during washing. If it accidentally gets into their eyes, gently rinse with clean water until the irritation subsides. Skin reaction: If persistent redness, itching, or blistering occurs, discontinue use and consult a pediatrician. Storage and handling: Keep out of reach of children, store in a cool, dark place, and avoid direct sunlight and high temperatures. Use within the expiration date indicated on the packaging after opening."
    ],
    "indications_and_usage": [
      "Shampoo is used to cleanse the hair and scalp, while also providing a foundation for styling, making hair smooth and nourished, and preventing split ends."
    ],
    "warnings": [
      "(I) Shampoo 1. Warning: If it accidentally gets into your eyes, rinse immediately with plenty of water. If irritation persists, seek medical attention. 2. Note: Everyone's hair type is different, and the results may vary. If you experience scalp discomfort or other issues, you may want to switch to a different product. 3. Tip: Use the shampoo correctly according to the instructions. Avoid frequent washing to prevent damage to your scalp and hair."
    ],
    "inactive_ingredient": [
      "Water Sodium Laureth Sulfate Ammonium Lauryl Sulfate Disodium Laureth Sulfosuccinate Cocamidopropyl Betaine Glycerin Polyquaternium-7 Cocamide MEA Collagen Keratin Niacinamide Rosmarinus Officinalis (Rosemary) Leaf Oil Bergamot Oil Melaleuca Alternifolia (Tea Tree) Leaf Oil Biotin Tripeptide-1 Sodium Chloride Panthenol Hydroxyacetophenone 1,2-Hexanediol Citric Acid Disodium EDTA Panax Ginseng Extract Aloe Barbadensis Extract CI 19140 CI 15985 CI 16035 Parfum"
    ],
    "recent_major_changes": [
      ""
    ],
    "purpose": [
      "It cleanses the hair and scalp, removing oil, dirt, dust, and styling product residue, thus maintaining a clean and healthy scalp environment."
    ],
    "dosage_and_administration": [
      "These highlights do not include all the information needed to use see full prescribing information for initial U.S. Approver Apply or spray onto the scalp in the areas of hair loss, not on the hair itself."
    ],
    "package_label_principal_display_panel": [
      "1"
    ],
    "set_id": "486e1fbb-5de7-feaf-e063-6294a90ac678",
    "id": "486e1fc4-ff08-0588-e063-6294a90a851b",
    "effective_time": "20260115",
    "version": "1",
    "openfda": {
      "application_number": [
        "M032"
      ],
      "brand_name": [
        "Abbasi and co Minoxidil"
      ],
      "generic_name": [
        "ABBASI CO MINOXIDIL SHAMPOO"
      ],
      "manufacturer_name": [
        "Guangzhou Yilong Cosmetics.,Ltd"
      ],
      "product_ndc": [
        "74458-132"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "MINOXIDIL"
      ],
      "spl_id": [
        "486e1fc4-ff08-0588-e063-6294a90a851b"
      ],
      "spl_set_id": [
        "486e1fbb-5de7-feaf-e063-6294a90ac678"
      ],
      "package_ndc": [
        "74458-132-01"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175379",
        "N0000175564"
      ],
      "pharm_class_pe": [
        "Arteriolar Vasodilation [PE]"
      ],
      "pharm_class_epc": [
        "Arteriolar Vasodilator [EPC]"
      ],
      "unii": [
        "5965120SH1"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO. SPF-30 OCTOCRYLENE, ZINC OXIDE, OCTISALATE GLYCERYL MONOSTEARATE ALOE VERA LEAF BENZYL ALCOHOL SHEA BUTTER CALENDULA OFFICINALIS FLOWER GREEN TEA LEAF MEDIUM-CHAIN TRIGLYCERIDES CETOSTEARYL ALCOHOL CITRIC ACID MONOHYDRATE WATERMELON COCONUT OIL DECYL GLUCOSIDE DEHYDROACETIC ACID FUCUS VESICULOSUS GLYCERIN HELIANTHUS ANNUUS FLOWERING TOP HYDROXYETHYL CELLULOSE, UNSPECIFIED AVOCADO OIL JOJOBA OIL COCOA .ALPHA.-TOCOPHEROL ACETATE TRIDECYL SALICYLATE WATER XANTHAN GUM OCTOCRYLENE OCTOCRYLENE ZINC OXIDE ZINC CATION OCTISALATE OCTISALATE"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information: Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Octocrylene 5.0% Octisalate 5.0% Zinc Oxide 5.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses: \u2022 Helps prevent sunburn. \u2022 Higher SPF gives more sunburn protection. \u2022 Retains SPF after 80 minutes of swimming or sweating."
    ],
    "warnings": [
      "Warnings: For external use only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions: \u2022 Apply liberally 15 minutes before sun exposure and as needed. \u2022 Children under 6 months: ask a doctor. \u2022 Reapply: \u2022 After 80 minutes of swimming or sweating \u2022 Immediately after towel drying \u2022 A t least every two hours. \u2022 Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: \u2022 Limit time in the sun, especially from 10 a.m. \u2013 2 p.m. \u2022 Wear long-sleeve shirts, pants, hats and sunglasses. Sun Protection Measures:"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients: Algae Extract, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Benzyl Alcohol, Butyrospermum Parkii (Shea) Butter), Calendula Officinalis Extract, Camellia Sinensis (Green Tea) Extract, Caprylic/Capric Triglyceride, Cetearyl Alcohol, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Decyl Glucoside, Dehydroacetic Acid, Fucus Vesiculosus (Bladderwrack Seaweed) Extract, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Hydroxyethylcellulose, Natural Fragrance, Persea Gratissima (Avocado) Oil, Polyhydroxystearic Acid, Simmondsia Chinensis (Jojoba) Oil, Theobroma Cacao (Cocoa) Butter, Tocopheryl Acetate (Vitamin E), Tridecyl Salicylate, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Bottle3"
    ],
    "set_id": "4df55434-fb9a-442d-82cf-16a4957f0a2a",
    "id": "09e272c0-a7c7-0c1f-e063-6394a90ac62e",
    "effective_time": "20231111",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO. SPF-30"
      ],
      "generic_name": [
        "OCTOCRYLENE, ZINC OXIDE, OCTISALATE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-133"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "OCTISALATE",
        "OCTOCRYLENE",
        "ZINC OXIDE"
      ],
      "spl_id": [
        "09e272c0-a7c7-0c1f-e063-6394a90ac62e"
      ],
      "spl_set_id": [
        "4df55434-fb9a-442d-82cf-16a4957f0a2a"
      ],
      "package_ndc": [
        "81159-133-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007385"
      ],
      "unii": [
        "4X49Y0596W",
        "5A68WGF6WM",
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "AVMAPKI FAKZYNJA CO-PACK avutometinib potassium and defactinib hydrochloride AVMAPKI avutometinib potassium avutometinib potassium avutometinib Mannitol Magnesium stearate HYPROMELLOSE, UNSPECIFIED Titanium Dioxide Water Potassium Chloride Carrageenan Shellac ALCOHOL Isopropyl Alcohol Butyl Alcohol Propylene Glycol AMMONIA FERROSOFERRIC OXIDE Potassium Hydroxide 6766 FAKZYNJA defactinib hydrochloride defactinib hydrochloride defactinib MICROCRYSTALLINE CELLULOSE 102 Lactose monohydrate SODIUM STARCH GLYCOLATE TYPE A Magnesium stearate white to off-white VS2"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 , 14 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION AVMAPKI 3.2 mg administered orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle. ( 2.3 ) FAKZYNJA 200 mg administered orally twice daily for the first 3 weeks of each 4-week cycle. ( 2.3 ) 2.1 Patient Selection Select patients for the treatment of recurrent LGSOC with AVMAPKI FAKZYNJA CO-PACK based on the presence of a KRAS mutation in tumor specimens [see Clinical Studies (14) ] . An FDA-approved test for the detection of a KRAS mutation in LGSOC for selecting patients for treatment with AVMAPKI FAKZYNJA CO-PACK is not available. 2.2 Eye Exams and Prophylactic Skin Medications Ophthalmic Exams Conduct a comprehensive ophthalmic exam at baseline, prior to cycle 2, and every three cycles thereafter regardless of baseline exam findings, and as clinically indicated [see Warnings and Precautions (5.1) ]. Prophylactic Medications for Skin Reactions With initiation of and during at least the first 2 cycles of AVMAPKI FAKZYNJA CO-PACK administer [see Warnings and Precautions (5.2) ] : Topical corticosteroid (applied to the face, scalp, neck, upper chest and upper back) Systemic oral antibiotics 2.3 Recommended Dosage and Administration AVMAPKI Capsules The recommended dosage of AVMAPKI capsules is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity. Take AVMAPKI at the same time with each dose. AVMAPKI should be taken with food [see Clinical Pharmacology (12.3) ] . Swallow capsules whole. Do not chew, break, or open the capsules. If a dose of AVMAPKI is missed by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking AVMAPKI, do not take an additional dose. Take the next scheduled dose as prescribed. FAKZYNJA Tablets The recommended dosage of FAKZYNJA tablets is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity. Take each dose of FAKZYNJA with food [see Clinical Pharmacology (12.3) ] . Swallow tablets whole. Do not chew, break or crush the tablets. If a dose of FAKZYNJA is missed by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two tablets at the same time to make up for a missed dose. If vomiting occurs after taking FAKZYNJA, do not take an additional dose. Take the next scheduled dose as prescribed. 2.4 Dosage Modifications for Adverse Reactions Dose reductions due to adverse reactions due to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 1. Table 1 Recommended Dose Reductions for Adverse Reactions Dose Level AVMAPKI Capsule FAKZYNJA Tablet Starting dose 3.2 mg twice weekly for first 3 weeks of each 4-week cycle 200 mg twice daily for first 3 weeks of each 4-week cycle Dose reduction 2.4 mg twice weekly for first 3 weeks of each 4-week cycle 200 mg once daily for first 3 weeks of each 4-week cycle Permanently discontinue both AVMAPKI and FAKZYNJA in patients unable to tolerate after one dose reduction of both products. Dosage modifications for adverse reactions to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 2. Table 2 AVMAPKI FAKZYNJA CO-PACK Dosage Modifications Adverse Reaction Severity Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 Dose Modification N/A: Not applicable Keratitis [see Warnings and Precautions (5.1) ] Confluent superficial keratitis, a cornea epithelial defect, or 3-line or more loss in best corrected distance visual acuity Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluent superficial keratitis, then resume at same dose. Corneal ulcer or stromal opacity or best corrected distance visual acuity 20/200 or worse Corneal perforation Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluence superficial keratitis, then resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK. Blurred vision [see Warnings and Precautions (5.1) ] BCVA worse than baseline but no worse than 20/200 Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume treatment at same dose. BCVA 20/200 or worse Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume at reduced dose. Conjunctivitis [see Warnings and Precautions (5.1) ] Confluent superficial punctate staining, moderate to severe vasodilation Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at same dose. Conjunctival ulcer or neovascularization Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at reduced dose. Retinal Pigment Epithelial (RPE) Detachment [see Warnings and Precautions (5.1) ] N/A First occurrence Repeat Optical Coherence Tomography (OCT) examination in two weeks. First follow-up OCT examination and RPE present Reduce dose of AVMAPKI FAKZYNJA CO-PACK Repeat OCT examination in two weeks. Second follow-up OCT examination and RPE present and/or loss of 1 line in BCVA : Withhold AVMAPKI FAKZYNJA CO-PACK Repeat OCT examination in two weeks. Third follow-up OCT examination RPE resolving/resolved, resume at reduced dose. No resolution, permanently discontinue AVMAPKI FAKZYNJA CO-PACK Rash [see Warnings and Precautions (5.2) ] Grade \u2264 2 Consider withholding AVMAPKI FAKZYNJA CO-PACK if rash does not respond to supportive care or recurs after resolution to Grade \u22641. Dose reduce AVMAPKI FAKZYNJA CO-PACK for intolerable Grade 2. Grade 3 Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to Grade 2 then resume at reduced dose. Resume at same dose if resolved to Grade \u22641. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction. Grade 4 Permanently discontinue AVMAPKI FAKZYNJA CO-PACK. Hepatotoxicity [see Warnings and Precautions (5.3) ] Grade 2 Withhold AVMAPKI FAKZYNJA CO-PACK for Grade 2 hyperbilirubinemia (without Gilbert's syndrome) with Grade \u22641 increase in AST and/or ALT until hyperbilirubinemia Grade \u22641, then resume at same dose. Grade 2 hyperbilirubinemia with Grade 2 increase in AST and/or ALT until hyperbilirubinemia Grade \u22641 or baseline, then resume at same dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 2 hyperbilirubinemia associated with Grade >2 increase in AST and/or ALT. Grade 3 Withhold AVMAPKI FAKZYNJA CO-PACK if Grade 3 hyperbilirubinemia is associated with Grade \u22641 increase in AST and/or ALT until hyperbilirubinemia Grade \u22641 or at baseline, then resume at same dose. if recurrent Grade 3 hyperbilirubinemia is associated with Grade \u22641 increase in AST and/or ALT until hyperbilirubinemia Grade \u22642 or at baseline, then resume at reduced dose. if Grade 3 increased AST and/or ALT is not associated with hyperbilirubinemia until Grade \u22642 or at baseline, then resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 3 hyperbilirubinemia associated with Grade \u22652 increase in AST and/or ALT. Grade 4 Withhold AVMAPKI FAKZYNJA CO-PACK for Grade 4 hyperbilirubinemia associated with Grade \u22641 increase in AST and/or ALT and if resolves within one week resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 4 increase in AST and/or ALT. Grade 4 hyperbilirubinemia associated with Grade \u22641 increase in AST and/or ALT that does not resolve within 1 week. Grade 4 hyperbilirubinemia associated with Grade \u22652 increase in AST and/or ALT. Increased Blood Creatine Phosphokinase (CPK) [see Warnings and Precautions (5.4) ] Grade 3 Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade \u22641 within three weeks resume at same dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks. Grade 4 Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade \u22641 within three weeks resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks. Any grade CPK elevation with rhabdomyolysis or other event related to CPK elevation Permanently discontinue AVMAPKI FAKZYNJA CO-PACK Other Adverse Reactions Grade 2 Consider withholding AVMAPKI FAKZYNJA CO-PACK if adverse reaction does not respond to supportive care or recurs after resolution to Grade \u22641. Grade 3 First occurrence: Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade \u22641 then resume at same dose. Second occurrence: Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade \u22641 then resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction. Grade 4 Permanently discontinue AVMAPKI FAKZYNJA CO-PACK."
    ],
    "dosage_and_administration_table": [
      "<table width=\"85%\"><caption>Table 1 Recommended Dose Reductions for Adverse Reactions</caption><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"35%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Dose Level</th><th styleCode=\"Rrule\">AVMAPKI Capsule</th><th styleCode=\"Rrule\">FAKZYNJA Tablet</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Starting dose</td><td styleCode=\"Rrule\">3.2 mg twice weekly for first 3 weeks of each 4-week cycle</td><td styleCode=\"Rrule\">200 mg twice daily for first 3 weeks of each 4-week cycle</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dose reduction</td><td styleCode=\"Rrule\">2.4 mg twice weekly for first 3 weeks of each 4-week cycle</td><td styleCode=\"Rrule\">200 mg once daily for first 3 weeks of each 4-week cycle</td></tr><tr><td colspan=\"3\" styleCode=\"Lrule Rrule\" align=\"center\">Permanently discontinue both AVMAPKI and FAKZYNJA in patients unable to tolerate after one dose reduction of both products.</td></tr></tbody></table>",
      "<table width=\"90%\"><caption>Table 2 AVMAPKI FAKZYNJA CO-PACK Dosage Modifications</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"40%\" align=\"left\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Adverse Reaction</th><th align=\"center\" styleCode=\"Rrule\">Severity<footnote>Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</footnote></th><th align=\"center\" styleCode=\"Rrule\">Dose Modification</th></tr></thead><tfoot><tr><td align=\"left\" valign=\"top\" colspan=\"3\">N/A: Not applicable</td></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\"><content styleCode=\"bold\">Keratitis</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.1\">Warnings and Precautions (5.1)</linkHtml>]</content></td><td styleCode=\"Rrule\">Confluent superficial keratitis, a cornea epithelial defect, or 3-line or more loss in best corrected distance visual acuity</td><td styleCode=\"Rrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluent superficial keratitis, then resume at same dose.</td></tr><tr><td styleCode=\"Rrule Botrule\">Corneal ulcer or stromal opacity or best corrected distance visual acuity 20/200 or worse Corneal perforation</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluence superficial keratitis, then resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\"><content styleCode=\"bold\">Blurred vision</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.1\">Warnings and Precautions (5.1)</linkHtml>]</content></td><td styleCode=\"Rrule\">BCVA worse than baseline but no worse than 20/200</td><td styleCode=\"Rrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume treatment at same dose.</td></tr><tr><td styleCode=\"Rrule Botrule\">BCVA 20/200 or worse</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume at reduced dose.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\"><content styleCode=\"bold\">Conjunctivitis</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.1\">Warnings and Precautions (5.1)</linkHtml>]</content></td><td styleCode=\"Rrule\">Confluent superficial punctate staining, moderate to severe vasodilation</td><td styleCode=\"Rrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at same dose.</td></tr><tr><td styleCode=\"Rrule Botrule\">Conjunctival ulcer or neovascularization</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at reduced dose.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Retinal Pigment Epithelial (RPE) Detachment</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.1\">Warnings and Precautions (5.1)</linkHtml>]</content></td><td styleCode=\"Rrule\">N/A</td><td styleCode=\"Rrule\"><content styleCode=\"underline\">First occurrence</content><list listType=\"unordered\" styleCode=\"disc\"><item>Repeat Optical Coherence Tomography (OCT) examination in two weeks.</item></list><content styleCode=\"underline\">First follow-up OCT examination and RPE present</content><list listType=\"unordered\" styleCode=\"disc\"><item>Reduce dose of AVMAPKI FAKZYNJA CO-PACK</item><item>Repeat OCT examination in two weeks.</item></list><content styleCode=\"underline\">Second follow-up OCT examination and RPE present and/or loss of 1 line in BCVA</content>:<list listType=\"unordered\" styleCode=\"disc\"><item>Withhold AVMAPKI FAKZYNJA CO-PACK</item><item>Repeat OCT examination in two weeks.</item></list><content styleCode=\"underline\">Third follow-up OCT examination</content><list listType=\"unordered\" styleCode=\"disc\"><item>RPE resolving/resolved, resume at reduced dose.</item><item>No resolution, permanently discontinue AVMAPKI FAKZYNJA CO-PACK </item></list></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\"><content styleCode=\"bold\">Rash</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.2\">Warnings and Precautions (5.2)</linkHtml>]</content></td><td styleCode=\"Rrule\">Grade &#x2264; 2</td><td styleCode=\"Rrule\">Consider withholding AVMAPKI FAKZYNJA CO-PACK if rash does not respond to supportive care or recurs after resolution to Grade &#x2264;1. Dose reduce AVMAPKI FAKZYNJA CO-PACK for intolerable Grade 2.</td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 3</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to Grade 2 then resume at reduced dose. Resume at same dose if resolved to Grade &#x2264;1. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction.</td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 4</td><td valign=\"middle\" styleCode=\"Rrule Botrule\">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK.</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\"><content styleCode=\"bold\">Hepatotoxicity</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.3\">Warnings and Precautions (5.3)</linkHtml>]</content></td><td styleCode=\"Rrule\">Grade 2</td><td styleCode=\"Rrule\">Withhold AVMAPKI FAKZYNJA CO-PACK for <list listType=\"unordered\" styleCode=\"disc\"><item>Grade 2 hyperbilirubinemia (without Gilbert&apos;s syndrome) with Grade &#x2264;1 increase in AST and/or ALT until hyperbilirubinemia Grade &#x2264;1, then resume at same dose.</item><item>Grade 2 hyperbilirubinemia with Grade 2 increase in AST and/or ALT until hyperbilirubinemia Grade &#x2264;1 or baseline, then resume at same dose.</item></list> Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 2 hyperbilirubinemia associated with Grade &gt;2 increase in AST and/or ALT. </td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 3</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK <list listType=\"unordered\" styleCode=\"disc\"><item>if Grade 3 hyperbilirubinemia is associated with Grade &#x2264;1 increase in AST and/or ALT until hyperbilirubinemia Grade &#x2264;1 or at baseline, then resume at same dose.</item><item>if recurrent Grade 3 hyperbilirubinemia is associated with Grade &#x2264;1 increase in AST and/or ALT until hyperbilirubinemia Grade &#x2264;2 or at baseline, then resume at reduced dose.</item><item>if Grade 3 increased AST and/or ALT is not associated with hyperbilirubinemia until Grade &#x2264;2 or at baseline, then resume at reduced dose. </item></list> Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 3 hyperbilirubinemia associated with Grade &#x2265;2 increase in AST and/or ALT. </td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 4</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK for <list listType=\"unordered\" styleCode=\"disc\"><item>Grade 4 hyperbilirubinemia associated with Grade &#x2264;1 increase in AST and/or ALT and if resolves within one week resume at reduced dose.</item></list> Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for <list listType=\"unordered\" styleCode=\"disc\"><item>Grade 4 increase in AST and/or ALT.</item><item>Grade 4 hyperbilirubinemia associated with Grade &#x2264;1 increase in AST and/or ALT that does not resolve within 1 week.</item></list> Grade 4 hyperbilirubinemia associated with Grade &#x2265;2 increase in AST and/or ALT. </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\"><content styleCode=\"bold\">Increased Blood Creatine Phosphokinase (CPK)</content> <content styleCode=\"italics\">[see <linkHtml href=\"#S5.4\">Warnings and Precautions (5.4)</linkHtml>]</content></td><td styleCode=\"Rrule\">Grade 3</td><td styleCode=\"Rrule\">Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade &#x2264;1 within three weeks resume at same dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks.</td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 4</td><td styleCode=\"Rrule Botrule\">Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade &#x2264;1 within three weeks resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks.</td></tr><tr><td styleCode=\"Rrule Botrule\">Any grade CPK elevation with rhabdomyolysis or other event related to CPK elevation</td><td styleCode=\"Rrule Botrule\">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\"><content styleCode=\"bold\">Other Adverse Reactions</content></td><td styleCode=\"Rrule\">Grade 2</td><td styleCode=\"Rrule\">Consider withholding AVMAPKI FAKZYNJA CO-PACK if adverse reaction does not respond to supportive care or recurs after resolution to Grade &#x2264;1.</td></tr><tr><td styleCode=\"Rrule Botrule\">Grade 3</td><td styleCode=\"Rrule Botrule\"><content styleCode=\"underline\">First occurrence:</content> Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade &#x2264;1 then resume at same dose. <content styleCode=\"underline\">Second occurrence:</content> Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade &#x2264;1 then resume at reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction.</td></tr><tr><td styleCode=\"Rrule\">Grade 4</td><td valign=\"middle\" styleCode=\"Rrule\">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK.</td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS AVMAPKI FAKZYNJA CO-PACK is AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets. AVMAPKI capsules contain 0.8 mg avutometinib and are white capsules with \"6766\" printed on the cap and the strength \"0.8 mg\" printed on the body in black ink. FAKZYNJA tablets contain 200 mg defactinib and are white to off-white tablets, oval and debossed with \"VS2\" on one side. AVMAPKI Capsules: 0.8 mg of avutometinib ( 3 ) FAKZYNJA Tablets: 200 mg of defactinib ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity. ( 2.4 , 5.1 ) Serious Skin Toxicities : Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration. ( 2.4 , 5.2 ) Hepatotoxicity : Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality. ( 2.4 , 5.3 ) Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction. ( 2.4 , 5.4 ) Embryo-Fetal Toxicity : AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. ( 5.5 , 8.1 , 8.3 ) 5.1 Ocular Toxicities AVMAPKI FAKZYNJA CO-PACK can cause ocular adverse reactions, including visual impairment and vitreoretinal disorders. Ocular adverse reactions occurred in 68% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK. Common ocular adverse reactions (\u2265 5%) were visual impairment (38%), dry eye (13%), orbital/periorbital edema (8%), and vitreous floaters (5%). Thirty-five patients (26%) experienced vitreoretinal disorders, including retinal detachment (9%), and retinal vein occlusion (0.7%). Eighteen patients (13%) experienced an ocular adverse reaction that resulted in dose interruption of AVMAPKI FAKZYNJA CO-PACK and one patient experienced an ocular adverse reaction that resulted in dose reduction. The median time to onset of symptomatic ocular adverse reactions was 5 days (range 1 to 943 days) and to onset of asymptomatic ocular adverse reactions was 112 days (range 23 to 943 days). The median time to onset of retinal detachment was 27 days (range 2 to 535 days). Of the patients who experienced ocular adverse reactions, 29% had ongoing ocular events at last follow-up. Refer patients to a qualified eye care professional for a comprehensive ophthalmic exam at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs or symptoms. Monitor for ocular adverse reactions and withhold, reduce, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of ocular adverse reactions [see Dosage and Administration (2.4) ]. 5.2 Serious Skin Toxicities AVMAPKI FAKZYNJA CO-PACK can cause serious skin toxicities, including Severe Cutaneous Adverse Reactions (SCARs). Cases of acute generalized exanthematous pustulosis, erythema multiforme and drug reaction with eosinophilia and systemic symptoms have been reported in clinical trials of avutometinib (a drug in AVMAPKI FAKZYNJA CO-PACK). Skin toxicities occurred in 94% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK. The most common skin toxicities (\u2265 10%) were rash (67%), dermatitis acneiform (43%), dry skin (43%), pruritus (32%), and photosensitivity (13%). Grade 3 skin reactions occurred in 12% of patients including dermatitis acneiform (7%), rash (7%), and pruritus (1.5%). Thirteen patients (10%) developed bacterial skin infections. Skin toxicity led to dose interruption of AVMAPKI FAKZYNJA CO-PACK in 10%, to dose reduction in 7%, and to permanent discontinuation in 0.7% of patients. The median time to onset of the first skin toxicity was 14 days (range 1 to 500 days). At last follow-up, 66% of patients had ongoing skin toxicity. Patients in RAMP-201 used topical corticosteroids (applied to the face, scalp, neck, upper chest and upper back) and systemic oral antibiotics for prophylaxis of skin adverse reactions. These medications were initiated at the start of AVMAPKI FAKZYNJA CO-PACK and administered during at least the first two cycles of treatment. Limit unnecessary exposure to sunlight and apply daily sunscreen (sun protection factor [SPF] \u2265 30). Monitor for skin toxicity and withhold, reduce dose, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence [see Dosage and Administration (2.4) ]. 5.3 Hepatotoxicity AVMAPKI FAKZYNJA CO-PACK can cause hepatotoxicity. In patients with recurrent LGSOC who received AVMAPKI FAKZYNJA CO-PACK, increased AST (73%), bilirubin (51%), ALT (49%), and alkaline phosphatase (46%) occurred. Grade 3-4 elevations in ALT was 3%, AST was 3%, bilirubin was 2.3% and alkaline phosphatase was 0.8%. Elevations in one or more liver related laboratory values led to dose interruption for 20%, dose reduction for 2.2%, and permanent discontinuation for 0.7% of patients. Increased blood bilirubin may be attributed to defactinib (a component of AVMAPKI FAKZYNJA CO-PACK) due to the inhibition of enzymes responsible for metabolizing (uridine diphosphate-glucuronosyltransferase (UGT)1A1) and transporting (Organic Anion Transporting Polypeptides (OATP)1B1/1B3) bilirubin [see Clinical Pharmacology (12.3) ]. Monitor liver related laboratory values prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. Withhold, reduce dose, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of these adverse reactions [see Dosage and Administration (2.4) ]. 5.4 Rhabdomyolysis AVMAPKI FAKZYNJA CO-PACK can cause increased creatine phosphokinase (CPK). Increased CPK occurred in 75% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK, including Grade 3-4 elevations in 18% of patients. Among the patients who experienced an elevation in CPK, concurrent increase in creatinine occurred in 19% (n=19/102) and myalgia occurred in 10% (n=10/102). Elevation of CPK >10 times the baseline value with a concurrent increase in serum creatinine of \u22651.5 times the baseline value occurred in 0.7% of patients. Increased CPK resulted in dose interruption for 22%, in dose reduction for 7%, and in discontinuation for 2.9% of patients. Rhabdomyolysis has occurred in a patient with LGSOC treated with AVMAPKI FAKZYNJA CO-PACK at the recommended dosage in a clinical trial. Monitor CPK prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reactions [see Dose Modifications (2.4) ] . 5.5 Embryo-Fetal Toxicity Based on the mechanisms of action, AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . Inhibition of either molecular pathway has been associated with embryo-fetal anomalies and lethality in animals. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose [see Use in Specific Populations (8.3) ] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Ocular Toxicities [see Warnings and Precautions (5.1) ] Serious Skin Toxicities [see Warnings and Precautions (5.2) ] Hepatotoxicity [see Warnings and Precautions (5.3) ] Rhabdomyolysis [see Warnings and Precautions (5.4) ] The most common (\u2265 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Verastem at 1-833-633-8786 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The pooled safety population described in Warnings and Precautions reflect exposure to the AVMAPKI FAKZYNJA CO-PACK (combination of AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity in 136 adult patients with recurrent LGSOC treated on RAMP-201 and FRAME (NCT03875820). The median duration of treatment was 10 months (range 0 to 51 months). RAMP-201 The safety of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201, a single-arm multicenter trial in 57 patients with KRAS- mutated recurrent LGSOC [see Clinical Studies (14) ] . Patients received AVMAPKI FAKZYNJA CO-PACK (AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity. The median duration of treatment was 12 months (range 0.03-40). Serious adverse reactions occurred in 32% of patients who received AVMAPKI FAKZYNJA CO-PACK. The most common (\u22652%) serious adverse reactions were sepsis (9%), intestinal obstruction (3.6%), pyelonephritis (3.6%), and hydronephrosis (3.6%). Fatal adverse reactions occurred in 3.6% of patients who received AVMAPKI FAKZYNJA CO-PACK, including intestinal obstruction (1.8%) and perforation (1.8%). Permanent discontinuation of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 14% of patients. The adverse reactions leading to permanent discontinuation included elevations in creatine phosphokinase, dyspnea, malaise, decreased glomerular filtration rate, hyperbilirubinemia, increased alanine aminotransferase, and abdominal pain (1.8% each). Dosage interruptions of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 84% of patients. Adverse reactions which required dosage interruptions in \u2265 5% of patients included elevations in creatine phosphokinase (25%), hyperbilirubinemia (25%), diarrhea (12%), edema (11%), fatigue (9%), vision blurred (9%), vitreoretinal disorders (7%), transaminitis (7%), paronychia (5%), nausea (5%), abdominal pain (5%), vomiting (5%), dyspnea (5%), sepsis (5%), and rash (5%). Dose reductions of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 44% of patients. Adverse reactions which required dose reductions in \u2265 5% of patients were elevations in creatine phosphokinase (9%), fatigue (5%), hyperbilirubinemia (5%), and dermatitis acneiform (5%). The most common (\u226525%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. Table 3 summarizes the adverse reactions in RAMP-201. Table 3 Adverse Reactions (\u226510%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201 Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Adverse Reaction AVMAPKI FAKZYNJA CO-PACK N = 57 All Grades % Grade 3 or 4 No Grade 4 treatment-emergent adverse events occurred. % Gastrointestinal disorders Nausea 74 1.8 Diarrhea 68 7 Vomiting 49 3.5 Abdominal pain Includes multiple terms 39 1.8 Dyspepsia 37 0 Stomatitis 35 3.5 Constipation 30 0 Dry mouth 18 0 Decreased Weight 11 0 General disorders and administration site condition Fatigue 72 3.5 Edema 67 1.8 Skin and subcutaneous tissue disorders Rash Includes: butterfly rash, dermatitis, drug eruption, erythema, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pruritic 72 3.5 Dermatitis acneiform Includes: acne, dermatitis acneiform, folliculitis, perioral dermatitis, and rash pustular 37 5.3 Pruritus 35 1.8 Dry skin 30 0 Alopecia 23 0 Photosensitivity 16 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain 68 1.8 Joint swelling 11 0 Eye disorders Vitreoretinal disorders Includes: chorioretinopathy, detachment of retinal pigment epithelium, macular fibrosis, macular hole, maculopathy, retinal detachment, retinal drusen, retinal vein occlusion, retinopathy, serous retinal detachment, serous retinopathy, subretinal fluid, vitreous detachment, and vitreous floaters 37 3.5 Visual impairment Includes: asthenopia, astigmatism, halo vision, metamorphopsia, photophobia, photopsia, vision blurred, visual field defect, and visual impairment 35 0 Dry eye 12 0 Respiratory disorders Dyspnea 26 5.3 Cough 25 0 Nervous system disorders Dizziness 23 1.8 Headache 16 0 Neuropathy peripheral 14 0 Dysgeusia 11 0 Vascular disorders Hemorrhage 23 0 Hypertension 16 5.3 Venous thromboembolism 14 5.3 Metabolism and nutrition disorders Decreased appetite 18 1.8 Infections and infestations Urinary tract infection 25 3.5 Paronychia 14 1.8 Upper respiratory tract infection 11 0 Clinically relevant adverse reactions in < 10% of patients who received AVMAPKI FAKZYNJA CO-PACK included urticaria and decreased ejection fraction. Table 4 summarizes the laboratory abnormalities in RAMP-201. Table 4 Select Laboratory Abnormalities (\u2265 10%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201 Laboratory Abnormality AVMAPKI FAKZYNJA CO-PACK All Grades (%) The denominator used to calculate the rate varied from 45 to 57 based on the number of patients with a baseline value and at least one post-treatment value. Grade 3 or 4 (%) Chemistry Increased creatine phosphokinase 82 19 Increased aspartate aminotransferase 70 3.5 Decreased albumin 70 0 Increased alanine aminotransferase 58 3.5 Increased blood bilirubin 48 3.5 Increased triglycerides 46 3.5 Increased alkaline phosphatase 37 1.8 Decreased potassium 23 9 Hematology Decreased hemoglobin 65 5 Decreased lymphocyte count 40 1.8 Decreased platelet count 35 0 Decreased neutrophil count 25 1.8 Urine Proteinuria 22 4.4 Clinically relevant laboratory abnormalities in < 10% of patients who received AVMAPKI FAKZYNJA CO-PACK included increased INR and prolonged activated partial thromboplastin time."
    ],
    "adverse_reactions_table": [
      "<table width=\"85%\"><caption>Table 3 Adverse Reactions (&#x2265;10%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201<footnote>Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</footnote></caption><col width=\"33%\" align=\"left\" valign=\"top\"/><col width=\"34%\" align=\"center\" valign=\"top\"/><col width=\"33%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Adverse Reaction</th><th colspan=\"2\" styleCode=\"Botrule Rrule\">AVMAPKI FAKZYNJA CO-PACK N = 57</th></tr><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">All Grades %</th><th styleCode=\"Rrule\">Grade 3 or 4<footnote>No Grade 4 treatment-emergent adverse events occurred.</footnote> %</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Nausea</td><td styleCode=\"Rrule\">74</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Diarrhea</td><td styleCode=\"Rrule\">68</td><td styleCode=\"Rrule\">7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Vomiting</td><td styleCode=\"Rrule\">49</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Abdominal pain<footnote ID=\"Tb3ft\">Includes multiple terms</footnote></td><td styleCode=\"Rrule\">39</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dyspepsia<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Stomatitis<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">35</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Constipation</td><td styleCode=\"Rrule\">30</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dry mouth</td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased Weight</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">General disorders and administration site condition</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Fatigue<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">72</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Edema<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">67</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Rash<footnote>Includes: butterfly rash, dermatitis, drug eruption, erythema, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pruritic</footnote></td><td styleCode=\"Rrule\">72</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dermatitis acneiform<footnote>Includes: acne, dermatitis acneiform, folliculitis, perioral dermatitis, and rash pustular</footnote></td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">5.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Pruritus<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">35</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dry skin<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">30</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Alopecia<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Photosensitivity<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">16</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Musculoskeletal pain<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">68</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Joint swelling</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Eye disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Vitreoretinal disorders<footnote>Includes: chorioretinopathy, detachment of retinal pigment epithelium, macular fibrosis, macular hole, maculopathy, retinal detachment, retinal drusen, retinal vein occlusion, retinopathy, serous retinal detachment, serous retinopathy, subretinal fluid, vitreous detachment, and vitreous floaters</footnote></td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Visual impairment<footnote>Includes: asthenopia, astigmatism, halo vision, metamorphopsia, photophobia, photopsia, vision blurred, visual field defect, and visual impairment</footnote></td><td styleCode=\"Rrule\">35</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dry eye</td><td styleCode=\"Rrule\">12</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Respiratory disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dyspnea<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">26</td><td styleCode=\"Rrule\">5.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Cough</td><td styleCode=\"Rrule\">25</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dizziness</td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Headache</td><td styleCode=\"Rrule\">16</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Neuropathy peripheral<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Dysgeusia</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Vascular disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hemorrhage<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Hypertension</td><td styleCode=\"Rrule\">16</td><td styleCode=\"Rrule\">5.3</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Venous thromboembolism<footnoteRef IDREF=\"Tb3ft\"/></td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">5.3</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased appetite</td><td styleCode=\"Rrule\">18</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Urinary tract infection</td><td styleCode=\"Rrule\">25</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Paronychia</td><td styleCode=\"Rrule\">14</td><td styleCode=\"Rrule\">1.8</td></tr><tr><td styleCode=\"Lrule Rrule\">Upper respiratory tract infection</td><td styleCode=\"Rrule\">11</td><td styleCode=\"Rrule\">0</td></tr></tbody></table>",
      "<table width=\"75%\"><caption>Table 4 Select Laboratory Abnormalities (&#x2265; 10%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201</caption><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"top\"/><col width=\"35%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\">Laboratory Abnormality</th><th colspan=\"2\" styleCode=\"Botrule Rrule\">AVMAPKI FAKZYNJA CO-PACK</th></tr><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">All Grades (%)<footnote ID=\"Tb4ft\">The denominator used to calculate the rate varied from 45 to 57 based on the number of patients with a baseline value and at least one post-treatment value.</footnote></th><th styleCode=\"Rrule\">Grade 3 or 4  (%)<footnoteRef IDREF=\"Tb4ft\"/></th></tr></thead><tbody><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased creatine phosphokinase</td><td styleCode=\"Rrule\">82</td><td styleCode=\"Rrule\">19</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased aspartate aminotransferase </td><td styleCode=\"Rrule\">70</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased albumin</td><td styleCode=\"Rrule\">70</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased alanine aminotransferase</td><td styleCode=\"Rrule\">58</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased blood bilirubin</td><td styleCode=\"Rrule\">48</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased triglycerides</td><td styleCode=\"Rrule\">46</td><td styleCode=\"Rrule\">3.5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Increased alkaline phosphatase</td><td styleCode=\"Rrule\">37</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased potassium</td><td styleCode=\"Rrule\">23</td><td styleCode=\"Rrule\">9</td></tr><tr styleCode=\"Botrule\"><td colspan=\"3\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Hematology</content></td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased hemoglobin</td><td styleCode=\"Rrule\">65</td><td styleCode=\"Rrule\">5</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased lymphocyte count</td><td styleCode=\"Rrule\">40</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased platelet count</td><td styleCode=\"Rrule\">35</td><td styleCode=\"Rrule\">0</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">Decreased neutrophil count</td><td styleCode=\"Rrule\">25</td><td styleCode=\"Rrule\">1.8</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Urine</content></td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr><tr><td styleCode=\"Lrule Rrule\">Proteinuria</td><td styleCode=\"Rrule\">22</td><td styleCode=\"Rrule\">4.4</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Strong and moderate CYP3A4 inhibitors : Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK. ( 7.1 ) Strong and moderate CYP3A4 inducers : Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK. ( 7.1 ) Warfarin : Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin. ( 7.2 ) Gastric acid reducing agents : Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid. ( 7.1 ) 7.1 Effect of Other Drugs on AVMAPKI FAKZYNJA CO-PACK Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inhibitors. Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inhibitor increases defactinib exposure [see Clinical Pharmacology (12.3) ], which may increase the risk of AVMAPKI FAKZYNJA CO-PACK adverse reactions. Strong and Moderate CYP3A4 Inducers Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inducers. Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inducer decreases defactinib exposure, which may reduce the effectiveness of FAKZYNJA [see Clinical Pharmacology (12.3) ] . Gastric Acid Reducing Agents Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If concomitant use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid. Concomitant use of FAKZYNJA with gastric acid reducing agents decreases defactinib exposure, which may reduce the effectiveness of AVMAPKI FAKZYNJA CO-PACK [see Clinical Pharmacology (12.3) ] . 7.2 Effect of AVMAPKI FAKZYNJA CO-PACK on Other Drugs Warfarin Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin. For patients requiring anticoagulation, an alternative to warfarin is recommended. If concomitant use is unavoidable, monitor INR frequently during treatment with AVMAPKI FAKZYNJA CO-PACK. Cases of bleeding and increased INR occurred in patients taking FAKZYNJA concomitantly with warfarin in clinical trials."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) Infertility : May impair fertility in males and females. ( 8.3 ) 8.1 Pregnancy Risk Summary Based on the mechanisms of action, AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of AVMAPKI FAKZYNJA CO-PACK in pregnant women to inform a drug-associated risk. Animal reproductive and developmental toxicity studies have not been conducted with avutometinib or defactinib; however, inhibition of either molecular pathway has been associated with embryo-fetal anomalies and lethality in animals. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of avutometinib, defactinib, or their metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with AVMAPKI FAKZYNJA CO-PACK and for 2 weeks after the last dose. 8.3 Females and Males of Reproductive Potential AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating treatment with AVMAPKI FAKZYNJA CO-PACK. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose. Males Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose. Infertility Based on animal studies, AVMAPKI FAKZYNJA CO-PACK may impair fertility in females and males of reproductive potential. The effects on fertility were not reversible in animals [see Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use The safety and effectiveness of AVMAPKI FAKZYNJA CO-PACK in pediatric patients has not been established. 8.5 Geriatric Use Of the 136 patients in clinical studies of AVMAPKI FAKZYNJA CO-PACK, 29% were age 65 years or older. No overall differences in safety were observed between patients age 65 years or older and younger patients. Clinical studies of AVMAPKI FAKZYNJA CO-PACK did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on the mechanisms of action, AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on the use of AVMAPKI FAKZYNJA CO-PACK in pregnant women to inform a drug-associated risk. Animal reproductive and developmental toxicity studies have not been conducted with avutometinib or defactinib; however, inhibition of either molecular pathway has been associated with embryo-fetal anomalies and lethality in animals. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and effectiveness of AVMAPKI FAKZYNJA CO-PACK in pediatric patients has not been established."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 136 patients in clinical studies of AVMAPKI FAKZYNJA CO-PACK, 29% were age 65 years or older. No overall differences in safety were observed between patients age 65 years or older and younger patients. Clinical studies of AVMAPKI FAKZYNJA CO-PACK did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients."
    ],
    "description": [
      "11 DESCRIPTION AVMAPKI FAKZYNJA CO-PACK contains AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets. AVMAPKI capsules contain avutometinib, a kinase inhibitor. The chemical name of avutometinib is N-(3-Fluoro-4-{[4-methyl-7-(2-pyrimidinyloxy)-2H-chromen-2-on-3-yl]methyl}-2-pyridyl)-N'-methylsulfamide potassium salt. The molecular formula for avutometinib is C 21 H 17 FN 5 O 5 S (as potassium salt) and its molecular weight is 509.55. The chemical structure of avutometinib is shown below: Avutometinib potassium is a white to pale yellow powder. It is practically insoluble in the pH range of 1 to 7 in aqueous media. The pKa is 7.02. AVMAPKI capsules for oral administration contain 0.8 mg of avutometinib (equivalent to 0.864 mg as the avutometinib potassium salt) with the following inactive ingredients: magnesium stearate and mannitol in a hypromellose capsule shell (carrageenan, hypromellose, potassium chloride, purified water, and titanium oxide) printed with black ink (black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution). FAKZYNJA tablets contain defactinib, a kinase inhibitor. The chemical name of defactinib is N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride. The molecular formula for defactinib is C 20 ClH 22 F 3 N 8 O 3 S (as hydrochloride [HCl] salt) and its molecular weight is 546.96. The chemical structure of defactinib is shown below: Defactinib hydrochloride is a white to pale yellow powder. It is very slightly soluble at pH 1 and practically insoluble in the pH range of 4.5 to 6.8 in aqueous media. The pKa is 3.81. FAKZYNJA tablets are available for oral administration. Each FAKZYNJA tablet contains 200 mg defactinib (equivalent to 214.36 mg as the defactinib hydrochloride salt) and the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. Chemical Structure Chemical Structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Avutometinib Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines harboring KRAS mutations. Treatment of cancer cells with avutometinib increased the level of phosphorylated focal adhesion kinase (FAK). Defactinib Defactinib is an inhibitor of FAK and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. Defactinib inhibited FAK autophosphorylation in cancer cells in vitro and in mouse xenograft models. Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and anti-tumor activity in mouse tumor models including LGSOC. 12.2 Pharmacodynamics Avutometinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. Defactinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. Cardiac Electrophysiology At the recommended doses for AVMAPKI FAKZYNJA CO-PACK, a mean increase in the QTc interval >20 msec was not observed. For the 88 patients with PR interval measured in RAMP-201, the mean PR interval increased by 16 msec from baseline to Cycle 1 Day 15 4-hours post dose. 12.3 Pharmacokinetics The pharmacokinetics of avutometinib and defactinib were studied in healthy subjects and in patients with advanced solid tumors and are presented as mean (%CV) unless otherwise specified. Avutometinib Avutometinib exhibits dose proportional increases peak plasma concentrations (C max ) and area under the concentration time curve (AUC) with a single dose ranging from 0.1 mg to 5 mg (0.03 to 1.6 times the approved recommended dose). No significant accumulation of avutometinib was observed at the recommended dosage. Defactinib Defactinib exhibits dose proportional increases in C max and AUC with twice daily dosing ranging from 12.5 mg to 450 mg (0.06 to 2.25 times the approved recommended dosage). Defactinib steady-state plasma concentrations are reached in approximately 15 days. Defactinib accumulation is approximately 1.5-fold at the approved recommended dosage. Absorption The median time to avutometinib peak plasma concentration (T max ) under fasted conditions is approximately 2 hours. The median time to defactinib T max under fed conditions is approximately 4 hours. Effect of Food No clinically significant differences in avutometinib AUC were observed following administration with a high-fat meal. Avutometinib C max was decreased by 29% following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat). Defactinib AUC increased by 2.7-fold and C max increased by 1.9-fold following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat). Distribution Avutometinib steady state apparent volume of distribution (V d ) is 25 L (19%). Avutometinib human plasma protein binding is 99% in vitro . Defactinib steady state apparent V d is 1,560 L (59%). Defactinib human plasma protein binding is 90% in vitro . Elimination Avutometinib estimated elimination half-life is 51 hours (28%) and the apparent oral clearance (CL/F) is 0.3 L/h (30%). Defactinib estimated elimination half-life is 9 hours (171%) and the CL/F is 69 L/h (173%). Metabolism Avutometinib is primarily metabolized by CYP3A4 and nonenzymatic degradation. Defactinib is metabolized primarily by CYP3A4 and CYP2C9. Two major metabolites, N-desmethyl sulfonamide (M2) and N-desmethyl amide (M4), were identified in plasma. M2 and M4 AUCs represent 92% and 28% of defactinib exposure, respectively. M2 is inactive and M4 is equipotent when compared to defactinib. Excretion After a single dose of radiolabeled avutometinib 2.4 mg (0.8 times the approved recommended dose), 39% (9.5% unchanged) of the dose was recovered in feces and 52% (3.2% unchanged) in urine. After a single dose of radiolabeled defactinib 400 mg (2 times the approved recommended dose), 87% (52% unchanged) of the dose was recovered in feces and 7.6% (0.8% unchanged) in urine. Specific Populations No clinically significant differences in the pharmacokinetics of avutometinib were observed based on age (21 to 87 years), sex, race (84% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min, estimated by Cockcroft-Gault), or mild hepatic impairment (AST > ULN or total bilirubin >1 \u00d7 ULN to 1.5 \u00d7 ULN). The effect of severe renal impairment (CLcr < 30 mL/min) or moderate to severe hepatic impairment (AST or ALT \u2265 2.5 \u00d7 ULN or total bilirubin \u2265 1.5 \u00d7 ULN) on avutometinib pharmacokinetics is unknown. No clinically meaningful differences in the pharmacokinetics of defactinib were observed based on age (21 to 87 years), sex, race (82% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min), or mild hepatic impairment (AST > ULN or total bilirubin >1 \u00d7 ULN to 1.5 \u00d7 ULN). The effect of severe renal impairment (CLcr < 30 mL/min) or moderate to severe hepatic impairment (AST or ALT \u2265 2.5 \u00d7 ULN or total bilirubin \u2265 1.5 \u00d7 ULN) on defactinib pharmacokinetics is unknown. Drug Interaction Studies Clinical Studies Strong CYP3A4 Inhibitors: No clinically significant differences in avutometinib pharmacokinetics were observed when used concomitantly with itraconazole (strong CYP3A4 inhibitor). Defactinib C max increased by 2.2-fold and AUC by 3.9-fold following concomitant use with itraconazole (strong CYP3A4 inhibitor) 200 mg daily for 10 days. M4 AUC increased by 2.2-fold and C max decreased by 6.8%. Strong CYP3A4 Inducers: Avutometinib AUC decreased by 34% with no clinically significant change in C max following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of avutometinib 2.4 mg (0.8 times the approved recommended dose) on Day 17. Defactinib C max decreased by 83% and AUC by 87% following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of defactinib 200 mg (1.0 times the approved recommended dose) on Day 14. M4 AUC decreased by 79% and C max decreased by 70%. Proton Pump Inhibitors (PPIs): Defactinib displayed pH-dependent aqueous solubility [see Description (11) ] . Defactinib AUC decreased by 79% and C max decreased by 85% following concomitant use of multiple doses of omeprazole (PPI) 40 mg daily. M4 AUC decreased by 83% and C max decreased by 88%. In Vitro Studies CYP450 Enzymes: Avutometinib is a CYP3A4 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inhibitor of CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inducer of CYP3A4, CYP2B6, and CYP1A2. Defactinib is a CYP3A4 and CYP2C9 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a reversible inhibitor of CYP3A4 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a time-dependent inhibitor of CYP3A4. Defactinib is an inducer of CYP2B6, and CYP1A2, but not CYP3A4. UGT Enzymes: Defactinib may inhibit UGT1A1 at clinically relevant concentrations. Transporter Systems: Avutometinib is a substrate of P-gp and BCRP, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2. Avutometinib is not an inhibitor of P-gp, BCRP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2. Defactinib is a BCRP and P-gp substrate, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2. Defactinib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, and MATE2-K, but not an inhibitor of MATE1, OAT1, OAT3, OCT1, and OCT2."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Avutometinib Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines harboring KRAS mutations. Treatment of cancer cells with avutometinib increased the level of phosphorylated focal adhesion kinase (FAK). Defactinib Defactinib is an inhibitor of FAK and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. Defactinib inhibited FAK autophosphorylation in cancer cells in vitro and in mouse xenograft models. Avutometinib in combination with defactinib enhanced inhibition of cell proliferation in vitro and anti-tumor activity in mouse tumor models including LGSOC."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics Avutometinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. Defactinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. Cardiac Electrophysiology At the recommended doses for AVMAPKI FAKZYNJA CO-PACK, a mean increase in the QTc interval >20 msec was not observed. For the 88 patients with PR interval measured in RAMP-201, the mean PR interval increased by 16 msec from baseline to Cycle 1 Day 15 4-hours post dose."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The pharmacokinetics of avutometinib and defactinib were studied in healthy subjects and in patients with advanced solid tumors and are presented as mean (%CV) unless otherwise specified. Avutometinib Avutometinib exhibits dose proportional increases peak plasma concentrations (C max ) and area under the concentration time curve (AUC) with a single dose ranging from 0.1 mg to 5 mg (0.03 to 1.6 times the approved recommended dose). No significant accumulation of avutometinib was observed at the recommended dosage. Defactinib Defactinib exhibits dose proportional increases in C max and AUC with twice daily dosing ranging from 12.5 mg to 450 mg (0.06 to 2.25 times the approved recommended dosage). Defactinib steady-state plasma concentrations are reached in approximately 15 days. Defactinib accumulation is approximately 1.5-fold at the approved recommended dosage. Absorption The median time to avutometinib peak plasma concentration (T max ) under fasted conditions is approximately 2 hours. The median time to defactinib T max under fed conditions is approximately 4 hours. Effect of Food No clinically significant differences in avutometinib AUC were observed following administration with a high-fat meal. Avutometinib C max was decreased by 29% following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat). Defactinib AUC increased by 2.7-fold and C max increased by 1.9-fold following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat). Distribution Avutometinib steady state apparent volume of distribution (V d ) is 25 L (19%). Avutometinib human plasma protein binding is 99% in vitro . Defactinib steady state apparent V d is 1,560 L (59%). Defactinib human plasma protein binding is 90% in vitro . Elimination Avutometinib estimated elimination half-life is 51 hours (28%) and the apparent oral clearance (CL/F) is 0.3 L/h (30%). Defactinib estimated elimination half-life is 9 hours (171%) and the CL/F is 69 L/h (173%). Metabolism Avutometinib is primarily metabolized by CYP3A4 and nonenzymatic degradation. Defactinib is metabolized primarily by CYP3A4 and CYP2C9. Two major metabolites, N-desmethyl sulfonamide (M2) and N-desmethyl amide (M4), were identified in plasma. M2 and M4 AUCs represent 92% and 28% of defactinib exposure, respectively. M2 is inactive and M4 is equipotent when compared to defactinib. Excretion After a single dose of radiolabeled avutometinib 2.4 mg (0.8 times the approved recommended dose), 39% (9.5% unchanged) of the dose was recovered in feces and 52% (3.2% unchanged) in urine. After a single dose of radiolabeled defactinib 400 mg (2 times the approved recommended dose), 87% (52% unchanged) of the dose was recovered in feces and 7.6% (0.8% unchanged) in urine. Specific Populations No clinically significant differences in the pharmacokinetics of avutometinib were observed based on age (21 to 87 years), sex, race (84% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min, estimated by Cockcroft-Gault), or mild hepatic impairment (AST > ULN or total bilirubin >1 \u00d7 ULN to 1.5 \u00d7 ULN). The effect of severe renal impairment (CLcr < 30 mL/min) or moderate to severe hepatic impairment (AST or ALT \u2265 2.5 \u00d7 ULN or total bilirubin \u2265 1.5 \u00d7 ULN) on avutometinib pharmacokinetics is unknown. No clinically meaningful differences in the pharmacokinetics of defactinib were observed based on age (21 to 87 years), sex, race (82% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min), or mild hepatic impairment (AST > ULN or total bilirubin >1 \u00d7 ULN to 1.5 \u00d7 ULN). The effect of severe renal impairment (CLcr < 30 mL/min) or moderate to severe hepatic impairment (AST or ALT \u2265 2.5 \u00d7 ULN or total bilirubin \u2265 1.5 \u00d7 ULN) on defactinib pharmacokinetics is unknown. Drug Interaction Studies Clinical Studies Strong CYP3A4 Inhibitors: No clinically significant differences in avutometinib pharmacokinetics were observed when used concomitantly with itraconazole (strong CYP3A4 inhibitor). Defactinib C max increased by 2.2-fold and AUC by 3.9-fold following concomitant use with itraconazole (strong CYP3A4 inhibitor) 200 mg daily for 10 days. M4 AUC increased by 2.2-fold and C max decreased by 6.8%. Strong CYP3A4 Inducers: Avutometinib AUC decreased by 34% with no clinically significant change in C max following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of avutometinib 2.4 mg (0.8 times the approved recommended dose) on Day 17. Defactinib C max decreased by 83% and AUC by 87% following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of defactinib 200 mg (1.0 times the approved recommended dose) on Day 14. M4 AUC decreased by 79% and C max decreased by 70%. Proton Pump Inhibitors (PPIs): Defactinib displayed pH-dependent aqueous solubility [see Description (11) ] . Defactinib AUC decreased by 79% and C max decreased by 85% following concomitant use of multiple doses of omeprazole (PPI) 40 mg daily. M4 AUC decreased by 83% and C max decreased by 88%. In Vitro Studies CYP450 Enzymes: Avutometinib is a CYP3A4 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inhibitor of CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inducer of CYP3A4, CYP2B6, and CYP1A2. Defactinib is a CYP3A4 and CYP2C9 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a reversible inhibitor of CYP3A4 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a time-dependent inhibitor of CYP3A4. Defactinib is an inducer of CYP2B6, and CYP1A2, but not CYP3A4. UGT Enzymes: Defactinib may inhibit UGT1A1 at clinically relevant concentrations. Transporter Systems: Avutometinib is a substrate of P-gp and BCRP, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2. Avutometinib is not an inhibitor of P-gp, BCRP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2. Defactinib is a BCRP and P-gp substrate, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2. Defactinib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, and MATE2-K, but not an inhibitor of MATE1, OAT1, OAT3, OCT1, and OCT2."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Avutometinib Carcinogenesis Carcinogenicity studies have not been conducted with avutometinib. Mutagenesis Avutometinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an in vitro Chinese hamster lung chromosome aberration assay or an in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with avutometinib. In repeat dose toxicity studies, avutometinib was administered orally once daily for up to 13-weeks duration in rats and monkeys. In female rats, atrophy of the ovary was observed at doses \u2265 0.04 mg/kg/day (approximately \u2265 0.25 times the human exposure at the recommended dose based on AUC). Atrophy of the uterus and thinning of the mucosa and increased single cell necrosis of the mucosal epithelium in the vagina were observed at 0.16 mg/kg/day (0.5 times the human exposure at the recommended dose based on AUC). In female monkeys, thinning of the vaginal mucosa was observed at doses \u2265 0.02 mg/kg/day (\u2265 0.7 times the human exposure at the recommended dose based on AUC). All findings were reversible. Defactinib Carcinogenesis Carcinogenicity studies have not been conducted with defactinib. Mutagenesis Defactinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an in vitro Chinese hamster lung cell chromosome aberration assay. Defactinib was positive in the in vitro micronucleus assay through an aneugenic mechanism and in the in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with defactinib. In male rats administered defactinib for up to 13 weeks, small prostate, seminal vesicle, and testes, decreased prostate weight, diffuse tubule degeneration/atrophy of the testes and sperm granuloma of the epididymis were observed at doses \u2265 125 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes were observed. In male dogs administered defactinib for up to 13 weeks, increased prostate and testes weights and testicular degeneration and cellular debris in the epididymis were observed at doses \u2265 1 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes and epididymis that included cellular debris, duct dilation, and hypospermia were observed. 13.2 Animal Toxicology and/or Pharmacology Avutometinib In repeat-dose toxicity studies up to 13-weeks duration in rats and monkeys, tissue mineralization in multiple organs was observed at doses \u2265 0.01 mg/kg/day and 0.03 mg/kg/day, respectively (\u2265 0.06 and 1.4 times the human exposure at the recommended dose based on AUC, respectively) as well as increased inorganic phosphorus in rats. In a cardiovascular telemetry study in monkeys, a single oral dose of avutometinib increased systolic, diastolic, and mean blood pressure at 1 mg/kg (approximately 15 times the human C max at the recommended dose). In the repeat-dose toxicology studies up to 13-weeks duration in rats, myocardial degeneration and necrosis were observed at doses \u2265 0.01 mg/kg/day (below the human exposure at the recommended dose based on AUC). Defactinib In a cardiovascular telemetry study in dogs, a single oral dose of defactinib decreased myocardial contractility at doses \u2265 5 mg/kg (approximately the human exposure at the recommended dose based on AUC) and increased ventricular systolic, diastolic and mean blood pressure at doses \u2265 25 mg/kg/day (\u2265 2.7 times the human exposure at the recommended dose based on AUC). In the 13-week repeat-dose toxicology study in dogs, myocardium hypertrophy was observed at doses \u2265 1 mg/kg/day (below the human exposure at the recommended dose based on AUC) at the end of the dosing and recovery periods."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Avutometinib Carcinogenesis Carcinogenicity studies have not been conducted with avutometinib. Mutagenesis Avutometinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an in vitro Chinese hamster lung chromosome aberration assay or an in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with avutometinib. In repeat dose toxicity studies, avutometinib was administered orally once daily for up to 13-weeks duration in rats and monkeys. In female rats, atrophy of the ovary was observed at doses \u2265 0.04 mg/kg/day (approximately \u2265 0.25 times the human exposure at the recommended dose based on AUC). Atrophy of the uterus and thinning of the mucosa and increased single cell necrosis of the mucosal epithelium in the vagina were observed at 0.16 mg/kg/day (0.5 times the human exposure at the recommended dose based on AUC). In female monkeys, thinning of the vaginal mucosa was observed at doses \u2265 0.02 mg/kg/day (\u2265 0.7 times the human exposure at the recommended dose based on AUC). All findings were reversible. Defactinib Carcinogenesis Carcinogenicity studies have not been conducted with defactinib. Mutagenesis Defactinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an in vitro Chinese hamster lung cell chromosome aberration assay. Defactinib was positive in the in vitro micronucleus assay through an aneugenic mechanism and in the in vivo rat bone marrow micronucleus assay. Impairment of Fertility Dedicated fertility studies have not been conducted with defactinib. In male rats administered defactinib for up to 13 weeks, small prostate, seminal vesicle, and testes, decreased prostate weight, diffuse tubule degeneration/atrophy of the testes and sperm granuloma of the epididymis were observed at doses \u2265 125 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes were observed. In male dogs administered defactinib for up to 13 weeks, increased prostate and testes weights and testicular degeneration and cellular debris in the epididymis were observed at doses \u2265 1 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes and epididymis that included cellular debris, duct dilation, and hypospermia were observed."
    ],
    "animal_pharmacology_and_or_toxicology": [
      "13.2 Animal Toxicology and/or Pharmacology Avutometinib In repeat-dose toxicity studies up to 13-weeks duration in rats and monkeys, tissue mineralization in multiple organs was observed at doses \u2265 0.01 mg/kg/day and 0.03 mg/kg/day, respectively (\u2265 0.06 and 1.4 times the human exposure at the recommended dose based on AUC, respectively) as well as increased inorganic phosphorus in rats. In a cardiovascular telemetry study in monkeys, a single oral dose of avutometinib increased systolic, diastolic, and mean blood pressure at 1 mg/kg (approximately 15 times the human C max at the recommended dose). In the repeat-dose toxicology studies up to 13-weeks duration in rats, myocardial degeneration and necrosis were observed at doses \u2265 0.01 mg/kg/day (below the human exposure at the recommended dose based on AUC). Defactinib In a cardiovascular telemetry study in dogs, a single oral dose of defactinib decreased myocardial contractility at doses \u2265 5 mg/kg (approximately the human exposure at the recommended dose based on AUC) and increased ventricular systolic, diastolic and mean blood pressure at doses \u2265 25 mg/kg/day (\u2265 2.7 times the human exposure at the recommended dose based on AUC). In the 13-week repeat-dose toxicology study in dogs, myocardium hypertrophy was observed at doses \u2265 1 mg/kg/day (below the human exposure at the recommended dose based on AUC) at the end of the dosing and recovery periods."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES The efficacy of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS -mutated recurrent LGSOC. Patients were required to have received at least one prior systemic therapy, including a platinum-based regimen. KRAS mutation status was determined by prospective local testing using next generation sequencing (NGS) or polymerase chain reaction of tumor tissue specimens. Patients were excluded if they were candidates for debulking surgery, were on treatment with warfarin, had an active skin disorder requiring systemic therapy within the past year, or had an ocular disorder (including a history of retinal pathology, an active or chronic visually significant corneal disorder, or a history of glaucoma). Patients received AVMAPKI 3.2 mg orally twice weekly for the first 3 weeks out of a 4-week cycle and FAKZYNJA 200 mg orally twice daily for the first 3 weeks out of a 4-week cycle until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR) assessed by blinded independent review committee (BIRC) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. An additional efficacy outcome measure was duration of response (DoR). Tumor response assessments occurred every 8 weeks for the first 72 weeks and every 12 weeks thereafter. The median age was 60 years (range: 29 to 87); 75% were White, 3.5% were Asian, 3.5% were Black or African American, and 18% did not have race reported; 3.5% of patients were Hispanic or Latino; 72% had an ECOG PS of 0 and 28% had ECOG PS of 1. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). Fourteen percent of patients had received 1 prior line of systemic therapy, 25% of patients had received 2 prior lines, 18% had received 3 prior lines and 40% had received more than 3 prior lines of systemic therapy. All patients had received prior platinum-based chemotherapy, 84% received prior hormonal therapy (as maintenance or treatment), 40% received prior bevacizumab and 21% received a prior MEK inhibitor. Efficacy results are presented in Table 5. Table 5 Efficacy Results in RAMP-201 AVMAPKI FAKZYNJA CO-PACK N = 57 Confirmed Overall Response Rate (95% CI) ORR 95% CI calculated using Clopper-Pearson method 44% (31,58) Complete response 3.5% Partial response 40% Duration of Response (DoR) Range (months) 3.3, 31.1 The tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H."
    ],
    "clinical_studies_table": [
      "<table width=\"85%\"><caption>Table 5 Efficacy Results in RAMP-201</caption><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"center\" valign=\"top\"/><thead><tr><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">AVMAPKI FAKZYNJA CO-PACK N = 57</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Confirmed Overall Response Rate (95% CI)</content><footnote>ORR 95% CI calculated using Clopper-Pearson method</footnote></td><td styleCode=\"Rrule\">44% (31,58)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Complete response</td><td styleCode=\"Rrule\">3.5%</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"> Partial response</td><td styleCode=\"Rrule\">40%</td></tr><tr styleCode=\"Botrule\"><td colspan=\"2\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Duration of Response (DoR)</content></td></tr><tr><td styleCode=\"Lrule Rrule\"> Range (months)</td><td styleCode=\"Rrule\">3.3, 31.1</td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING AVMAPKI FAKZYNJA CO-PACK is supplied in a carton that contains: AVMAPKI capsules in a 24-count bottle with child-resistant closure (NDC 71779-660-02) NDC 71779-623-01 FAKZYNJA tablets in a 42-count bottle with child-resistant closure (NDC 71779-630-01) AVMAPKI (avutometinib) 0.8 mg capsules are supplied as white capsules with \"6766\" printed on the cap and the strength \"0.8 mg\" printed on the body in black ink in a bottle containing 24 capsules. The bottle contains a desiccant that should not be discarded. FAKZYNJA (defactinib) 200 mg tablets are supplied as white to off-white, oval and debossed with \"VS2\" on one side of the tablet in a bottle containing 42 tablets. Store AVMAPKI capsules and FAKZYNJA tablets refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in their original bottles."
    ],
    "how_supplied_table": [
      "<table width=\"85%\"><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"left\" valign=\"top\"/><tbody><tr><td styleCode=\"Lrule Rrule Botrule\">AVMAPKI capsules in a 24-count bottle with child-resistant closure (NDC 71779-660-02)</td><td styleCode=\"Rrule\">NDC 71779-623-01</td></tr><tr><td styleCode=\"Lrule Rrule\">FAKZYNJA tablets in a 42-count bottle with child-resistant closure (NDC 71779-630-01)</td><td styleCode=\"Rrule\"/></tr></tbody></table>"
    ],
    "storage_and_handling": [
      "Store AVMAPKI capsules and FAKZYNJA tablets refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in their original bottles."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Ocular Toxicities Inform patients of the need for eye exams before and during treatment with AVMAPKI FAKZYNJA CO-PACK. Advise patients to contact their healthcare provider if they experience any visual changes, pain, or inflammation around their eye(s) [see Warnings and Precautions (5.1) ] . Serious Skin Toxicities Inform patients that skin reactions have occurred during treatment with AVMAPKI FAKZYNJA CO-PACK. Advise patients to use prophylactic topical steroids and oral antibiotics [see Dosage and Administration (2.2) ] and to limit unnecessary exposure to sunlight with application of daily sunscreen (sun protection factor [SPF] \u2265 30) [see Warnings and Precautions (5.2) ] . Advise patients to contact their healthcare provider if they develop a rash, progressively worsening skin reactions, or blistering of the skin or mouth [see Warnings and Precautions (5.2) ] . Hepatotoxicity Advise patients that they will need to undergo laboratory testing to monitor their liver function. Advise patients to contact their healthcare provider for signs or symptoms of liver dysfunction [see Warnings and Precautions (5.3) ]. Rhabdomyolysis Inform patients that they will need to undergo laboratory testing to monitor CPK levels. Advise patients to contact their healthcare provider for signs or symptoms of rhabdomyolysis [see Warnings and Precautions (5.4) ]. Drug Interactions Inform patients to avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with PPIs or H2 receptor antagonists. Advise patients that if use of an acid reducing agent cannot be avoided, to take FAKZYNJA 2 hours prior to, or 2 hours after, the administration of a locally acting antacid [see Drug Interactions (7.1) ] . Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare providers of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose [see Warnings and Precautions (5.5) and Use in Specific Population (8.1 , 8.3) ] . Lactation Advise women not to breastfeed during treatment with AVMAPKI FAKZYNJA CO-PACK and for 2 weeks after the last dose [see Use in Specific Populations (8.2) ] . Infertility Advise males and females of reproductive potential that AVMAPKI FAKZYNJA CO-PACK may impair fertility [see Use in Specific Populations (8.3) ] ."
    ],
    "spl_unclassified_section": [
      "Manufactured for and Distributed by: Verastem, Inc. Needham, Massachusetts 02494 1-877-878-6662 \u00a9 2025 Verastem, Inc."
    ],
    "spl_patient_package_insert": [
      "PATIENT INFORMATION AVMAPKI\u2122 FAKZYNJA\u2122 CO-PACK (ave-MAP-kee Fak-zin-jah koh-pak) (avutometinib capsules; defactinib tablets) co-packaged for oral use This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 05/2025 What is AVMAPKI FAKZYNJA CO-PACK? AVMAPKI FAKZYNJA CO-PACK is a prescription medicine used to treat adults who have: low-grade serous ovarian cancer (LGSOC) that has come back (recurrent), and LGSOC with an abnormal KRAS gene, and previously been treated with medicine for their cancer. It is not known if AVMAPKI FAKZYNJA CO-PACK is safe and effective in children. Before taking AVMAPKI FAKZYNJA CO-PACK, tell your healthcare provider about all of your medical conditions, including if you: have a history of eye or vision problems have had severe skin reactions have liver problems are pregnant or plan to become pregnant. AVMAPKI FAKZYNJA CO-PACK can harm your unborn baby. Females who are able to become pregnant : Your healthcare provider should do a pregnancy test before you start treatment with AVMAPKI FAKZYNJA CO- PACK. You should use effective birth control (contraception) during treatment and for 1 month after the last dose of AVMAPKI FAKZYNJA CO-PACK. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with AVMAPKI FAKZYNJA CO-PACK. Males with a female partner who is able to become pregnant : You should use effective birth control (contraception) during treatment and for 4 months after the last dose of AVMAPKI FAKZYNJA CO-PACK. are breastfeeding or plan to breastfeed. It is not known if AVMAPKI FAKZYNJA CO-PACK passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of AVMAPKI FAKZYNJA CO-PACK. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. AVMAPKI FAKZYNJA CO-PACK may affect the way other medicines work, and other medicines may affect how AVMAPKI FAKZYNJA CO-PACK works. Especially tell your healthcare provider if you take : proton pump inhibitors (PPIs) or H2 receptor antagonists a blood thinner called warfarin Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine. How should I take AVMAPKI FAKZYNJA CO-PACK? Take AVMAPKI FAKZYNJA CO-PACK exactly as directed by your healthcare provider. Do not change your dose or stop taking AVMAPKI FAKZYNJA CO-PACK without talking to your healthcare provider. If you develop certain side effects your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with AVMAPKI FAKZYNJA CO-PACK. Take AVMAPKI capsules and FAKZYNJA tablets with food. If you vomit after taking AVMAPKI capsules or FAKZYNJA tablets, do not take an additional dose. Take the next scheduled dose as prescribed by your healthcare provider. AVMAPKI capsules : Take each dose at the same time. Swallow the capsules whole. Do not chew, break, or open the capsules. If you miss a dose of AVMAPKI by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose. FAKZYNJA tablets: Swallow the tablets whole. Do not chew, break, or crush the tablets. If you take antacids, take FAKZYNJA tablets 2 hours before or 2 hours after taking the antacid. If you miss a dose of FAKZYNJA by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose. Before and during treatment with AVMAPKI FAKZYNJA CO-PACK, your health care provider will give you medicines to apply to your face, scalp, neck, upper chest and upper back, and antibiotic medicines to take by mouth to help prevent skin reactions. What should I avoid while taking AVMAPKI FAKZYNJA CO-PACK? Limit your time in the sun. AVMAPKI FAKZYNJA CO-PACK can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You may burn more easily and get a severe sunburn. Apply daily sunscreen with a Sun Protection Factor (SPF) of 30 or greater and wear a hat and clothes that cover your skin to protect against sunburn. Talk to your healthcare provider if you get a sunburn. What are the possible side effects of AVMAPKI FAKZYNJA CO-PACK? AVMAPKI FAKZYNJA CO-PACK may cause serious side effects, including: eye problems. Eye problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Your healthcare provider will send you to see an eye care professional before starting treatment, during treatment, and for any new or worsening eye problems. Tell your healthcare provider if you get any new or worsening eye problems including: changes in vision, such as blurred vision, double vision, or vision loss dry eye(s) eye and eyelid inflammation, including redness, swelling, and itching eye pain new or increased floaters (small dark spots or squiggly lines that float across your vision) light hurting eyes or seeing flashes of light severe skin reactions . Skin reactions are common with AVMAPKI FAKZYNJA CO-PACK and can be severe or life threatening. Tell your healthcare provider if you develop any new or worsening skin reactions including: skin rash or acne dry skin itching blisters on your skin redness or swelling of your face, hands, or soles of your feet blisters or sores in your mouth peeling of your skin skin infection liver problems. Liver problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of aspartate aminotransferase, alanine aminotransferase, and bilirubin in your blood. Your healthcare provider will do blood tests before starting each treatment cycle and during treatment to check your liver function. Tell your healthcare provider if you get any signs or symptoms of severe liver problems including: yellowing of your skin or the white part of your eyes itchy skin feeling very tired flu-like symptoms nausea or vomiting upper right side stomach pain dark or tea colored urine bleeding or bruising more easily than normal muscle problems (rhabdomyolysis). AVMAPKI FAKZYNJA CO-PACK may cause muscle problems that can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider will perform blood tests to check your levels of CPK before starting each treatment cycle and during treatment. Tell your healthcare provider if you get any signs or symptoms of increased CPK including: weakness or difficulty moving arms and legs muscle or bone aches or pain that does not go away dark, red colored urine or decreased urine output The most common side effects of AVMAPKI FAKZYNJA CO-PACK include : nausea tiredness increased aspartate aminotransferase diarrhea swelling in the body (edema) decreased hemoglobin increased alanine aminotransferase vomiting increased blood bilirubin increased triglycerides stomach-area pain acid reflux increased alkaline phosphatase decreased platelets constipation shortness of breath cough urinary tract infection decreased lymphocytes decreased neutrophils proteinuria AVMAPKI FAKZYNJA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of AVMAPKI FAKZYNJA CO-PACK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store AVMAPKI FAKZYNJA CO-PACK? Store AVMAPKI capsules and FAKZYNJA tablets in the refrigerator between 36\u00b0F to 46\u00b0F (2\u00b0C to 8\u00b0C) in the original bottles. The AVMAPKI capsules and FAKZYNJA tablets come in child-resistant bottles. Keep AVMAPKI FAKZYNJA CO-PACK and all medicines out of the reach of children. General information about the safe and effective use of AVMAPKI FAKZYNJA CO-PACK. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AVMAPKI FAKZYNJA CO-PACK for a condition for which it was not prescribed. Do not give AVMAPKI FAKZYNJA CO- PACK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about AVMAPKI FAKZYNJA CO-PACK that is written for health professionals. What are the ingredients in AVMAPKI FAKZYNJA CO-PACK? AVMAPKI (avutometinib) capsules: Active ingredient : avutometinib Inactive ingredients : magnesium stearate, mannitol, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution. The capsule shell contains carrageenan, hypromellose, potassium chloride, purified water, and titanium oxide. FAKZYNJA (defactinib) tablets: Active ingredient : defactinib Inactive ingredients : lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Manufactured for and Distributed by: Verastem, Inc., Needham, Massachusetts 02494 \u00a9 2025 Verastem, Inc. For more information, go to www.AvmapkiFakzynjaCo-Pack.com or call 1-877-878-6662."
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"3%\" align=\"left\" valign=\"top\"/><col width=\"22%\" align=\"left\" valign=\"top\"/><col width=\"5%\" align=\"left\" valign=\"top\"/><col width=\"15%\" align=\"left\" valign=\"top\"/><col width=\"2%\" align=\"left\" valign=\"top\"/><col width=\"3%\" align=\"left\" valign=\"top\"/><col width=\"5%\" align=\"left\" valign=\"top\"/><col width=\"5%\" align=\"left\" valign=\"top\"/><col width=\"10%\" align=\"left\" valign=\"top\"/><col width=\"30%\" align=\"left\" valign=\"top\"/><thead><tr><th colspan=\"10\" align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\">PATIENT INFORMATION AVMAPKI&#x2122; FAKZYNJA&#x2122; CO-PACK (ave-MAP-kee Fak-zin-jah koh-pak) (avutometinib capsules; defactinib tablets) co-packaged for oral use</th></tr></thead><tfoot><tr><td colspan=\"9\" align=\"left\" valign=\"top\"> This Patient Information has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\" valign=\"top\">Issued: 05/2025 </td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr></tfoot><tbody><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What is AVMAPKI FAKZYNJA CO-PACK?</content> AVMAPKI FAKZYNJA CO-PACK is a prescription medicine used to treat adults who have: <list listType=\"unordered\" styleCode=\"disc\"><item>low-grade serous ovarian cancer (LGSOC) that has come back (recurrent), <content styleCode=\"bold\">and</content></item><item>LGSOC with an abnormal <content styleCode=\"italics\">KRAS</content> gene, <content styleCode=\"bold\">and</content></item><item>previously been treated with medicine for their cancer.</item></list> It is not known if AVMAPKI FAKZYNJA CO-PACK is safe and effective in children. </td></tr><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Before taking AVMAPKI FAKZYNJA CO-PACK, tell your healthcare provider about all of your medical conditions, including if you:</content><list listType=\"unordered\" styleCode=\"disc\"><item>have a history of eye or vision problems</item><item>have had severe skin reactions</item><item>have liver problems</item><item>are pregnant or plan to become pregnant. AVMAPKI FAKZYNJA CO-PACK can harm your unborn baby. <content styleCode=\"bold\">Females who are able to become pregnant</content>:<list listType=\"unordered\" styleCode=\"circle\"><item>Your healthcare provider should do a pregnancy test before you start treatment with AVMAPKI FAKZYNJA CO- PACK.</item><item>You should use effective birth control (contraception) during treatment and for 1 month after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item><item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with AVMAPKI FAKZYNJA CO-PACK.</item></list><content styleCode=\"bold\">Males with a female partner who is able to become pregnant</content>:<list listType=\"unordered\" styleCode=\"circle\"><item>You should use effective birth control (contraception) during treatment and for 4 months after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item></list></item><item>are breastfeeding or plan to breastfeed. It is not known if AVMAPKI FAKZYNJA CO-PACK passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. AVMAPKI FAKZYNJA CO-PACK may affect the way other medicines work, and other medicines may affect how AVMAPKI FAKZYNJA CO-PACK works. <content styleCode=\"bold\">Especially tell your healthcare provider if you take</content>: <list listType=\"unordered\" styleCode=\"disc\"><item>proton pump inhibitors (PPIs) or H2 receptor antagonists</item><item>a blood thinner called warfarin</item></list> Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine. <content styleCode=\"bold\">How should I take AVMAPKI FAKZYNJA CO-PACK?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Take AVMAPKI FAKZYNJA CO-PACK exactly as directed by your healthcare provider.</item><item>Do not change your dose or stop taking AVMAPKI FAKZYNJA CO-PACK without talking to your healthcare provider.</item><item>If you develop certain side effects your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with AVMAPKI FAKZYNJA CO-PACK.</item></list> Take AVMAPKI capsules and FAKZYNJA tablets with food. <list listType=\"unordered\" styleCode=\"disc\"><item>If you vomit after taking AVMAPKI capsules or FAKZYNJA tablets, do not take an additional dose. Take the next scheduled dose as prescribed by your healthcare provider.</item></list><content styleCode=\"bold\">AVMAPKI capsules</content>: <list listType=\"unordered\" styleCode=\"disc\"><item>Take each dose at the same time.</item><item>Swallow the capsules whole. Do not chew, break, or open the capsules.</item><item>If you miss a dose of AVMAPKI by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose.</item></list><content styleCode=\"bold\">FAKZYNJA tablets:</content><list listType=\"unordered\" styleCode=\"disc\"><item>Swallow the tablets whole. Do not chew, break, or crush the tablets.</item><item>If you take antacids, take FAKZYNJA tablets 2 hours before or 2 hours after taking the antacid.</item><item>If you miss a dose of FAKZYNJA by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose.</item></list> Before and during treatment with AVMAPKI FAKZYNJA CO-PACK, your health care provider will give you medicines to apply to your face, scalp, neck, upper chest and upper back, and antibiotic medicines to take by mouth to help prevent skin reactions. </td></tr><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What should I avoid while taking AVMAPKI FAKZYNJA CO-PACK?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Limit your time in the sun. AVMAPKI FAKZYNJA CO-PACK can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You may burn more easily and get a severe sunburn. Apply daily sunscreen with a Sun Protection Factor (SPF) of 30 or greater and wear a hat and clothes that cover your skin to protect against sunburn. Talk to your healthcare provider if you get a sunburn.</item></list></td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the possible side effects of AVMAPKI FAKZYNJA CO-PACK? AVMAPKI FAKZYNJA CO-PACK may cause serious side effects, including:</content><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">eye problems.</content> Eye problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Your healthcare provider will send you to see an eye care professional before starting treatment, during treatment, and for any new or worsening eye problems. Tell your healthcare provider if you get any new or worsening eye problems including:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td colspan=\"3\"><list listType=\"unordered\" styleCode=\"circle\"><item>changes in vision, such as blurred vision, double vision, or vision loss</item><item>dry eye(s)</item><item>eye and eyelid inflammation, including redness, swelling, and itching</item></list></td><td colspan=\"6\" styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>eye pain</item><item>new or increased floaters (small dark spots or squiggly lines that float across your vision)</item><item>light hurting eyes or seeing flashes of light</item></list></td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">severe skin reactions</content>. Skin reactions are common with AVMAPKI FAKZYNJA CO-PACK and can be severe or life threatening. Tell your healthcare provider if you develop any new or worsening skin reactions including:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td><list listType=\"unordered\" styleCode=\"circle\"><item>skin rash or acne</item><item>dry skin</item><item>itching</item></list></td><td colspan=\"5\"><list listType=\"unordered\" styleCode=\"circle\"><item>blisters on your skin</item><item>redness or swelling of your face, hands, or soles of your feet</item></list></td><td colspan=\"3\" styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>blisters or sores in your mouth</item><item>peeling of your skin</item><item>skin infection</item></list></td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">liver problems.</content> Liver problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of aspartate aminotransferase, alanine aminotransferase, and bilirubin in your blood. Your healthcare provider will do blood tests before starting each treatment cycle and during treatment to check your liver function. Tell your healthcare provider if you get any signs or symptoms of severe liver problems including:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td colspan=\"5\"><list listType=\"unordered\" styleCode=\"circle\"><item>yellowing of your skin or the white part of your eyes</item><item>itchy skin</item><item>feeling very tired</item><item>flu-like symptoms</item></list></td><td colspan=\"4\" styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>nausea or vomiting</item><item>upper right side stomach pain</item><item>dark or tea colored urine</item><item>bleeding or bruising more easily than normal</item></list></td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item><content styleCode=\"bold\">muscle problems (rhabdomyolysis).</content> AVMAPKI FAKZYNJA CO-PACK may cause muscle problems that can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider will perform blood tests to check your levels of CPK before starting each treatment cycle and during treatment. Tell your healthcare provider if you get any signs or symptoms of increased CPK including:</item></list></td></tr><tr><td styleCode=\"Lrule\"/><td colspan=\"2\"><list listType=\"unordered\" styleCode=\"circle\"><item>weakness or difficulty moving arms and legs</item></list></td><td colspan=\"5\"><list listType=\"unordered\" styleCode=\"circle\"><item>muscle or bone aches or pain that does not go away</item></list></td><td colspan=\"2\" styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"circle\"><item>dark, red colored urine or decreased urine output</item></list></td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">The most common side effects of AVMAPKI FAKZYNJA CO-PACK include</content>:</td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"><list listType=\"unordered\" styleCode=\"disc\"><item>nausea</item><item>tiredness</item><item>increased aspartate aminotransferase</item><item>diarrhea</item><item>swelling in the body (edema)</item></list></td><td colspan=\"3\"><list listType=\"unordered\" styleCode=\"disc\"><item>decreased hemoglobin</item><item>increased alanine aminotransferase</item><item>vomiting</item><item>increased blood bilirubin</item><item>increased triglycerides</item></list></td><td colspan=\"4\"><list listType=\"unordered\" styleCode=\"disc\"><item>stomach-area pain</item><item>acid reflux</item><item>increased alkaline phosphatase</item><item>decreased platelets</item><item>constipation</item><item>shortness of breath</item></list></td><td styleCode=\"Rrule\"><list listType=\"unordered\" styleCode=\"disc\"><item>cough</item><item>urinary tract infection</item><item>decreased lymphocytes</item><item>decreased neutrophils</item><item>proteinuria</item></list></td></tr><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\">AVMAPKI FAKZYNJA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of AVMAPKI FAKZYNJA CO-PACK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">How should I store AVMAPKI FAKZYNJA CO-PACK?</content><list listType=\"unordered\" styleCode=\"disc\"><item>Store AVMAPKI capsules and FAKZYNJA tablets in the refrigerator between 36&#xB0;F to 46&#xB0;F (2&#xB0;C to 8&#xB0;C) in the original bottles.</item><item>The AVMAPKI capsules and FAKZYNJA tablets come in child-resistant bottles.</item></list><content styleCode=\"bold\">Keep AVMAPKI FAKZYNJA CO-PACK and all medicines out of the reach of children.</content></td></tr><tr styleCode=\"Botrule\"><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">General information about the safe and effective use of AVMAPKI FAKZYNJA CO-PACK.</content> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AVMAPKI FAKZYNJA CO-PACK for a condition for which it was not prescribed. Do not give AVMAPKI FAKZYNJA CO- PACK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about AVMAPKI FAKZYNJA CO-PACK that is written for health professionals.</td></tr><tr><td colspan=\"10\" styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">What are the ingredients in AVMAPKI FAKZYNJA CO-PACK?</content> <content styleCode=\"bold\">AVMAPKI (avutometinib) capsules: Active ingredient</content>: avutometinib <content styleCode=\"bold\">Inactive ingredients</content>: magnesium stearate, mannitol, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution. The capsule shell contains carrageenan, hypromellose, potassium chloride, purified water, and titanium oxide. <content styleCode=\"bold\">FAKZYNJA (defactinib) tablets:</content> <content styleCode=\"bold\">Active ingredient</content>: defactinib <content styleCode=\"bold\">Inactive ingredients</content>: lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Manufactured for and Distributed by: Verastem, Inc., Needham, Massachusetts 02494 &#xA9; 2025 Verastem, Inc. For more information, go to www.AvmapkiFakzynjaCo-Pack.com or call 1-877-878-6662.</td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL - Kit Carton NDC 71779-623-01 Rx only AVMAPKI\u2122 (avutometinib) capsules 0.8 mg FAKZYNJA\u2122 (defactinib) tablets 200 mg CO-PACK This carton contains: AVMAPKI\u2122 (avutometinib): 1 bottle of 24 capsules FAKZYNJA\u2122 (defactinib): 1 bottle of 42 tablets Prescribing Information Patient Dosing Card KEEP REFRIGERATED VERASTEM\u2122 ONCOLOGY PRINCIPAL DISPLAY PANEL - Kit Carton",
      "PRINCIPAL DISPLAY PANEL - 0.8 mg Capsule Bottle Label NDC 71779-660-02 Rx only AVMAPKI\u2122 (avutometinib) capsules 0.8 mg KEEP REFRIGERATED 24 capsules 773622 Recommended Dosage: See printed Prescribing Information inside the carton. Manufactured for: Verastem, Inc. Needham, MA 02494 USA For information, call toll-free 1-877-878-6662 or visit us at www.AvmapkiFakzynjaCo-Pack.com VERASTEM\u2122 ONCOLOGY \u00a9 2025 Verastem, Inc. PRINCIPAL DISPLAY PANEL - 0.8 mg Capsule Bottle Label",
      "PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label NDC 71779-630-01 Rx only FAKZYNJA\u2122 (defactinib) tablets 200 mg KEEP REFRIGERATED 42 tablets VERASTEM\u2122 ONCOLOGY Recommended Dosage: See printed Prescribing Information inside the carton. Manufactured for: Verastem, Inc. Needham, MA 02494 USA For information, call toll-free 1-877-878-6662 or visit us at www.AvmapkiFakzynjaCo-Pack.com \u00a9 2025 Verastem, Inc. 773624 PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label"
    ],
    "set_id": "65889527-1406-45df-8a85-e2690dcf427d",
    "id": "e6def323-179c-432e-957d-fc4ea03e1b78",
    "effective_time": "20250501",
    "version": "2",
    "openfda": {
      "application_number": [
        "NDA219616"
      ],
      "brand_name": [
        "AVMAPKI FAKZYNJA CO-PACK"
      ],
      "generic_name": [
        "AVUTOMETINIB POTASSIUM AND DEFACTINIB HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Verastem Inc."
      ],
      "product_ndc": [
        "71779-623"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "2714507",
        "2714513",
        "2714520",
        "2714526",
        "2714921",
        "2714922"
      ],
      "spl_id": [
        "e6def323-179c-432e-957d-fc4ea03e1b78"
      ],
      "spl_set_id": [
        "65889527-1406-45df-8a85-e2690dcf427d"
      ],
      "package_ndc": [
        "71779-623-01",
        "71779-660-02",
        "71779-630-01"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Seaweed Bath Co Playful Papaya Kids Sunscreen SPF 50 ZINC OXIDE ALLANTOIN ALOE VERA LEAF WATER BUTYLOCTYL SALICYLATE SHEA BUTTER C13-16 ISOPARAFFIN MEDIUM-CHAIN TRIGLYCERIDES CAPRYLYL GLYCOL CARNOSINE POLYOXYL 20 CETOSTEARYL ETHER CITRIC ACID MONOHYDRATE WATERMELON COCONUT OIL CYSTOSEIRA TAMARISCIFOLIA FUCUS VESICULOSUS GLYCERIN GLYCERYL LAURATE GLYCERYL MONOSTEARATE METHYL ABIETATE MAGNESIUM ALUMINUM SILICATE POLYSORBATE 20 PROPANEDIOL SORBITAN MONOSTEARATE SQUALANE TOCOPHEROL TRIHEPTANOIN ULVA LACTUCA XANTHAN GUM ZINC OXIDE ZINC CATION"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Oxide 17.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses Helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun."
    ],
    "warnings": [
      "Warnings For external use only. Flammable: Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120\u00b0F (49\u00b0C). Do not use on damaged or broken skin. When using this product keep out of eyes. rinse with water to remove. stop use and ask a doctor if rash occurs. Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. rinse with water to remove."
    ],
    "stop_use": [
      "stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions Apply liberally 15 minutes before sun exposure and as needed. Children under 6 months: ask a doctor. Reapply: After 80 minutes of swimming or sweating Immediately after towel drying At least every two hours. Sun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. - 2 p.m. wear long-sleeved shirts, pants, hats and sunglasses."
    ],
    "inactive_ingredient": [
      "Inactive Ingredients Algae Extract, Allantoin, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Aqua, a-Bisabalol, Butyloctyl Salicylate, Butyrospermum Parkii (Shea) Butter, C13-16 Isoalkane, Caprylic/Capric Triglyceride, Caprylyl Glycol, l-Carnosine, Ceteareth-20, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Cystoseira Tamariscifolia (Rainbow Seaweed) Extract, Fucus Vesiculosus (Seaweed) Extract, Glycerin, Glyceryl Laurate, Glyceryl Stearate, Glyceryl Undecylenate, Methyl Abietate, Magnesium Aluminum Silicate, Natural Fragrance, Polyhydroxystearic Acid, Polysorbate-20, Propanediol, SD Alcohol, Sorbitan Stearate, Squalane, Tocopherol (Vitamin E), Triheptanoin, Ulva Lactuca (Sea Lettuce) Extract, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Label"
    ],
    "set_id": "65c9c131-2545-4d88-aa9a-85197b654d74",
    "id": "1b3ebe24-cea6-16ef-e063-6294a90af3e0",
    "effective_time": "20240619",
    "version": "1",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "Seaweed Bath Co Playful Papaya Kids Sunscreen SPF 50"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-504"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "1b3ebe24-cea6-16ef-e063-6294a90af3e0"
      ],
      "spl_set_id": [
        "65c9c131-2545-4d88-aa9a-85197b654d74"
      ],
      "package_ndc": [
        "81159-504-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007675"
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Bio Co Enzyme Phase Aconiticum Acidum, Cis-, Adenosinum Triphosphoricum Dinatrum, Adrenalinum, , Alpha-Ketoglutaricum Acidum, Alpha-Lipoicum Acidum, Ascorbicum Acidum, Barium Oxalsuccinicum, Beta Vulgaris, Cerium Oxalicum, Citricum Acidum, Cysteinum, Fumaricum Acidum, Hepar Sulphuris Calcareum, Magnesium Oroticum Dihydricum, Malicum Acidum, Manganum Phosphoricum, Nadidum, Natrum Oxalaceticum, Natrum Pyruvicum, Nicotinamidum, Pantothenic Acid, Proteus (Morgani), Pulsatilla (Pratensis), Pyridoxinum Hydrochloricum, Riboflavinum, ACONITIC ACID ACONITIC ACID ADENOSINE TRIPHOSPHATE DISODIUM ADENOSINE TRIPHOSPHATE EPINEPHRINE EPINEPHRINE OXOGLURIC ACID .ALPHA.-KETOGLUTARIC ACID ALPHA LIPOIC ACID .ALPHA.-LIPOIC ACID ASCORBIC ACID ASCORBIC ACID BARIUM OXALOSUCCINATE BARIUM CATION BETA VULGARIS WHOLE BETA VULGARIS CEROUS OXALATE NONAHYDRATE CEROUS CATION ANHYDROUS CITRIC ACID ANHYDROUS CITRIC ACID CYSTEINE CYSTEINE FUMARIC ACID FUMARIC ACID CALCIUM SULFIDE CALCIUM SULFIDE MAGNESIUM OROTATE DIHYDRATE OROTIC ACID MALIC ACID MALIC ACID MANGANESE PHOSPHATE, DIBASIC MANGANOUS CATION NADIDE NADIDE SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE SODIUM PYRUVATE PYRUVIC ACID NIACINAMIDE NIACINAMIDE PANTOTHENIC ACID PANTOTHENIC ACID PROTEUS MORGANII PROTEUS MORGANII PULSATILLA PRATENSIS WHOLE PULSATILLA PRATENSIS WHOLE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE RIBOFLAVIN LACTOFLAVIN SUCCINIC ACID SUCCINIC ACID SULFUR SULFUR THIAMINE HYDROCHLORIDE THIAMINE ION WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENTS: Aconiticum Acidum 16X, Cis-, Adenosinum Triphosphoricum Dinatrum 10X, Adrenalinum 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Alpha-Ketoglutaricum Acidum 8X, Alpha-Lipoicum Acidum 8X, Ascorbicum Acidum 6X, Barium Oxalsuccinicum 34C, Beta Vulgaris 4X, Cerium Oxalicum 8X, Citricum Acidum 8X, Cysteinum 6X, Fumaricum Acidum 8X, Hepar Sulphuris Calcareum 16X, Magnesium Oroticum Dihydricum 8X, Malicum Acidum 8X, Manganum Phosphoricum 16X, Nadidum 8X, Natrum Oxalaceticum 6X, Natrum Pyruvicum 8X, Nicotinamidum 6X, Pantothenic Acid 8X, Proteus (Morgani) 30C, Pulsatilla (Pratensis) 6X, Pyridoxinum Hydrochloricum 6X, Riboflavinum 6X, Succinicum Acidum 8X, Sulphur 10X, Thiaminum Hydrochloricum 6X."
    ],
    "purpose": [
      "PURPOSE: Aconiticum Acidum, Cis - Fatigue, Adenosinum Triphosphoricum Dinatrum - Weakness, Adrenalinum - Exhaustion, Alpha-Ketoglutaricum Acidum - Weakness, Alpha-Lipoicum Acidum - Fatigue, Ascorbicum Acidum - Exhaustion, Barium Oxalsuccinicum - Fatigue, Beta Vulgaris - Exhaustion, Cerium Oxalicum - Fatigue, Citricum Acidum - Weakness, Cysteinum - Exhaustion, Fumaricum Acidum - Fatigue, Hepar Sulphuris Calcareum - Fatigue, Magnesium Oroticum Dihydricum - Weakness, Malicum Acidum - Exhaustion, Manganum Phosphoricum - Weakness, Nadidum - Exhaustion, Natrum Oxalaceticum - Fatigue, Natrum Pyruvicum - Exhaustion, Nicotinamidum - Fatigue, Pantothenic Acid - Fatigue, Proteus (Morgani) - Weakness, Pulsatilla (Pratensis) \u2013 Exhaustion, Pyridoxinum Hydrochloricum - Weakness, Riboflavinum - Fatigue, Succinicum Acidum - Weakness, Sulphur - Weakness, Thiaminum Hydrochloricum - Fatigue"
    ],
    "indications_and_usage": [
      "USES: \u2022 For the temporary relief of symptoms including: \u2022 exhaustion \u2022 fatigue \u2022 weakness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."
    ],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: In case of overdose, contact a physician or Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: 1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized water, 25% ethanol"
    ],
    "questions": [
      "QUESTIONS: Dist. By: Deseret Biologicals, Inc. 469 W. Parkland Drive Sandy, UT 84070 www.desbio.com 800-827-8204"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: DesBio Bio Co-Enzyme Phase Homeopathic NDC 43742-2259-1 1 FL OZ (30 ml) Bio Co-Enzyme Phase"
    ],
    "set_id": "6edee6eb-0ec9-4d2a-9dc9-dc2a6503a6db",
    "id": "3c6302e5-de52-4796-b6a8-d5aeffe919ca",
    "effective_time": "20250408",
    "version": "1",
    "openfda": {
      "brand_name": [
        "Bio Co Enzyme Phase"
      ],
      "generic_name": [
        "ACONITICUM ACIDUM, CIS-, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ADRENALINUM, , ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, ASCORBICUM ACIDUM, BARIUM OXALSUCCINICUM, BETA VULGARIS, CERIUM OXALICUM, CITRICUM ACIDUM, CYSTEINUM, FUMARICUM ACIDUM, HEPAR SULPHURIS CALCAREUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, MANGANUM PHOSPHORICUM, NADIDUM, NATRUM OXALACETICUM, NATRUM PYRUVICUM, NICOTINAMIDUM, PANTOTHENIC ACID, PROTEUS (MORGANI), PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM,"
      ],
      "manufacturer_name": [
        "Deseret Biologicals, Inc."
      ],
      "product_ndc": [
        "43742-2259"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ACONITIC ACID",
        "ADENOSINE TRIPHOSPHATE DISODIUM",
        "ALPHA LIPOIC ACID",
        "ANHYDROUS CITRIC ACID",
        "ASCORBIC ACID",
        "BARIUM OXALOSUCCINATE",
        "BETA VULGARIS WHOLE",
        "CALCIUM SULFIDE",
        "CEROUS OXALATE NONAHYDRATE",
        "CYSTEINE",
        "EPINEPHRINE",
        "FUMARIC ACID",
        "MAGNESIUM OROTATE DIHYDRATE",
        "MALIC ACID",
        "MANGANESE PHOSPHATE, DIBASIC",
        "NADIDE",
        "NIACINAMIDE",
        "OXOGLURIC ACID",
        "PANTOTHENIC ACID",
        "PROTEUS MORGANII",
        "PULSATILLA PRATENSIS WHOLE",
        "PYRIDOXINE HYDROCHLORIDE",
        "RIBOFLAVIN",
        "SODIUM DIETHYL OXALACETATE",
        "SODIUM PYRUVATE",
        "SUCCINIC ACID",
        "SULFUR",
        "THIAMINE HYDROCHLORIDE"
      ],
      "spl_id": [
        "3c6302e5-de52-4796-b6a8-d5aeffe919ca"
      ],
      "spl_set_id": [
        "6edee6eb-0ec9-4d2a-9dc9-dc2a6503a6db"
      ],
      "package_ndc": [
        "43742-2259-1"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0810151881652"
      ],
      "nui": [
        "N0000175833",
        "N0000175835",
        "N0000175980",
        "N0000008556",
        "N0000175089",
        "N0000193618",
        "M0001797",
        "N0000000209",
        "N0000000245",
        "N0000175552",
        "N0000175555",
        "N0000175570",
        "M0003647"
      ],
      "pharm_class_moa": [
        "Acidifying Activity [MoA]",
        "Calcium Chelating Activity [MoA]",
        "Adrenergic alpha-Agonists [MoA]",
        "Adrenergic beta-Agonists [MoA]"
      ],
      "pharm_class_epc": [
        "Calculi Dissolution Agent [EPC]",
        "Anti-coagulant [EPC]",
        "Vitamin C [EPC]",
        "alpha-Adrenergic Agonist [EPC]",
        "beta-Adrenergic Agonist [EPC]",
        "Catecholamine [EPC]"
      ],
      "pharm_class_pe": [
        "Decreased Coagulation Factor Activity [PE]"
      ],
      "pharm_class_cs": [
        "Ascorbic Acid [CS]",
        "Catecholamines [CS]"
      ],
      "unii": [
        "93371T1BXP",
        "5L51B4DR1G",
        "73Y7P0K73Y",
        "XF417D3PSL",
        "PQ6CK8PD0R",
        "L7A49804ZQ",
        "4G174V5051",
        "1MBW07J51Q",
        "0UV74P3R0J",
        "K848JZ4886",
        "YKH834O4BH",
        "88XHZ13131",
        "VQ922CRY87",
        "817L1N4CKP",
        "VZ3U1H7Q5B",
        "0U46U6E8UK",
        "25X51I8RD4",
        "8ID597Z82X",
        "19F5HK2737",
        "56X6LID5ZY",
        "8E272251DI",
        "68Y4CF58BV",
        "TLM2976OFR",
        "6CA025Y4FG",
        "POD38AIF08",
        "AB6MNQ6J6L",
        "70FD1KFU70",
        "M572600E5P"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "As I Am Dry and Itchy Scalp Care Co Wash PYRITHIONE ZINC PYRITHIONE ZINC PYRITHIONE ZINC CETRIMONIUM CHLORIDE PROPYLENE GLYCOL DICAPRYLATE/DICAPRATE PHENOXYETHANOL .BETA.-SITOSTEROL POLYACRYLAMIDE (10000 MW) MENTHOL PROPYLENE GLYCOL PPG-1 TRIDECETH-6 OREGANO CITRIC ACID MONOHYDRATE .BETA.-CITRONELLOL, (R)- .ALPHA.-HEXYLCINNAMALDEHYDE CAPRYLYL GLYCOL POLYSORBATE 60 QUATERNIUM-18 PROPANEDIOL POTASSIUM CHLORIDE WATER ALOE VERA LEAF COCONUT OIL GERANIOL LINALOOL, (+/-)- CETOSTEARYL ALCOHOL BETAINE GLYCERIN OLIVE OIL TEA TREE OIL PEPPERMINT OIL PEPPERMINT POLIDOCANOL STEARDIMONIUM HYDROXYPROPYL PEG-7 DIMETHICONE PHOSPHATE CHLORIDE CERAMIDE NG CETEARETH-25 POTASSIUM SORBATE SODIUM LAUROYL LACTYLATE SODIUM COCOYL ISETHIONATE SODIUM LAUROYL GLUTAMATE PEG-3 DISTEARATE POLYETHYLENE GLYCOL 400 SODIUM BENZOATE POLYQUATERNIUM-37 (10000 MPA.S) LINSEED OIL PIROCTONE OLAMINE PIROCTONE STEARAMIDOPROPYL DIMETHYLAMINE CAPRYLIC ACID"
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Pyrithione 1%"
    ],
    "purpose": [
      "Purpose Anti-Dandruff, Seborrheic Dermatitis"
    ],
    "indications_and_usage": [
      "Uses For the relief of scalp itching, flaking, and irritation associated with dandruff and seborrheic dermatitis."
    ],
    "warnings": [
      "Warnings For external use only."
    ],
    "when_using": [
      "When Using This Product Avoid contact with eyes. If contact occurs, rinse eyes thoroughly with water."
    ],
    "stop_use": [
      "Stop use and ask a doctor if Condition worsens or does not improve with regular use."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions For best results, use at least twice a week, or as directed by a doctor. Shake well before use. Rub a liberal amount of product between palms and distribute throughout hair and scalp. Work product through hair & massage scalp with fingertips as you would a conventional shampoo. For easy detangling carefully comb through hair with a wide-tooth comb before rinsing co-wash from hair. Rinse and repeat if needed. Follow with conditioning."
    ],
    "inactive_ingredient": [
      "Inactive Ingredient Aqua/Water/Eau, Betaine, Cetearyl Alcohol, Aloe Barbadensis Leaf Juice, Cetrimonium Chloride, Glycerin, Quaternium-18, Polysorbate 60, Olea Europaea (Olive) Fruit Oil, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Phytosterols, Mentha Piperita (Peppermint) Oil, Stearamidopropyl Dimethylamine,Caprylic Acid, Quaternium-80, Propanediol, Cocos Nucifera (Coconut) Oil, Fragrance/Parfum, Phenoxyethanol, Potassium Chloride, Linum Usitatissimum (Linseed) Seed Extract, Ceramide NG, Sodium Lauroyl Lactylate, Caprylyl Glycol, Piroctone Olamine, Menthol, Polyacrylamide, Origanum Vulgare Leaf Extract, Propylene Glycol Dicaprylate/Dicaprate, Sodium Cocoyl Isethionate, Sodium Lauroyl Glutamate, PEG-3 Distearate, Laureth-9, PEG-8, Ceteareth-25, Propylene Glycol, Citric Acid, Polyquaternium-37, PPG-1 Trideceth-6, Potassium Sorbate, Sodium Benzoate, Citronellol, Geraniol, Hexyl Cinnamal, Linalool."
    ],
    "questions": [
      "Questions or comments? www.asiamnaturally.com"
    ],
    "package_label_principal_display_panel": [
      "As I Am - Dry & Itchy Scalp Care - Olive and Tea Tree Oil Co-Wash 16 OZ (454g) NDC 72474-103-01 Label"
    ],
    "set_id": "71edee79-87ed-ff7c-e053-2995a90ae130",
    "id": "2413c890-1ca0-cfe9-e063-6394a90a1927",
    "effective_time": "20241009",
    "version": "5",
    "openfda": {
      "application_number": [
        "M032"
      ],
      "brand_name": [
        "As I Am Dry and Itchy Scalp Care Co Wash"
      ],
      "generic_name": [
        "PYRITHIONE ZINC"
      ],
      "manufacturer_name": [
        "Salon Commodities, Inc."
      ],
      "product_ndc": [
        "72474-103"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "PYRITHIONE ZINC"
      ],
      "rxcui": [
        "209884"
      ],
      "spl_id": [
        "2413c890-1ca0-cfe9-e063-6394a90a1927"
      ],
      "spl_set_id": [
        "71edee79-87ed-ff7c-e053-2995a90ae130"
      ],
      "package_ndc": [
        "72474-103-01"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "R953O2RHZ5"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO Everyday Mineral SPF 40 ZINC OXIDE ZINC OXIDE ZINC CATION ALOE VERA LEAF BENZYL ALCOHOL BUTYLOCTYL SALICYLATE SHEA BUTTER CALENDULA OFFICINALIS FLOWER GREEN TEA LEAF MEDIUM-CHAIN TRIGLYCERIDES CETOSTEARYL ALCOHOL CITRIC ACID MONOHYDRATE WATERMELON COCONUT OIL DECYL GLUCOSIDE DEHYDROACETIC ACID DODECANE FUCUS VESICULOSUS GLYCERIN GLYCERYL MONOSTEARATE HELIANTHUS ANNUUS FLOWERING TOP HYDROXYETHYL CELLULOSE, UNSPECIFIED AVOCADO OIL JOJOBA OIL PROPANEDIOL SORBITAN MONOSTEARATE COCOA .ALPHA.-TOCOPHEROL ACETATE TRIDECYL SALICYLATE WATER XANTHAN GUM"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information: Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Oxide 15.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses: Helps prevent sunburn Higher SPF gives more sunburn protection Retains SPF after 80 minutes of swimming or sweating."
    ],
    "warnings": [
      "Warnings: For external use only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor ir rash occurs. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor ir rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions: Apply liberally 15 minutes before sun exposure and as needed. Children under 6 months: ask a doctor. Reapply: After 80 minutes of swimming or sweating Immediately after towel drying At least every two hours. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: Sun Protection Measures: limit time in the sun, especially from 10 a.m. -2 p.m. wear long-sleeved shirts, pants, hats and sunglasses."
    ],
    "inactive_ingredient": [
      "Inactive Ingredients: Algae Extract, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Benzyl Alcohol, Butyloctyl Salicylate, Butyrospermum Parkii (Shea) Butter, Calendula Officinalis Extract, Camellia Sinensis (Green Tea) Extract, Caprylic/Capric Triglyceride, Cetearyl Alcohol, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Crambe Maritima (Sea Kale) Extract, Decyl Glucoside, Dehydroacetic Acid, Dodecane, Fucus Vesiculosus (Bladderwrack Seaweed) Extract, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Hydroxyethylcellulose, Lactococcus Ferment Lysate, Natural Fragrance, Persea Gratissima (Avocado) Oil, Polyhydroxystearic Acid, Simmondsia Chinensis (Jojoba) Oil, Propanediol, Sorbitan Stearate, Theobroma Cacao (Cocoa) Butter, Tocopheryl Acetate (Vitamin E), Tridecyl Salicylate, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: SeaweedBathMineral3.4oz"
    ],
    "set_id": "8380bb3f-47d0-4675-b326-620ffb74dbdf",
    "id": "1bca54eb-7143-1603-e063-6394a90a3039",
    "effective_time": "20240626",
    "version": "3",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO Everyday Mineral SPF 40"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-259"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "1bca54eb-7143-1603-e063-6394a90a3039"
      ],
      "spl_set_id": [
        "8380bb3f-47d0-4675-b326-620ffb74dbdf"
      ],
      "package_ndc": [
        "81159-259-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007637"
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "effective_time": "20210627",
    "inactive_ingredient": [
      "Water, Glycerin, Alcohol, Menthol, Mentha Piperita (Peppermint) Oil, Pinus Pumilio Branch/Leaf Oil, PEG-60 Hydrogenated Castor Oil, Aloe Barbadensis Leaf Extract, Carbomer, Triethanolamine, Methylparaben, Allantoin, Eucalyptus Globulus Leaf Oil"
    ],
    "purpose": [
      "Co Cool is an essence oil that is the main ingredient of the herb extract of nature. If you put it in your nose when you feel stuffy, your nose feels cool and your head clear."
    ],
    "keep_out_of_reach_of_children": [
      "keep out of reach of the children"
    ],
    "warnings": [
      "\u25a0 don\u2019t use on the part where there is injury, eczema, or dermatitis \u25a0 if swallowed, get medical help or contact a person control center immediately"
    ],
    "spl_product_data_elements": [
      "CO COOL menthol, peppermint oil, pinus pumilio branch/leaf oil WATER MENTHOL MENTHOL PEPPERMINT OIL PEPPERMINT PINE NEEDLE OIL (PINUS MUGO) PINE NEEDLE OIL (PINUS MUGO)"
    ],
    "openfda": {
      "brand_name": [
        "CO COOL"
      ],
      "generic_name": [
        "MENTHOL, PEPPERMINT OIL, PINUS PUMILIO BRANCH/LEAF OIL"
      ],
      "manufacturer_name": [
        "Lydia Co., Ltd."
      ],
      "product_ndc": [
        "72988-0013"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "NASAL"
      ],
      "substance_name": [
        "MENTHOL",
        "PEPPERMINT OIL",
        "PINE NEEDLE OIL (PINUS MUGO)"
      ],
      "spl_id": [
        "c5c92ffd-bf92-09d4-e053-2a95a90a2497"
      ],
      "spl_set_id": [
        "90b213fe-f7b9-555c-e053-2a95a90a1df3"
      ],
      "package_ndc": [
        "72988-0013-1"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "L7T10EIP3A",
        "AV092KU4JH",
        "6KF1RLN1CI"
      ]
    },
    "version": "2",
    "dosage_and_administration": [
      "for nasal use only"
    ],
    "package_label_principal_display_panel": [
      "label"
    ],
    "indications_and_usage": [
      "Apply it on the inside of the nose and under the nose as often as necessary, and gently rub the nose."
    ],
    "set_id": "90b213fe-f7b9-555c-e053-2a95a90a1df3",
    "id": "c5c92ffd-bf92-09d4-e053-2a95a90a2497",
    "active_ingredient": [
      "Menthol, Mentha Piperita (Peppermint) Oil, Pinus Pumilio Branch/Leaf Oil"
    ]
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO Cooling Mist SPF-60 Sport HOMOSALATE, OCTISALATE, ZINC OXIDE ALOE VERA LEAF BUTYLOCTYL SALICYLATE GREEN TEA LEAF CAPRYLYL/CAPRYL OLIGOGLUCOSIDE CAPRYLYL GLYCOL WATERMELON COCONUT OIL CUCUMBER CARROT DODECANE FUCUS VESICULOSUS GLYCERIN GLYCERYL LAURATE GLYCERYL STEARATE CITRATE GLYCERYL 1-UNDECYLENATE METHYL ABIETATE PEPPERMINT OIL AVOCADO OIL POLYSORBATE 20 PROPANEDIOL STEARIC ACID .ALPHA.-TOCOPHEROL ACETATE TRIDECYL SALICYLATE WATER XANTHAN GUM HOMOSALATE HOMOSALATE OCTISALATE OCTISALATE ZINC OXIDE ZINC CATION"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information: Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Homosalate 10.0% Octisalate 5.0% Zinc Oxide 5.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses: Helps prevent sunburn Higher SPF gives more sunburn protection Retains SPF after 80 minutes of swimming or sweating."
    ],
    "warnings": [
      "Warnings: Contents under pressure. Do not punture or incinerate container. Do not expose to heat or store at temperatures above 120\u00b0F (49\u00b0C). For external use only. Flammable: Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor ir rash occurs. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor ir rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions: Apply liberally 15 minutes before sun exposure and as needed. Children under 6 months: ask a doctor. Reapply: After 80 minutes of swimming or sweating Immediately after towel drying At least every two hours. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: Sun Protection Measures: limit time in the sun, especially from 10 a.m. -2 p.m. wear long-sleeved shirts, pants, hats and sunglasses."
    ],
    "inactive_ingredient": [
      "Inactive Ingredients: Algae Extract, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Butyloctyl Salicylate, Camellia Sinensis (Green Tea) Extract, Caprylyl/Capryl Glucoside, Caprylyl Glycol, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Cucumis Sativus (Cucumber) Extract, Daucus Carota Sativa (Carrot) Extract, Dodecane, Fucus Vesiculosus (Bladderwrack Seaweed) Extract, Glycerin, Glyceryl Laurate, Glyceryl Stearate Citrate, Glyceryl Undecylenate, Methyl Abietate, Lecithin, Mentha Piperita (Peppermint) Oil, Natural Fragrance, Persea Gratissima (Avocado) Oil, Polyhydroxystearic Acid, Polysorbate-20, Propanediol, Stearic Acid, Tocopheryl Acetate (Vitamin E), Tridecyl Salicylate, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Label"
    ],
    "set_id": "98ccbb70-6e1a-4e92-a095-cbc4be12fcbf",
    "id": "09e279a0-3ad0-daa2-e063-6294a90a623d",
    "effective_time": "20231111",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO Cooling Mist SPF-60 Sport"
      ],
      "generic_name": [
        "HOMOSALATE, OCTISALATE, ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-258"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "HOMOSALATE",
        "OCTISALATE",
        "ZINC OXIDE"
      ],
      "spl_id": [
        "09e279a0-3ad0-daa2-e063-6294a90a623d"
      ],
      "spl_set_id": [
        "98ccbb70-6e1a-4e92-a095-cbc4be12fcbf"
      ],
      "package_ndc": [
        "81159-258-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007620"
      ],
      "unii": [
        "V06SV4M95S",
        "4X49Y0596W",
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO. Super Sheer Face Serum SPF-50 ZINC OXIDE WATER CHLORELLA VULGARIS ALOE VERA LEAF POLYSORBATE 20 TRIDECYL SALICYLATE BUTYLOCTYL SALICYLATE DODECANE ISODODECANE COCAMIDOPROPYL BETAINE MEDIUM-CHAIN TRIGLYCERIDES GLYCERYL STEARATE CITRATE SQUALANE SILICON DIOXIDE CETOSTEARYL ALCOHOL CETEARYL GLUCOSIDE CERAMIDE NG CAPRYLYL GLYCOL GLYCERYL LAURATE GIGARTINA SKOTTSBERGII COCONUT OIL GLYCERIN WATERMELON GREEN TEA LEAF CALENDULA OFFICINALIS FLOWER ADANSONIA DIGITATA SEED OIL HYALURONIC ACID TOCOPHEROL ASCORBIC ACID CITRIC ACID MONOHYDRATE CHAMOMILE XANTHAN GUM PUNICA GRANATUM ROOT BARK ZINC OXIDE ZINC CATION"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Oxide 18.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses \u2022 Helps prevent sunburn \u2022 if used as directed with other sun protection measures (see ), decreases the risk of skin cancer and early skin aging caused by the sun. Directions"
    ],
    "warnings": [
      "Warnings For external use only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions \u2022 Apply liberally and evenly as the last step in your skin care routine and 15 minutes before sun exposure. Wear alone or under makeup \u2022 Reapply at least every two hours \u2022 Use a water-resistant sunscreen if swimming or sweating. \u2022 Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: \u2022 limit time in the sun, especially from 10 a.m. - 2 p.m. \u2022 wear long-sleeved shirts, pants, hats and sunglasses. Sun Protection Measures:"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients Aqua/Water/Eau with Fucus Vesiculosus (Bladderwrack Seaweed) and Chlorella Vulgaris (Algae) Extracts, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Polysorbate-20, Tridecyl Salicylate, Butyloctyl Salicylate, Dodecane, Isododecane, Trimethylsiloxysilicate, Cocamidopropyl Betaine, Caprylic/Capric Triglyceride, Glyceryl Stearate Citrate, Polyhydroxystearic Acid, Squalane, Silica, Polyisobutene, Cetearyl Alcohol, Cetearyl Glucoside, Ceramide NG, Caprylyl Glycol, Sr-Hydrozoan Polypeptide- 7 (Collagen)**, Glyceryl Laurate, Red Algae (Gigartina Skottsbergii) Extract, Glyceryl Undecylenate, Cocos Nucifera (Coconut) Oil, Glycerin, Citrullus Lanatus (Watermelon) Extract, Camellia Sinensis (Green Tea) Extract, Calendula officianalis Extract, Adansonia Digitata (Baobab) Oil, Moringa Oleifera Oil, Hyaluronic Acid, Tocopherol (Vitamin E), Ascorbic Acid (Vitamin C), Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Polymer, Natural Fragrance, Citric Acid, Chamomilla Matricaria (Chamomile) Extract, Xanthan Gum, Punica Granatum (Pomegranate) Extract. **Bio-mimicking without animal inputs"
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Label"
    ],
    "set_id": "a45b46f9-681f-4a8d-b561-165b995ccf80",
    "id": "2cc5237f-ecee-eff2-e063-6394a90a6c5f",
    "effective_time": "20250128",
    "version": "4",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO. Super Sheer Face Serum SPF-50"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-388"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "2cc5237f-ecee-eff2-e063-6394a90a6c5f"
      ],
      "spl_set_id": [
        "a45b46f9-681f-4a8d-b561-165b995ccf80"
      ],
      "package_ndc": [
        "81159-388-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007859"
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "KISQALI FEMARA CO-PACK letrozole and ribociclib Femara letrozole LETROZOLE LETROZOLE SILICON DIOXIDE FERRIC OXIDE RED HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE dark yellow FV;CG slightly biconvex with beveled edges KISQALI ribociclib RIBOCICLIB SUCCINATE RIBOCICLIB SILICON DIOXIDE CROSPOVIDONE HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE FERROSOFERRIC OXIDE FERRIC OXIDE RED LECITHIN, SOYBEAN POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE XANTHAN GUM light greyish violet RIC;NVR KISQALI FEMARA CO-PACK letrozole and ribociclib Femara letrozole LETROZOLE LETROZOLE SILICON DIOXIDE FERRIC OXIDE RED HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE dark yellow FV;CG slightly biconvex with beveled edges KISQALI ribociclib RIBOCICLIB SUCCINATE RIBOCICLIB SILICON DIOXIDE CROSPOVIDONE HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE FERROSOFERRIC OXIDE FERRIC OXIDE RED LECITHIN, SOYBEAN POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE XANTHAN GUM light greyish violet RIC;NVR KISQALI FEMARA CO-PACK letrozole and ribociclib Femara letrozole LETROZOLE LETROZOLE SILICON DIOXIDE FERRIC OXIDE RED HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, CORN CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE dark yellow FV;CG slightly biconvex with beveled edges KISQALI ribociclib RIBOCICLIB SUCCINATE RIBOCICLIB SILICON DIOXIDE CROSPOVIDONE HYDROXYPROPYL CELLULOSE, UNSPECIFIED MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE FERROSOFERRIC OXIDE FERRIC OXIDE RED LECITHIN, SOYBEAN POLYVINYL ALCOHOL, UNSPECIFIED TALC TITANIUM DIOXIDE XANTHAN GUM light greyish violet RIC;NVR"
    ],
    "recent_major_changes": [
      "Indications and Usage ( 1.1 ) 9/2024 Dosage and Administration ( 2.1 , 2.2 ) 9/2024 Warnings and Precautions ( 5.1 , 5.3 , 5.4 , 5.5 ) 9/2024"
    ],
    "recent_major_changes_table": [
      "<table width=\"100%\"><col width=\"79%\"/><col width=\"21%\"/><tbody><tr><td>Indications and Usage (<linkHtml href=\"#s1p1\">1.1</linkHtml>)</td><td align=\"center\">9/2024</td></tr><tr><td>Dosage and Administration (<linkHtml href=\"#s2p1\">2.1</linkHtml>, <linkHtml href=\"#s2p2\">2.2</linkHtml>)</td><td align=\"center\">9/2024</td></tr><tr><td>Warnings and Precautions (<linkHtml href=\"#s5p1\">5.1</linkHtml>, <linkHtml href=\"#s5p3\">5.3</linkHtml>, <linkHtml href=\"#s5p4\">5.4</linkHtml>, <linkHtml href=\"#s5p5\">5.5</linkHtml>)</td><td align=\"center\">9/2024</td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated: for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer therapy. ( 1 ) 1.1 Early Breast Cancer KISQALI \u00ae FEMARA \u00ae CO-PACK is indicated for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. 1.2 Advanced or Metastatic Breast Cancer KISQALI \u00ae FEMARA \u00ae CO-PACK indicated as initial endocrine-based therapy for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer."
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION KISQALI FEMARA CO-PACK tablets are taken in combination orally with or without food. ( 2 ) Early Breast Cancer KISQALI recommended starting dose: 400 mg orally (two 200 mg tablets) taken once daily for 21 consecutive days followed by 7 days off KISQALI treatment. ( 2.1 ) Advanced or Metastatic Breast Cancer KISQALI recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily for 21 consecutive days followed by 7 days off KISQALI treatment. ( 2.1 ) KISQALI dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability. ( 2.2 ) FEMARA: 2.5 mg (one tablet) continuously for a 28-day cycle. ( 2.1 ) 2.1 Recommended Dosage Important Administration Instructions The KISQALI FEMARA CO-PACK is comprised of ribociclib tablets co-packaged with letrozole tablets, to provide a 28-day treatment regimen. KISQALI FEMARA CO-PACK can be taken with or without food [ see Clinical Pharmacology (12.3) ]. Pre/perimenopausal women, or men, treated with KISQALI FEMARA CO-PACK should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards. Patients should take their doses of KISQALI FEMARA CO-PACK at approximately the same time each day, preferably in the morning. If the patient vomits after taking the dose or misses a dose, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time. Tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact. Early Breast Cancer KISQALI: The recommended dosage of KISQALI is 400 mg (two 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off in 28-day treatment cycles. FEMARA: 2.5 mg (one tablet) taken once daily throughout the 28-day cycle. In patients with early breast cancer, treatment with KISQALI should continue for 3 years or until disease recurrence or unacceptable toxicity occurs. Advanced or Metastatic Breast Cancer KISQALI: The recommended dosage for KISQALI is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off in 28-day treatment cycles. FEMARA: 2.5 mg (one tablet) taken once daily throughout the 28-day cycle. Refer to the Full Prescribing Information for the recommended dosage for each product. 2.2 Dose Modifications Dose Modifications for Adverse Reactions The recommended dose modifications of KISQALI for adverse reactions are listed in Table 1. Dose modifications are not recommended for FEMARA when administered with KISQALI for the adverse reactions of KISQALI, including neutropenia, hepatobiliary toxicity, or QT prolongation [see Dosage and Administration (2)] . Table 1: Recommended Dose Modification of KISQALI FEMARA CO-PACK for Adverse Reactions Level KISQALI FEMARA Dose Number of tablets Dose Number of tablets Early breast cancer Starting dose 400 mg/day two 200 mg tablets 2.5 mg/day one 2.5 mg tablet Dose reduction 200 mg/day * one 200 mg tablet 2.5 mg/day one 2.5 mg tablet Advanced or metastatic breast cancer Starting dose 600 mg/day three 200 mg tablets 2.5 mg/day one 2.5 mg tablet First dose reduction 400 mg/day two 200 mg tablets 2.5 mg/day one 2.5 mg tablet Second dose reduction 200 mg/day* one 200 mg tablet 2.5 mg/day one 2.5 mg tablet *If dose reduction below 200 mg/day is required, discontinue KISQALI. Tables 2, 3, 4, 5, 6, and 7 summarize recommendations for dose interruption, reduction, or discontinuation of KISQALI in the management of specific adverse reactions. Dose modification of KISQALI FEMARA CO-PACK is recommended based on individual patient safety and tolerability. Table 2: Dose Modification and Management for Interstitial Lung Disease/Pneumonitis Grade 1 (asymptomatic) Grade 2 (symptomatic) Grade 3 (severe symptomatic) or 4 (life-threatening) ILD/Pneumonitis [see Warnings and Precautions (5.1)] No dose interruption or adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Dose interruption until recovery to Grade \u2264 1 then consider resuming KISQALI at the next lower dose level*. If Grade 2 recurs, discontinue KISQALI. Discontinue KISQALI. Abbreviation: ILD, interstitial lung disease. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. *An individualized benefit-risk assessment should be performed when considering resuming KISQALI. Table 3: Dose Modification and Management for Cutaneous Adverse Reactions, Including SCARs Grade 1 (< 10% body surface area (BSA) with active skin toxicity, no signs of systemic involvement) Grade 2 (10%-30% BSA with active skin toxicity, no signs of systemic involvement) Grade 3 (severe rash not responsive to medical management; > 30% BSA with active skin toxicity, signs of systemic involvement present; SJS*) Grade 4 (any % BSA associated with extensive superinfection, with IV antibiotics indicated; life threatening consequences; TEN**) Cutaneous adverse reactions, including SCARs [see Warnings and Precautions (5.2)] No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Interrupt KISQALI until the etiology of the reaction has been determined. If the etiology is a SCAR, permanently discontinue KISQALI. If the etiology is not a SCAR, interrupt dose until recovery to Grade \u2264 1, then resume KISQALI at same dose level. If the cutaneous adverse reaction still recurs at Grade 3, resume KISQALI at the next lower dose level. Permanently discontinue KISQALI. Abbreviations: BSA, body surface area; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. *SJS (Grade 3 and 4) is defined as skin sloughing covering < 10% BSA and 10%-30% BSA, respectively, with associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment). **TEN (Grade 4) is defined as skin sloughing covering \u2265 30% BSA with associated symptoms (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment). Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Table 4: Dose Modification and Management of KISQALI for QT Prolongation QTcF* prolongation Early breast cancer Advanced or metastatic breast cancer > 480 ms and \u2264 500 ms Interrupt KISQALI treatment and wait until QTcF resolves to \u2264 480 ms Resume at the same dose Reduce to the next lower dose level If QTcF > 480 ms recurs, interrupt KISQALI treatment and wait until QTcF resolves to \u2264 480 ms, then resume at next lower dose level. > 500 ms Interrupt KISQALI treatment and wait until QTcF resolves to \u2264 480 ms, then resume at next lower dose level. If QTcF > 500 ms recurs, discontinue KISQALI. Permanently discontinue KISQALI if QTcF interval prolongation is either > 500 ms or > 60 ms change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia. Note: If dose reduction below 200 mg/day is required, discontinue KISQALI. Electrocardiograms (ECGs) should be assessed prior to initiation of treatment in all patients. Repeat ECGs at approximately Day 14 of the first cycle, and as clinically indicated. In case of QTcF prolongation at any given time during treatment, monitor ECG more frequently, and as clinically indicated. * QTcF = QT interval corrected by Fridericia\u2019s formula. Table 5: Dose Modification and Management of KISQALI for Hepatobiliary Toxicity Grade 1 (> ULN \u2013 3 x ULN) Grade 2 (> 3 to 5 x ULN) Grade 3 (> 5 to 20 x ULN) Grade 4 (> 20 x ULN) AST and/or ALT elevations from baseline*, WITHOUT increase in total bilirubin above 2 x ULN [see Warnings and Precautions (5.4)] No dose adjustment is required. Baseline* at < Grade 2: Dose interruption until recovery to \u2264 baseline grade, and then resume KISQALI at same dose level. If Grade 2 recurs, resume KISQALI at next lower dose level. ----------------------------- Baseline* at Grade 2: No dose interruption. Dose interruption until recovery to \u2264 baseline* grade, and then resume at next lower dose level. If Grade 3 recurs, discontinue KISQALI. Discontinue KISQALI. Combined elevations in AST and/or ALT WITH total bilirubin increase, in the absence of cholestasis [see Warnings and Precautions (5.4)] If patients develop ALT and/or AST > 3 x ULN along with total bilirubin > 2 x ULN irrespective of baseline grade, discontinue KISQALI. Perform Liver Function Tests (LFTs) before initiating treatment with KISQALI. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. If Grade \u2265 2 abnormalities are noted, monitor more frequently, and as clinically indicated. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal. *Baseline = prior to treatment initiation. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Table 6: Dose Modification and Management of KISQALI for Neutropenia Grade 1 or 2 (ANC 1000/mm 3 \u2013 < LLN) Grade 3 (ANC 500 - < 1000/mm 3 ) Grade 3 Febrile* Neutropenia Grade 4 (ANC < 500/mm 3 ) Neutropenia [see Warnings and Precautions (5.5)] No dose adjustment is required. Dose interruption until recovery to Grade \u2264 2. Resume KISQALI at the same dose level. If toxicity recurs at Grade 3, dose interruption until recovery, then resume KISQALI at the next lower dose level. Dose interruption until recovery of neutropenia to Grade \u2264 2. Resume KISQALI at the next lower dose level. Dose interruption until recovery to Grade \u2264 2. Resume KISQALI at the next lower dose level. Perform complete blood counts (CBCs) before initiating treatment with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. Abbreviations: ANC, absolute neutrophil count; LLN, lower limit of normal. *Grade 3 neutropenia with single episode of fever > 38.3\u00b0C (or) 38\u00b0C or above for more than one hour and/or concurrent infection. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Table 7: Dose Modification and Management of KISQALI for Other Toxicities* Grade 1 or 2 Grade 3 Grade 4 Other toxicities No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated. Dose interruption until recovery to Grade \u2264 1 then resume KISQALI at same dose level. If Grade 3 recurs, resume KISQALI at the next lower dose level. Discontinue KISQALI. *Excluding interstitial lung disease (ILD)/pneumonitis, cutaneous adverse reactions, including severe cutaneous adverse reactions (SCARs), QT interval prolongation, hepatobiliary toxicity, and neutropenia. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Refer to the Full Prescribing Information for the coadministered aromatase inhibitor for dose modification guidelines in the event of toxicity and other relevant safety information. Dose Modification for Use with Strong CYP3A Inhibitors Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition [see Drug Interactions (7.1)] . If a strong CYP3A inhibitor must be coadministered, reduce the KISQALI dose as shown in Table 8 Table 8: Dose Modification for Use with Strong CYP3A Inhibitors Indication Co-administration with Strong CYP3A Inhibitors Early breast cancer Reduce the KISQALI dose to 200 mg once daily. Advanced or metastatic breast cancer Reduce the KISQALI dose to 400 mg once daily. If the strong inhibitor is discontinued, change the KISQALI dose (after at least 5 half-lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)] . Dose Modification for Hepatic Impairment The recommended dose modifications for patients with hepatic impairment are shown in Table 9 [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)] . Table 9: Dose Modification for Hepatic Impairment Indication Mild hepatic impairment (Child-Pugh class A) Moderate and severe hepatic impairment (Child-Pugh class B or C) Early breast cancer No dose adjustment is necessary No dose adjustment is necessary Advanced or metastatic breast cancer No dose adjustment is necessary KISQALI 400 mg once daily The dose of FEMARA in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Clinical Pharmacology (12.3)] . The recommended dose of FEMARA for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined [see Clinical Pharmacology (12.3)] . Review the Full Prescribing Information for the coadministered aromatase inhibitor or fulvestrant for dose modifications related to hepatic impairment. Dose Modification for Renal Impairment The recommended starting dose is 200 mg KISQALI once daily for patients with severe renal impairment [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)] . No dosage adjustment of FEMARA is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [see Clinical Pharmacology (12.3)] ."
    ],
    "dosage_and_administration_table": [
      "<table><caption>Table 1: Recommended Dose Modification of KISQALI FEMARA CO-PACK for Adverse Reactions</caption><col width=\"245\"/><col width=\"245\"/><col width=\"245\"/><col width=\"245\"/><col width=\"245\"/><tbody><tr><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Level</content></td><td align=\"center\" colspan=\"2\" styleCode=\"Botrule Toprule\" valign=\"top\"><content styleCode=\"bold\">KISQALI</content></td><td align=\"center\" colspan=\"2\" styleCode=\"Botrule Toprule\" valign=\"top\"><content styleCode=\"bold\">FEMARA</content></td></tr><tr><td/><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Dose</content></td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Number of tablets</content></td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Dose</content></td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Number of tablets</content></td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Early breast cancer</content></td></tr><tr><td>Starting dose</td><td>400 mg/day</td><td>two 200 mg tablets</td><td valign=\"top\"> 2.5 mg/day </td><td valign=\"top\"> one 2.5 mg tablet </td></tr><tr><td>Dose reduction</td><td>200 mg/day<sup>*</sup></td><td>one 200 mg tablet</td><td valign=\"top\"> 2.5 mg/day </td><td valign=\"top\"> one 2.5 mg tablet </td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Advanced or metastatic breast cancer</content></td></tr><tr><td valign=\"top\"> Starting dose </td><td valign=\"top\"> 600 mg/day </td><td valign=\"top\"> three 200 mg tablets </td><td valign=\"top\"> 2.5 mg/day </td><td valign=\"top\"> one 2.5 mg tablet </td></tr><tr><td valign=\"top\"> First dose reduction </td><td valign=\"top\"> 400 mg/day </td><td valign=\"top\"> two 200 mg tablets </td><td valign=\"top\"> 2.5 mg/day </td><td valign=\"top\"> one 2.5 mg tablet </td></tr><tr><td valign=\"top\"> Second dose reduction </td><td valign=\"top\"> 200 mg/day* </td><td valign=\"top\"> one 200 mg tablet </td><td valign=\"top\"> 2.5 mg/day </td><td valign=\"top\"> one 2.5 mg tablet </td></tr><tr><td colspan=\"5\" styleCode=\"Toprule Botrule\">*If dose reduction below 200 mg/day is required, discontinue KISQALI.</td></tr></tbody></table>",
      "<table><caption>Table 2: Dose Modification and Management for Interstitial Lung Disease/Pneumonitis</caption><col width=\"225\"/><col width=\"225\"/><col width=\"225\"/><col width=\"225\"/><tbody><tr><td styleCode=\"Toprule \"/><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 1 (asymptomatic)</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 2 (symptomatic)</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 3 (severe symptomatic) or 4 (life-threatening)</content></td></tr><tr><td valign=\"top\"><content styleCode=\"bold\">ILD/Pneumonitis</content> <content styleCode=\"italics\">[see Warnings and Precautions (5.1)]</content></td><td styleCode=\"Toprule \" valign=\"top\">No dose interruption or adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery to Grade &#x2264; 1 then consider resuming KISQALI at the next lower dose level*. If Grade 2 recurs, discontinue KISQALI.</td><td styleCode=\"Toprule \" valign=\"top\">Discontinue KISQALI.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"4\">Abbreviation: ILD, interstitial lung disease. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. *An individualized benefit-risk assessment should be performed when considering resuming KISQALI.</td></tr></tbody></table>",
      "<table><caption>Table 3: Dose Modification and Management for Cutaneous Adverse Reactions, Including SCARs</caption><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><tbody><tr><td/><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Grade 1</content> (&lt; 10% body surface area (BSA) with active skin toxicity, no signs of systemic involvement)</td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Grade 2</content> (10%-30% BSA with active skin toxicity, no signs of systemic involvement)</td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Grade 3</content> (severe rash not responsive to medical management; &gt; 30% BSA with active skin toxicity, signs of systemic involvement present; SJS*) </td><td styleCode=\"Toprule\" valign=\"top\"><content styleCode=\"bold\">Grade 4</content> (any % BSA associated with extensive superinfection, with IV antibiotics indicated; life threatening consequences; TEN**)</td></tr><tr><td valign=\"top\"><content styleCode=\"bold\">Cutaneous adverse reactions, including SCARs</content> <content styleCode=\"italics\">[see Warnings and Precautions (5.2)]</content></td><td styleCode=\"Toprule \" valign=\"top\" colspan=\"2\">No dose adjustment is required.   Initiate appropriate medical therapy and monitor as clinically indicated.</td><td styleCode=\"Toprule \" valign=\"top\">Interrupt KISQALI until the etiology of the reaction has been determined.  If the etiology is a SCAR, permanently discontinue KISQALI.  If the etiology is not a SCAR, interrupt dose until recovery to Grade &#x2264; 1, then resume KISQALI at same dose level.  If the cutaneous adverse reaction still recurs at Grade 3, resume KISQALI at the next lower dose level.</td><td styleCode=\"Toprule \" valign=\"top\">Permanently discontinue KISQALI.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"5\">Abbreviations: BSA, body surface area; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis. *SJS (Grade 3 and 4) is defined as skin sloughing covering &lt; 10% BSA and 10%-30% BSA, respectively, with associated signs (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment). **TEN (Grade 4) is defined as skin sloughing covering &#x2265; 30% BSA with associated symptoms (e.g., erythema, purpura, epidermal detachment, and mucous membrane detachment). Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</td></tr></tbody></table>",
      "<table><caption>Table 4: Dose Modification and Management of KISQALI for QT Prolongation</caption><col width=\"245\"/><col width=\"245\"/><col width=\"245\"/><tbody><tr><td styleCode=\"Toprule\" align=\"center\"><content styleCode=\"bold\">QTcF* prolongation</content></td><td styleCode=\"Toprule Lrule\" align=\"center\"><content styleCode=\"bold\">Early breast cancer</content></td><td styleCode=\"Toprule Lrule\" align=\"center\"><content styleCode=\"bold\">Advanced or metastatic breast cancer</content></td></tr><tr><td styleCode=\"Toprule\"><content styleCode=\"bold\">&gt; 480 ms and &#x2264; 500 ms</content></td><td styleCode=\"Toprule Lrule\" colspan=\"2\" align=\"center\">Interrupt KISQALI treatment and wait until QTcF resolves to &#x2264; 480 ms</td></tr><tr><td/><td styleCode=\"Toprule Lrule\" align=\"center\"> Resume at the same dose </td><td styleCode=\"Toprule Lrule\" align=\"center\"> Reduce to the next lower dose level </td></tr><tr><td/><td styleCode=\"Toprule Lrule\" colspan=\"2\" align=\"center\">If QTcF &gt; 480 ms recurs, interrupt KISQALI treatment and wait until QTcF resolves to &#x2264; 480 ms, then resume at next lower dose level.</td></tr><tr><td styleCode=\"Toprule \"><content styleCode=\"bold\">&gt; 500 ms</content></td><td styleCode=\"Toprule Lrule\" colspan=\"2\" align=\"center\"> Interrupt KISQALI treatment and wait until QTcF resolves to &#x2264; 480 ms, then resume at next lower dose level. If QTcF &gt; 500 ms recurs, discontinue KISQALI. </td></tr><tr><td styleCode=\"Toprule \" colspan=\"3\">Permanently discontinue KISQALI if QTcF interval prolongation is either &gt; 500 ms or &gt; 60 ms change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"3\"><content styleCode=\"italics\">Note:</content> If dose reduction below 200 mg/day is required, discontinue KISQALI.  Electrocardiograms (ECGs) should be assessed prior to initiation of treatment in all patients. Repeat ECGs at approximately Day 14 of the first cycle, and as clinically indicated. In case of QTcF prolongation at any given time during treatment, monitor ECG more frequently, and as clinically indicated. <sup>*</sup>QTcF = QT interval corrected by Fridericia&#x2019;s formula. </td></tr></tbody></table>",
      "<table><caption>Table 5: Dose Modification and Management of KISQALI for Hepatobiliary Toxicity</caption><col width=\"147\"/><col width=\"118\"/><col width=\"176\"/><col width=\"165\"/><col width=\"129\"/><tbody><tr><td styleCode=\"Toprule \"/><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 1</content> <content styleCode=\"bold\">(&gt; ULN &#x2013; 3 x ULN)</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 2 </content> <content styleCode=\"bold\">(&gt; 3 to 5 x ULN)</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 3 </content> <content styleCode=\"bold\"> (&gt; 5 to 20 x ULN)</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 4 </content> <content styleCode=\"bold\">(&gt; 20 x ULN)</content></td></tr><tr><td valign=\"top\"><content styleCode=\"bold\">AST and/or ALT elevations from baseline*, WITHOUT increase in total bilirubin above 2 x ULN</content> <content styleCode=\"italics\">[see Warnings and Precautions (5.4)]</content></td><td styleCode=\"Toprule \" valign=\"top\">No dose adjustment is required.</td><td styleCode=\"Toprule \"><content styleCode=\"underline\">Baseline* at &lt; Grade 2:</content> Dose interruption until recovery to &#x2264; baseline grade, and then resume KISQALI at same dose level. If Grade 2 recurs, resume KISQALI at next lower dose level.  ----------------------------- <content styleCode=\"underline\">Baseline* at Grade 2:</content> No dose interruption.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery to &#x2264; baseline* grade, and then resume at next lower dose level. If Grade 3 recurs, discontinue KISQALI.</td><td styleCode=\"Toprule \" valign=\"top\">Discontinue KISQALI.</td></tr><tr><td styleCode=\"Toprule \"><content styleCode=\"bold\">Combined elevations in AST and/or ALT WITH total bilirubin increase, in the absence of cholestasis</content> <content styleCode=\"italics\">[see Warnings and Precautions (5.4)]</content></td><td styleCode=\"Toprule \" colspan=\"4\" valign=\"top\">If patients develop ALT and/or AST &gt; 3 x ULN along with total bilirubin &gt; 2 x ULN irrespective of baseline grade, discontinue KISQALI.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"5\">Perform Liver Function Tests (LFTs) before initiating treatment with KISQALI. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.  If Grade &#x2265; 2 abnormalities are noted, monitor more frequently, and as clinically indicated.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"5\">Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal. *Baseline = prior to treatment initiation. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</td></tr></tbody></table>",
      "<table><caption>Table 6: Dose Modification and Management of KISQALI for Neutropenia</caption><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><col width=\"150\"/><tbody><tr><td/><td styleCode=\"Toprule \" valign=\"top\"><content styleCode=\"bold\">Grade 1 or 2</content> (ANC 1000/mm<sup>3</sup> &#x2013; &lt; LLN)</td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 3</content> (ANC 500 - &lt; 1000/mm<sup>3</sup>)</td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 3 Febrile* Neutropenia</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 4</content> (ANC &lt; 500/mm<sup>3</sup>)</td></tr><tr><td valign=\"top\"><content styleCode=\"bold\">Neutropenia</content> <content styleCode=\"italics\">[see Warnings and Precautions (5.5)]</content></td><td styleCode=\"Toprule \" valign=\"top\">No dose adjustment is required.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery to Grade &#x2264; 2. Resume KISQALI at the same dose level. If toxicity recurs at Grade 3, dose interruption until recovery, then resume KISQALI at the next lower dose level.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery of neutropenia to Grade &#x2264; 2. Resume KISQALI at the next lower dose level.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery to Grade &#x2264; 2. Resume KISQALI at the next lower dose level.</td></tr><tr><td/><td styleCode=\"Toprule \" colspan=\"4\">Perform complete blood counts (CBCs) before initiating treatment with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. </td></tr><tr><td styleCode=\"Toprule \" colspan=\"5\">Abbreviations: ANC, absolute neutrophil count; LLN, lower limit of normal. *Grade 3 neutropenia with single episode of fever &gt; 38.3&#xB0;C (or) 38&#xB0;C or above for more than one hour and/or concurrent infection. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</td></tr></tbody></table>",
      "<table><caption>Table 7: Dose Modification and Management of KISQALI for Other Toxicities*</caption><col width=\"155\"/><col width=\"155\"/><col width=\"155\"/><col width=\"155\"/><tbody><tr><td styleCode=\"Toprule \"/><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 1 or 2</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 3</content></td><td styleCode=\"Toprule \"><content styleCode=\"bold\">Grade 4</content></td></tr><tr><td valign=\"top\"><content styleCode=\"bold\">Other toxicities</content></td><td styleCode=\"Toprule \" valign=\"top\">No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td><td styleCode=\"Toprule \" valign=\"top\">Dose interruption until recovery to Grade &#x2264; 1 then resume KISQALI at same dose level. If Grade 3 recurs, resume KISQALI at the next lower dose level.</td><td styleCode=\"Toprule \" valign=\"top\">Discontinue KISQALI.</td></tr><tr><td styleCode=\"Toprule \" colspan=\"4\">*Excluding interstitial lung disease (ILD)/pneumonitis, cutaneous adverse reactions, including severe cutaneous adverse reactions (SCARs), QT interval prolongation, hepatobiliary toxicity, and neutropenia. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</td></tr></tbody></table>",
      "<table width=\"50%\"><caption>Table 8: Dose Modification for Use with Strong CYP3A Inhibitors</caption><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td styleCode=\"Toprule\"><content styleCode=\"bold\">Indication</content></td><td styleCode=\"Toprule\"><content styleCode=\"bold\">Co-administration with Strong CYP3A Inhibitors</content></td></tr><tr><td styleCode=\"Toprule \"><content styleCode=\"bold\">Early breast cancer</content></td><td styleCode=\"Toprule \">Reduce the KISQALI dose to 200 mg once daily. </td></tr><tr><td styleCode=\"Toprule\"><content styleCode=\"bold\">Advanced or metastatic breast cancer</content></td><td styleCode=\"Toprule\">Reduce the KISQALI dose to 400 mg once daily.</td></tr></tbody></table>",
      "<table width=\"50%\"><caption>Table 9: Dose Modification for Hepatic Impairment</caption><col width=\"25%\"/><col width=\"25%\"/><col width=\"50%\"/><tbody><tr><td styleCode=\"Toprule\"><content styleCode=\"bold\">Indication</content></td><td styleCode=\"Toprule\"><content styleCode=\"bold\">Mild hepatic impairment (Child-Pugh class A)</content></td><td styleCode=\"Toprule\"><content styleCode=\"bold\">Moderate and severe hepatic impairment (Child-Pugh class B or C)</content></td></tr><tr><td styleCode=\"Toprule \"><content styleCode=\"bold\">Early breast cancer</content></td><td styleCode=\"Toprule \">No dose adjustment is necessary</td><td styleCode=\"Toprule \">No dose adjustment is necessary</td></tr><tr><td styleCode=\"Toprule\"><content styleCode=\"bold\">Advanced or metastatic breast cancer</content></td><td styleCode=\"Toprule\">No dose adjustment is necessary</td><td styleCode=\"Toprule\">KISQALI 400 mg once daily</td></tr></tbody></table>"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS KISQALI FEMARA CO-PACK is KISQALI (ribociclib) tablets co-packaged with FEMARA (letrozole) tablets. Tablet: 200 mg ribociclib (equivalent to 254.40 mg ribociclib succinate). Film-coated, light greyish violet, round, curved with beveled edges, debossed with \u201cRIC\u201d on one side and \u201cNVR\u201d on the other side. Tablet: 2.5 mg letrozole. Dark yellow, film-coated, round, slightly biconvex, with beveled edges (imprinted with the letters \u201cFV\u201d on one side and \u201cCG\u201d on the other side). Tablets: KISQALI: 200 mg ( 3 ) FEMARA: 2.5 mg ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Known hypersensitivity to the active substance (letrozole), or to any of the excipients of FEMARA. Refer to FEMARA Prescribing Information. Known hypersensitivity to letrozole, or to any excipients of FEMARA. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Interstitial Lung Disease (ILD)/Pneumonitis: Patients treated with CDK 4/6 inhibitors should be monitored for pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and evaluate patients with new or worsening respiratory symptoms suspected to be due to ILD/pneumonitis. Permanently discontinue KISQALI in patients with recurrent symptomatic or severe ILD/pneumonitis. ( 2.2 , 5.1 ) Severe Cutaneous Adverse Reactions (SCARs): Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur with KISQALI treatment. Permanently discontinue KISQALI in patients with SCARs or other life-threatening cutaneous reactions. ( 2.2 , 5.2 ) QT Interval Prolongation: Monitor electrocardiograms (ECGs) and electrolytes prior to initiation of treatment with KISQALI. Repeat ECGs at approximately Day 14 of the first cycle, and as clinically indicated. Monitor electrolytes at the beginning of each cycle for 6 cycles, and as clinically indicated. Avoid using KISQALI with drugs known to prolong QT interval and/or strong CYP3A inhibitors. ( 2.2 , 5.3 , 7.1 , 7.4 ) Hepatobiliary Toxicity: Increases in serum transaminase and bilirubin levels have been observed. Perform liver function tests (LFTs) before initiating treatment with KISQALI FEMARA CO-PACK. Monitor LFTs every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. ( 2.2, 5.4 ) Neutropenia: Perform complete blood count (CBC) before initiating therapy with KISQALI FEMARA CO-PACK. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. ( 2.2, 5.5 ) Embryo-Fetal Toxicity: Can cause fetal harm when administered to pregnant women. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during therapy. ( 5.6 , 8.1 , 8.3 ) 5.1 Interstitial Lung Disease/Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with KISQALI and other CDK4/6 inhibitors. In patients with early breast cancer (NATALEE) who received 400 mg KISQALI plus a non-steroidal aromatase inhibitor (NSAI), 1.5% of patients had ILD/pneumonitis (Grade 1-2). In patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-7), 1.2% of KISQALI-treated patients had ILD/pneumonitis (any grade, 0.3% had Grade 3-4). Additional cases of ILD/pneumonitis have occurred in the postmarketing setting, some resulting in death [see Adverse Reactions (6.2)] . Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis which may include hypoxia, cough, and dyspnea. In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt KISQALI immediately and evaluate the patient. Permanently discontinue KISQALI in patients with severe ILD/pneumonitis or any recurrent symptomatic ILD/pneumonitis [see Dosage and Administration (2.2)] . Refer to the Full Prescribing Information for KISQALI \u00ae . 5.2 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), can occur in patients treated with KISQALI [see Adverse Reactions (6.2)] . If signs or symptoms of SCARs occur, interrupt KISQALI until the etiology of the reaction has been determined [see Dosage and Administration (2.2)] . Early consultation with a dermatologist is recommended to ensure greater diagnostic accuracy and appropriate management. If SJS, TEN, or DiHS/DRESS is confirmed, permanently discontinue KISQALI. Do not reintroduce KISQALI in patients who have experienced SCARs during KISQALI treatment. 5.3 QT Interval Prolongation KISQALI has been shown to prolong the QT interval in a concentration-dependent manner [see Clinical Pharmacology (12.2)] . Avoid KISQALI in patients who are at significant risk of developing Torsades de Pointes (TdP), including those with: congenital long QT syndrome; uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism; electrolyte abnormalities; taking drugs known to prolong QT interval and/or strong CYP3A inhibitors as this may lead to prolongation of the QTcF interval. Based on the observed QT prolongation during treatment, KISQALI may require dose interruption, reduction or discontinuation as described in Table 4 [see Dosage and Administration (2.2), Drug Interactions (7.4)] . In patients with early breast cancer (NATALEE) who received 400 mg KISQALI plus NSAI, 8 out of 2494 patients (0.3%) had > 500 ms post-baseline QTcF interval value and 50 out of 2494 patients (2%) had > 60 ms QTcF increase from baseline. QTcF prolongation was reversible with dose interruption. The majority of QTcF prolongation occurred within the first four weeks of KISQALI. There were no reported cases of Torsades de Pointes. In patients with advanced or metastatic breast cancer (MONALEESA-2 and MONALEESA-7) who received 600 mg KISQALI plus NSAI, 7 out of 574 patients (1%) had a > 500 ms post-baseline QTcF value, and 29 out of 574 patients (5%) had a > 60 ms QTcF increase from baseline. QTcF prolongation was reversible with dose interruption. The majority of QTcF prolongation occurred within the first four weeks of KISQALI. There were no reported cases of Torsades de Pointes. In MONALEESA-2, in the KISQALI plus letrozole treatment arm, there was one (0.3%) sudden death in a patient with Grade 3 hypokalemia and Grade 2 QT prolongation. No cases of sudden death were reported in MONALEESA-7 [see Adverse Reactions (6)] . Perform ECG in all patients prior to starting KISQALI FEMARA CO-PACK. Initiate treatment with KISQALI FEMARA CO-PACK only in patients with QTcF values less than 450 ms. Repeat ECG at approximately Day 14 of the first cycle, and as clinically indicated. Monitor serum electrolytes (including potassium, calcium, phosphorous, and magnesium) prior to the initiation of KISQALI FEMARA CO-PACK, at the beginning of the first 6 cycles, and as clinically indicated. Correct any abnormality before starting KISQALI FEMARA CO-PACK [see Dosage and Administration (2.2)] . 5.4 Hepatobiliary Toxicity In patients with early and advanced or metastatic breast cancer, drug-induced liver injury and increases in transaminases occurred with KISQALI. In patients with early breast cancer (NATALEE) treated with KISQALI, drug-induced liver injury was reported in 9 patients (0.4%), of which 5 were Grade \u2265 3, and 8 had resolved as of the data cutoff. There were 8 (0.3%) clinically confirmed Hy\u2019s Law cases (including 4 out of 9 drug-induced liver injury mentioned above), 6 of which had resolved within 303 days and 2 of which were improving, all after discontinuation of KISQALI. Grade 3 or 4 increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occurred in 8% and 4.7% respectively; including Grade 4 increases in ALT (1.5%) and AST (0.8%). In patients with advanced or metastatic breast cancer (MONALEESA-2 and MONALEESA-7), treated with KISQALI Grade 3 or 4 increases in ALT and AST occurred in 11% and 8%, respectively. Among the patients who had Grade \u2265 3 ALT/AST elevation, the median time-to-onset was 111 days for the KISQALI plus aromatase inhibitor treatment arm. The median time to resolution to Grade \u2264 2 was 22 days in the KISQALI plus aromatase inhibitor treatment arm. In MONALEESA-2, concurrent elevations in ALT or AST greater than three times the ULN and total bilirubin greater than two times the ULN, with normal alkaline phosphatase, in the absence of cholestasis (Hy\u2019s Law) occurred in 4 (1%) patients and all patients recovered after discontinuation of KISQALI. Perform liver function tests (LFTs) in all patients before initiating KISQALI FEMARA CO-PACK. Monitor LFTs every 2 weeks for first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated [see Dosage and Administration (2.2)] . Based on the severity of the transaminase elevations, KISQALI may require dose interruption, reduction, or discontinuation as described in Table 5 (Dose Modification and Management for Hepatobiliary Toxicity) [see Dosage and Administration (2.2)] . 5.5 Neutropenia KISQALI causes concentration-dependent neutropenia. In patients with early breast cancer (NATALEE) who received KISQALI plus NSAI, 94%, including 45% of Grade 3 or 4, had a decrease in neutrophil counts (based on laboratory findings), 63% had an adverse reaction of neutropenia, and 0.3% had febrile neutropenia. The median time to Grade \u2265 2 neutropenia was 18 days. The median time to resolution of Grade \u2265 3 neutropenia to Grade < 3 was 10 days. Treatment discontinuation due to neutropenia was required in 1.1% of patients. In patients with advanced or metastatic breast cancer (MONALEESA-2 and MONALEESA-7), who received KISQALI plus NSAI, 79% had neutropenia, 66% had Grade 3 or 4 decrease in neutrophil count (based on laboratory findings), and 2% had febrile neutropenia. The median time to Grade \u2265 2 neutropenia was 16 days. The median time to resolution of Grade \u2265 3 neutropenia to Grade < 3 was 15 days. Treatment discontinuation due to neutropenia was required in 1% of patients. Perform a complete blood count (CBC) in all patients before initiating KISQALI FEMARA CO-PACK. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated. Based on the severity of the neutropenia, KISQALI may require dose interruption, reduction or discontinuation as described in Table 6 [see Dosage and Administration (2.2)] . 5.6 Embryo-Fetal Toxicity Based on findings from animal studies and the mechanism of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of ribociclib to pregnant rats and rabbits during organogenesis caused embryo-fetal toxicities at maternal exposures that were 0.6 and 1.5 times the human clinical exposure, respectively, based on area under the curve (AUC). Letrozole caused embryo-fetal toxicities in rats and rabbits at maternal exposures that were below the maximum recommended human dose (MRHD) on a mg/m 2 basis. Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during therapy with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] QT Interval Prolongation [see Warnings and Precautions (5.3)] Hepatobiliary Toxicity [see Warnings and Precautions (5.4)] Neutropenia [see Warnings and Precautions (5.5)] In patients with early breast cancer, the most common (incidence \u2265 20%) adverse reactions, including laboratory abnormalities, are lymphocytes decreased, leukocytes decreased, neutrophils decreased, hemoglobin decreased, alanine aminotransferase increased, aspartate aminotransferase increased, infections, creatinine increased, platelets decreased, headache, nausea, and fatigue. ( 6 ) In patients with advanced or metastatic breast cancer, the most common (incidence \u2265 20%) adverse reactions, including laboratory abnormalities, are leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, alanine aminotransferase increased, aspartate aminotransferase increased, infections, nausea, fatigue, platelets decreased, diarrhea, headache, alopecia, vomiting, back pain, constipation, cough, rash, creatinine increased, and abdominal pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in WARNINGS AND PRECAUTIONS reflect exposure to KISQALI plus non-steroidal aromatase inhibitor (NSAI) in 2526 patients with early breast cancer (NATALEE), of whom 51% completed 36 months of KISQALI treatment. The most common (\u2265 20%) adverse reactions, including laboratory abnormalities, were lymphocytes decreased (97%), leukocytes decreased (95%), neutrophils decreased (94%), hemoglobin decreased (47%), alanine aminotransferase increased (45%), aspartate aminotransferase increased (44%), infections (37%), creatinine increased (33%), platelets decreased (28%), headache (23%), nausea (23%), and fatigue (22%). In additions, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to KISQALI in 582 patients with advanced or metastatic breast cancer (MONALEESA-2 and MONALEESA-7), of whom 80% were exposed for 6 months or longer and 65% were exposed for greater than one year. The most common (\u2265 20%) adverse reactions, including laboratory abnormalities, were leukocytes decreased (94%), neutrophils decreased (94%), hemoglobin decreased (72%), lymphocytes decreased (59%), alanine aminotransferase increased (53%), aspartate aminotransferase increased (53%), infections (46%), nausea (46%), fatigue (36%), platelets decreased (34%), diarrhea (33%), headache (29%), alopecia (29%), vomiting (29%), back pain (25%), constipation (25%), cough (24%), rash (22%), creatinine increased (20%), and abdominal pain (20%). NATALEE: KISQALI in Combination with a Non-steroidal Aromatase Inhibitor as Adjuvant Treatment Adults with HR-positive, HER2-negative Stage II and III Early Breast Cancer at High Risk of Recurrence The safety of KISQALI was evaluated in NATALEE, a clinical trial of 5101 patients who received KISQALI plus NSAI or NSAI alone, with or without goserelin [see Clinical Studies (14)] . The median duration of exposure to KISQALI was 33 months. Serious adverse reactions occurred in 14% of patients who received KISQALI. Serious adverse reactions in > 0.5% of patients who received KISQALI included COVID-19 (1.1%), pneumonia (0.8%), and pulmonary embolism (0.6%). Fatal adverse reactions occurred in 0.6% of patients who received KISQALI. Fatal adverse reactions in \u2265 0.1% of patients receiving KISQALI included COVID-19 or COVID-19 pneumonia (0.2%) and pulmonary embolism (0.1%). Permanent discontinuation of KISQALI due to an adverse reaction occurred in 20% of patients. Adverse reactions which resulted in permanent discontinuation of KISQALI in \u2265 2% of patients were alanine aminotransferase or aspartate aminotransferase increased (8%). Dosage interruptions of both KISQALI plus NSAI due to an adverse reaction occurred in 73% of patients. Adverse reactions which required dosage interruption in \u2265 5% of patients included neutropenia or neutrophil count decreased (43%), alanine aminotransferase or aspartate aminotransferase increased (11%), COVID-19 (10%), and hypomagnesemia (5%). Dose reductions of KISQALI due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dose reductions in \u2265 2% of patients included neutropenia or neutrophil count decreased (14%) and liver function abnormal (2.3%). The most common (\u2265 20% on KISQALI plus NSAI and \u2265 2% higher than placebo) adverse reactions, including laboratory abnormalities, were neutropenia, infections, nausea, headache, fatigue, leukopenia, and abnormal liver function tests. Table 10 summarizes the adverse reactions in NATALEE. Table 10: Adverse Reactions (\u2265 10% and \u2265 2% Higher Than NSAI Alone Arm) in NATALEE Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 1 Infections: urinary tract infections; respiratory tract infections. 2 Only includes a Grade 3 adverse reaction. Adverse reaction KISQALI + NSAI (n = 2526) NSAI (n = 2441) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Infections and infestations Infections 1 37 2.0 27 0.9 Nervous system disorders Headache 2 23 0.4 17 0.2 Gastrointestinal disorders Nausea 2 23 0.2 8 0.1 Diarrhea 2 15 0.6 6 0.1 Constipation 2 13 0.2 5 0 Abdominal pain 2 11 0.5 7 0.4 General disorders and administration-site conditions Fatigue 2 22 0.8 13 0.2 Asthenia 2 17 0.6 12 0.1 Pyrexia 2 11 0.2 6 0.1 Skin and subcutaneous tissue disorders Alopecia 15 0 4.6 0 Respiratory, thoracic, and mediastinal disorders Cough 2 13 0.1 8 0.1 Clinically relevant adverse reactions reported in < 10% of patients who received KISQALI plus NSAI included rash (9%), dizziness (9%), vomiting (8%), peripheral edema (7%), pruritis (7%), dyspnea (7%), stomatitis (6%), oropharyngeal pain (6%), hypocalcemia (5%), hypokalemia (4.8%), decreased appetite (4.8%). Table 11 summarizes the laboratory abnormalities in NATALEE. Table 11: Select Laboratory Abnormalities (\u2265 10%) in Patients in NATALEE Who Received KISQALI Plus NSAI Laboratory abnormality KISQALI + NSAI (n = 2526) NSAI (n = 2441) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Lymphocytes decreased 97 19 88 6 Leukocytes decreased 95 27 45 0.6 Neutrophils decreased 94 45 35 1.7 Hemoglobin decreased 47 0.6 26 0.3 Platelets decreased 28 0.4 13 0.3 Chemistry Alanine aminotransferase increased 45 8 35 1 Aspartate aminotransferase increased 44 5 33 1 Creatinine increased 33 0.3 11 0 Adverse reactions listed are based on the data of KISQALI in combination with NSAI [anastrozole or letrozole (FEMARA)]. For the complete list of known adverse reactions with KISQALI or FEMARA, see the Full Prescribing Information of KISQALI or FEMARA. MONALEESA-2: KISQALI in Combination with Letrozole Postmenopausal Women with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy The safety of KISQALI was evaluated in MONALEESA-2, a clinical study of 668 postmenopausal women receiving KISQALI plus letrozole or placebo plus letrozole [see Clinical Studies (14)] . The median duration of exposure to KISQALI plus letrozole was 13 months with 58% of patients exposed for \u2265 12 months. Serious adverse reactions occurred in 21% of patients who received KISQALI plus letrozole. Serious adverse reactions in \u22651% of patients receiving KISQALI plus letrozole included abdominal pain (1.5%), vomiting (1.5%), constipation (1.2%), nausea (1.2%), anemia (1.2%), febrile neutropenia (1.2%), dyspnea (1.2%), and alanine aminotransferase increased (1.2%). Fatal adverse reactions occurred in 1.8% of patients who received KISQALI. Fatal adverse reactions in \u2265 0.1% of patients receiving KISQALI included acute respiratory failure (0.6%), acute myocardial infarction, sudden death (with Grade 3 hypokalemia and Grade 2 QT prolongation), unknown cause, and pneumonia (0.3% each). Permanent discontinuation of both KISQALI and letrozole due to an adverse reaction occurred in 7% of patients. Permanent discontinuation of KISQALI alone occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of both KISQALI and letrozole in \u2265 2% of patients were alanine aminotransferase increased (5%), aspartate aminotransferase increased (3%), and vomiting (2%). Dosage interruptions of both KISQALI and letrozole due to an adverse reaction occurred in 71% of patients. Adverse reactions which required dosage interruption in \u2265 5% of patients included neutropenia (39%), neutrophils decreased (12%), vomiting (6%), nausea (5%), alanine aminotransferase increased (5%), and leukocytes decreased (5%). Dose reductions due to adverse reaction occurred in 45% of patients receiving KISQALI plus letrozole. Adverse reactions which required dose reductions in \u2265 2% of patients included neutropenia (24%), neutrophils decreased (8%), and alanine aminotransferase increased (3%). Antiemetics and antidiarrheal medications were used to manage symptoms as clinically indicated. The most common (\u2265 20% on the KISQALI arm and \u2265 2% higher than placebo) adverse reactions, including laboratory abnormalities, were neutrophils decreased, leukocytes decreased, hemoglobin decreased, nausea, lymphocytes decreased, alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, diarrhea, alopecia, vomiting, platelets decreased, constipation, headache, and back pain. Table 12 summarizes the adverse reactions in MONALEESA-2. Table 12: Adverse Reactions (\u2265 10% and \u2265 2% Higher Than Placebo Arm) in MONALEESA-2 Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 1 Only includes Grade 3 adverse reactions. Adverse reaction KISQALI + Letrozole (n = 334) Placebo + Letrozole (n = 330) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Gastrointestinal disorders Nausea 1 52 2.4 29 0.6 Diarrhea 1 35 1.2 22 0.9 Vomiting 1 29 3.6 16 0.9 Constipation 1 25 1.2 19 0 Stomatitis 1 12 0.3 7 0 Abdominal pain 1 11 1.2 8 0 General disorders and administration-site conditions Fatigue 37 2.4 30 0.9 Pyrexia 1 13 0.3 6 0 Edema peripheral 1 12 0 10 0 Skin and subcutaneous tissue disorders Alopecia 1 33 0 16 0 Rash 1 17 0.6 8 0 Pruritus 1 14 0.6 6 0 Nervous system disorders Headache 1 22 0.3 19 0.3 Insomnia 1 12 0.3 9 0 Musculoskeletal and connective tissue disorders Back pain 1 20 2.1 18 0.3 Metabolism and nutrition disorders Decreased appetite 1 19 1.5 15 0.3 Respiratory, thoracic and mediastinal disorders Dyspnea 1 12 1.2 9 0.6 Infections and infestations Urinary tract infections 1 11 0.6 8 0 Clinically relevant adverse reactions in < 10% of patients in MONALEESA-2 receiving KISQALI plus letrozole included interstitial lung disease (0.3%), lung infiltration (0.3%), pneumonitis (0.3%), and pulmonary fibrosis (0.6%). Table 13 summarizes the laboratory abnormalities in MONALEESA-2. Table 13: Select Laboratory Abnormalities (\u2265 10%) in Patients in MONALEESA-2 Who Received KISQALI Plus Letrozole Laboratory abnormality KISQALI + Letrozole (n = 334) Placebo + Letrozole (n = 330) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Leukocytes decreased 93 34 29 1.5 Neutrophils decreased 93 60 24 1.2 Hemoglobin decreased 57 1.8 26 1.2 Lymphocytes decreased 51 14 22 3.9 Platelets decreased 29 0.9 6 0.3 Chemistry Alanine aminotransferase increased 46 10 36 1.2 Aspartate aminotransferase increased 44 7 32 1.5 Creatinine increased 20 0.6 6 0 Phosphorous decreased 13 5 4 0.6 Potassium decreased 11 1.2 7 1.2 Adverse reactions listed are based on the data of KISQALI in combination with letrozole (FEMARA). For the complete list of known ARs with KISQALI or FEMARA, see the Full Prescribing Information of KISQALI or FEMARA. Bone Effects In MONALEESA-2, with a median duration of safety follow-up of 20.1 months, 12 patients (4%) in the ribociclib plus letrozole arm and 18 patients (6%) in the placebo plus letrozole arm experienced fractures. Osteoporosis (all Grades) was experienced in three patients (0.9%) in the ribociclib plus letrozole arm and 2 patients (0.6%) in the placebo plus letrozole arm. MONALEESA-7: KISQALI in Combination with an Aromatase Inhibitor Pre/perimenopausal Patients with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy The safety of KISQALI was evaluated in MONALEESA-7, a clinical trial of 672 pre/perimenopausal patients with HR-positive, HER2-negative advanced or metastatic breast cancer receiving either KISQALI plus NSAI or tamoxifen plus goserelin or placebo plus NSAI or tamoxifen plus goserelin [see Clinical Studies (14)] . The median duration of exposure in the KISQALI plus a NSAI arm was 15.2 months with 66% of patients exposed for \u2265 12 months. The safety data reported below are based on 495 pre/perimenopausal patients receiving KISQALI plus NSAI plus goserelin or placebo plus NSAI plus goserelin. Serious adverse reactions occurred in 17% of patients who received KISQALI plus NSAI plus goserelin. Serious adverse reactions in \u2265 1% of patients receiving KISQALI plus NSAI plus goserelin included drug-induced liver injury (1.6%), abdominal pain (1.2%), dyspnea (1.2%), febrile neutropenia (1.2%), and back pain (1.2%). Permanent discontinuation of both KISQALI and NSAI due to an adverse reaction occurred in 3% of patients. Permanent discontinuation of KISQALI alone occurred in 3% patients. Adverse reactions which resulted in permanent discontinuation of both KISQALI and NSAI in \u2265 2% of patients were alanine aminotransferase increased (2%), and aspartate aminotransferase increased (2%). Dosage interruptions of KISQALI plus NSAI plus goserelin due to an adverse reaction occurred in 73% of patients. Adverse reactions which required dosage interruption in \u2265 5% of patients included neutropenia (41%), neutrophils decreased (26%), and leukocytes decreased (6%). Dose reductions due to an adverse reaction occurred in 33% of patients receiving KISQALI plus NSAI plus goserelin. Adverse reactions which required dose reductions in \u2265 2% of patients included neutropenia (17%), neutrophils decreased (5%), and alanine aminotransferase increased (2%). The most common (\u2265 20% on the KISQALI arm and \u2265 2% higher than placebo) adverse reactions, including laboratory abnormalities, were leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, infections, arthralgia, alanine aminotransferase increased, nausea, platelets decreased, and alopecia. Table 14 summarizes the adverse reactions in MONALEESA-7. Table 14: Adverse Reactions (\u2265 10% and \u2265 2% Higher Than Placebo Arm) in MONALEESA-7 (NSAI) Abbreviation: NSAI, non-steroidal aromatase inhibitor. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 1 Infections: urinary tract infections; respiratory tract infections; gastroenteritis; sepsis (< 1%). 2 Only includes Grade 3 adverse reactions. Adverse reaction KISQALI + NSAI + Goserelin (n = 248) Placebo + NSAI + Goserelin (n = 247) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Infections and infestations Infections 1,2 36 1.6 24 0.4 Musculoskeletal and connective tissue disorders Arthralgia 2 34 0.8 29 1.2 Gastrointestinal disorders Nausea 2 32 0 20 0 Constipation 2 16 0 12 0 Stomatitis 2 10 0 8 0.4 Skin and subcutaneous tissue disorders Alopecia 2 21 0 13 0 Rash 2 17 0.4 9 0 Pruritus 2 11 0 4 0 General disorders and administration-site conditions Pyrexia 2 17 0.8 7 0 Pain in extremity 2 10 0 8 1.2 Respiratory, thoracic and mediastinal disorders Cough 2 15 0 10 0 Clinically relevant adverse reactions in < 10% of patients in MONALEESA-7 receiving KISQALI plus NSAI included thrombocytopenia (9%), dry skin (9%), oropharyngeal pain (7%), dyspepsia (5%), lacrimation increased (4%), dry eye (4%), vitiligo (3%), hypocalcemia (2%), blood bilirubin increased (1%), syncope (0.4%), and pneumonitis (0.4%). Table 15: Select Laboratory Abnormalities (\u2265 10%) in Patients in MONALEESA-7 Who Received KISQALI Plus NSAI Plus Goserelin Laboratory abnormality KISQALI + NSAI + Goserelin (n = 248) Placebo + NSAI + Goserelin (n = 247) All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Hematology Leukocytes decreased 93 36 30 0.8 Neutrophils decreased 92 63 27 2.4 Hemoglobin decreased 84 2.4 51 0.4 Lymphocytes decreased 55 14 18 2.8 Platelets decreased 26 0.4 9 0.4 Chemistry Gamma-glutamyl transferase increased 42 7 42 9 Aspartate aminotransferase increased 37 4.8 35 1.6 Alanine aminotransferase increased 33 6 31 1.6 Phosphorous decreased 14 1.6 11 0.8 Potassium decreased 11 1.2 14 1.2 Glucose serum decreased 10 0.4 10 0.4 Creatinine increased 8 0 2 0 Adverse reactions listed are based on the data of KISQALI in combination with NSAI [anastrozole or letrozole (FEMARA)]. For the complete list of known adverse reactions with KISQALI or FEMARA, see the Full Prescribing Information of KISQALI or FEMARA. Bone Effects In MONALEESA-7, with a median duration of safety follow-up of 26.5 months, 4 patients (2%) in the ribociclib plus NSAI subgroup and 7 patients (3%) in the placebo plus NSAI subgroup experienced fractures. No osteoporosis (all Grades) was reported in the ribociclib plus NSAI subgroup, and 1 patient (0.4%) experienced osteoporosis in the placebo plus NSAI subgroup. COMPLEEMENT-1: KISQALI in Combination with Letrozole and Goserelin or Leuprolide Men with HR-positive, HER2-negative Advanced Breast Cancer for Initial Endocrine-Based Therapy The safety of KISQALI in combination with letrozole was evaluated in men (n = 39) in an open-label, multicenter clinical study for the treatment of adult patients with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease (COMPLEEMENT-1) [see Clinical Studies (14)] . The median duration of exposure to KISQALI was 20.8 months (range, 0.5 to 30.6 months). Other adverse reactions occurring in men treated with KISQALI plus letrozole and goserelin or leuprolide were similar to those occurring in women treated with KISQALI plus endocrine therapy. 6.2 Postmarketing Experience The following adverse events have been reported during post-approval use of KISQALI. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory disorders: Interstitial lung disease/pneumonitis Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia, and systemic symptoms (DRESS)."
    ],
    "adverse_reactions_table": [
      "<table><caption>Table 10: Adverse Reactions (&#x2265; 10% and &#x2265; 2% Higher Than NSAI Alone Arm) in NATALEE</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tfoot><tr><td colspan=\"5\">Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. <sup>1</sup>Infections: urinary tract infections; respiratory tract infections. <sup>2</sup>Only includes a Grade 3 adverse reaction.</td></tr></tfoot><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Adverse reaction</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI (n = 2526)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">NSAI (n = 2441)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr><td>Infections<sup>1</sup></td><td align=\"center\">37</td><td align=\"center\">2.0</td><td align=\"center\">27</td><td align=\"center\">0.9</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr><td>Headache<sup>2</sup></td><td align=\"center\">23</td><td align=\"center\">0.4</td><td align=\"center\">17</td><td align=\"center\">0.2</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td>Nausea<sup>2</sup></td><td align=\"center\">23</td><td align=\"center\">0.2</td><td align=\"center\">8</td><td align=\"center\">0.1</td></tr><tr><td>Diarrhea<sup>2</sup></td><td align=\"center\">15</td><td align=\"center\">0.6</td><td align=\"center\">6</td><td align=\"center\">0.1</td></tr><tr><td>Constipation<sup>2</sup></td><td align=\"center\">13</td><td align=\"center\">0.2</td><td align=\"center\">5</td><td align=\"center\">0</td></tr><tr><td>Abdominal pain<sup>2</sup></td><td align=\"center\">11</td><td align=\"center\">0.5</td><td align=\"center\">7</td><td align=\"center\">0.4</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">General disorders and administration-site conditions</content></td></tr><tr><td>Fatigue<sup>2</sup></td><td align=\"center\">22</td><td align=\"center\">0.8</td><td align=\"center\">13</td><td align=\"center\">0.2</td></tr><tr><td>Asthenia<sup>2</sup></td><td align=\"center\">17</td><td align=\"center\">0.6</td><td align=\"center\">12</td><td align=\"center\">0.1</td></tr><tr><td>Pyrexia<sup>2</sup></td><td align=\"center\">11</td><td align=\"center\">0.2</td><td align=\"center\">6</td><td align=\"center\">0.1</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td>Alopecia </td><td align=\"center\">15</td><td align=\"center\">0</td><td align=\"center\">4.6</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></td></tr><tr><td>Cough<sup>2</sup></td><td align=\"center\">13</td><td align=\"center\">0.1</td><td align=\"center\">8</td><td align=\"center\">0.1</td></tr></tbody></table>",
      "<table><caption>Table 11: Select Laboratory Abnormalities (&#x2265; 10%) in Patients in NATALEE Who Received KISQALI Plus NSAI</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Laboratory abnormality</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI (n = 2526)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">NSAI (n = 2441)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td styleCode=\"Toprule\" colspan=\"5\"><content styleCode=\"bold\">Hematology</content></td></tr><tr><td>Lymphocytes decreased</td><td align=\"center\">97</td><td align=\"center\">19</td><td align=\"center\">88</td><td align=\"center\">6</td></tr><tr><td>Leukocytes decreased</td><td align=\"center\">95</td><td align=\"center\">27</td><td align=\"center\">45</td><td align=\"center\">0.6</td></tr><tr><td>Neutrophils decreased</td><td align=\"center\">94</td><td align=\"center\">45</td><td align=\"center\">35</td><td align=\"center\">1.7</td></tr><tr><td>Hemoglobin decreased</td><td align=\"center\">47</td><td align=\"center\">0.6</td><td align=\"center\">26</td><td align=\"center\">0.3</td></tr><tr><td>Platelets decreased</td><td align=\"center\">28</td><td align=\"center\">0.4</td><td align=\"center\">13</td><td align=\"center\">0.3</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr><td>Alanine aminotransferase increased</td><td align=\"center\">45</td><td align=\"center\">8</td><td align=\"center\">35</td><td align=\"center\">1</td></tr><tr><td>Aspartate aminotransferase increased</td><td align=\"center\">44</td><td align=\"center\">5</td><td align=\"center\">33</td><td align=\"center\">1</td></tr><tr><td>Creatinine increased</td><td align=\"center\">33</td><td align=\"center\">0.3</td><td align=\"center\">11</td><td align=\"center\">0</td></tr></tbody></table>",
      "<table><caption>Table 12: Adverse Reactions (&#x2265; 10% and &#x2265; 2% Higher Than Placebo Arm) in MONALEESA-2</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tfoot><tr><td colspan=\"5\">Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. <sup>1</sup>Only includes Grade 3 adverse reactions.</td></tr></tfoot><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Adverse reaction</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + Letrozole (n = 334)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Placebo + Letrozole (n = 330)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td styleCode=\"Toprule\" colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td>Nausea<sup>1</sup></td><td align=\"center\">52</td><td align=\"center\">2.4</td><td align=\"center\">29</td><td align=\"center\">0.6</td></tr><tr><td>Diarrhea<sup>1</sup></td><td align=\"center\">35</td><td align=\"center\">1.2</td><td align=\"center\">22</td><td align=\"center\">0.9</td></tr><tr><td>Vomiting<sup>1</sup></td><td align=\"center\">29</td><td align=\"center\">3.6</td><td align=\"center\">16</td><td align=\"center\">0.9</td></tr><tr><td>Constipation<sup>1</sup></td><td align=\"center\">25</td><td align=\"center\">1.2</td><td align=\"center\">19</td><td align=\"center\">0</td></tr><tr><td>Stomatitis<sup>1</sup></td><td align=\"center\">12</td><td align=\"center\">0.3</td><td align=\"center\">7</td><td align=\"center\">0</td></tr><tr><td>Abdominal pain<sup>1</sup></td><td align=\"center\">11</td><td align=\"center\">1.2</td><td align=\"center\">8</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">General disorders and administration-site conditions</content></td></tr><tr><td>Fatigue</td><td align=\"center\">37</td><td align=\"center\">2.4</td><td align=\"center\">30</td><td align=\"center\">0.9</td></tr><tr><td>Pyrexia<sup>1</sup></td><td align=\"center\">13</td><td align=\"center\">0.3</td><td align=\"center\">6</td><td align=\"center\">0</td></tr><tr><td>Edema peripheral<sup>1</sup></td><td align=\"center\">12</td><td align=\"center\">0</td><td align=\"center\">10</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td>Alopecia<sup>1</sup></td><td align=\"center\">33</td><td align=\"center\">0</td><td align=\"center\">16</td><td align=\"center\">0</td></tr><tr><td>Rash<sup>1</sup></td><td align=\"center\">17</td><td align=\"center\">0.6</td><td align=\"center\">8</td><td align=\"center\">0</td></tr><tr><td>Pruritus<sup>1</sup></td><td align=\"center\">14</td><td align=\"center\">0.6</td><td align=\"center\">6</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr><td>Headache<sup>1</sup></td><td align=\"center\">22</td><td align=\"center\">0.3</td><td align=\"center\">19</td><td align=\"center\">0.3</td></tr><tr><td>Insomnia<sup>1</sup></td><td align=\"center\">12</td><td align=\"center\">0.3</td><td align=\"center\">9</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr><td>Back pain<sup>1</sup></td><td align=\"center\">20</td><td align=\"center\">2.1</td><td align=\"center\">18</td><td align=\"center\">0.3</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr><td>Decreased appetite<sup>1</sup></td><td align=\"center\">19</td><td align=\"center\">1.5</td><td align=\"center\">15</td><td align=\"center\">0.3</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content></td></tr><tr><td>Dyspnea<sup>1</sup></td><td align=\"center\">12</td><td align=\"center\">1.2</td><td align=\"center\">9</td><td align=\"center\">0.6</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr><td>Urinary tract infections<sup>1</sup></td><td align=\"center\">11</td><td align=\"center\">0.6</td><td align=\"center\">8</td><td align=\"center\">0</td></tr></tbody></table>",
      "<table><caption>Table 13: Select Laboratory Abnormalities (&#x2265; 10%) in Patients in MONALEESA-2 Who Received KISQALI Plus Letrozole</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Laboratory abnormality</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + Letrozole (n = 334)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Placebo + Letrozole (n = 330)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td styleCode=\"Toprule\" colspan=\"5\"><content styleCode=\"bold\">Hematology</content></td></tr><tr><td>Leukocytes decreased</td><td align=\"center\">93</td><td align=\"center\">34</td><td align=\"center\">29</td><td align=\"center\">1.5</td></tr><tr><td>Neutrophils decreased</td><td align=\"center\">93</td><td align=\"center\">60</td><td align=\"center\">24</td><td align=\"center\">1.2</td></tr><tr><td>Hemoglobin decreased</td><td align=\"center\">57</td><td align=\"center\">1.8</td><td align=\"center\">26</td><td align=\"center\">1.2</td></tr><tr><td>Lymphocytes decreased</td><td align=\"center\">51</td><td align=\"center\">14</td><td align=\"center\">22</td><td align=\"center\">3.9</td></tr><tr><td>Platelets decreased</td><td align=\"center\">29</td><td align=\"center\">0.9</td><td align=\"center\">6</td><td align=\"center\">0.3</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr><td>Alanine aminotransferase increased</td><td align=\"center\">46</td><td align=\"center\">10</td><td align=\"center\">36</td><td align=\"center\">1.2</td></tr><tr><td>Aspartate aminotransferase increased</td><td align=\"center\">44</td><td align=\"center\">7</td><td align=\"center\">32</td><td align=\"center\">1.5</td></tr><tr><td>Creatinine increased</td><td align=\"center\">20</td><td align=\"center\">0.6</td><td align=\"center\">6</td><td align=\"center\">0</td></tr><tr><td>Phosphorous decreased</td><td align=\"center\">13</td><td align=\"center\">5</td><td align=\"center\">4</td><td align=\"center\">0.6</td></tr><tr><td>Potassium decreased</td><td align=\"center\">11</td><td align=\"center\">1.2</td><td align=\"center\">7</td><td align=\"center\">1.2</td></tr></tbody></table>",
      "<table><caption>Table 14: Adverse Reactions (&#x2265; 10% and &#x2265; 2% Higher Than Placebo Arm) in MONALEESA-7 (NSAI)</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tfoot><tr><td colspan=\"5\">Abbreviation: NSAI, non-steroidal aromatase inhibitor. Grading according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. <sup>1</sup>Infections: urinary tract infections; respiratory tract infections; gastroenteritis; sepsis (&lt; 1%). <sup>2</sup>Only includes Grade 3 adverse reactions.</td></tr></tfoot><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Adverse reaction</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI +  Goserelin (n = 248)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Placebo + NSAI +  Goserelin (n = 247)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td styleCode=\"Toprule\" colspan=\"5\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr><td>Infections<sup>1,2</sup></td><td align=\"center\">36</td><td align=\"center\">1.6</td><td align=\"center\">24</td><td align=\"center\">0.4</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr><td>Arthralgia<sup>2</sup></td><td align=\"center\">34</td><td align=\"center\">0.8</td><td align=\"center\">29</td><td align=\"center\">1.2</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td>Nausea<sup>2</sup></td><td align=\"center\">32</td><td align=\"center\">0</td><td align=\"center\">20</td><td align=\"center\">0</td></tr><tr><td>Constipation<sup>2</sup></td><td align=\"center\">16</td><td align=\"center\">0</td><td align=\"center\">12</td><td align=\"center\">0</td></tr><tr><td>Stomatitis<sup>2</sup></td><td align=\"center\">10</td><td align=\"center\">0</td><td align=\"center\">8</td><td align=\"center\">0.4</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td>Alopecia<sup>2</sup></td><td align=\"center\">21</td><td align=\"center\">0</td><td align=\"center\">13</td><td align=\"center\">0</td></tr><tr><td>Rash<sup>2</sup></td><td align=\"center\">17</td><td align=\"center\">0.4</td><td align=\"center\">9</td><td align=\"center\">0</td></tr><tr><td>Pruritus<sup>2</sup></td><td align=\"center\">11</td><td align=\"center\">0</td><td align=\"center\">4</td><td align=\"center\">0</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">General disorders and administration-site conditions</content></td></tr><tr><td>Pyrexia<sup>2</sup></td><td align=\"center\">17</td><td align=\"center\">0.8</td><td align=\"center\">7</td><td align=\"center\">0</td></tr><tr><td>Pain in extremity<sup>2</sup></td><td align=\"center\">10</td><td align=\"center\">0</td><td align=\"center\">8</td><td align=\"center\">1.2</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content></td></tr><tr><td>Cough<sup>2</sup></td><td align=\"center\">15</td><td align=\"center\">0</td><td align=\"center\">10</td><td align=\"center\">0</td></tr></tbody></table>",
      "<table><caption>Table 15: Select Laboratory Abnormalities (&#x2265; 10%) in Patients in MONALEESA-7 Who Received KISQALI Plus NSAI Plus Goserelin</caption><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><col width=\"200\"/><tbody><tr><td valign=\"top\"><content styleCode=\"bold\">Laboratory abnormality</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI + Goserelin (n = 248)</content></td><td colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Placebo + NSAI + Goserelin (n = 247)</content></td></tr><tr><td/><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades (%)</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3 or 4 (%)</content></td></tr><tr><td styleCode=\"Toprule\" colspan=\"5\"><content styleCode=\"bold\">Hematology</content></td></tr><tr><td>Leukocytes decreased</td><td align=\"center\">93</td><td align=\"center\">36</td><td align=\"center\">30</td><td align=\"center\">0.8</td></tr><tr><td>Neutrophils decreased</td><td align=\"center\">92</td><td align=\"center\">63</td><td align=\"center\">27</td><td align=\"center\">2.4</td></tr><tr><td>Hemoglobin decreased</td><td align=\"center\">84</td><td align=\"center\">2.4</td><td align=\"center\">51</td><td align=\"center\">0.4</td></tr><tr><td>Lymphocytes decreased</td><td align=\"center\">55</td><td align=\"center\">14</td><td align=\"center\">18</td><td align=\"center\">2.8</td></tr><tr><td>Platelets decreased</td><td align=\"center\">26</td><td align=\"center\">0.4</td><td align=\"center\">9</td><td align=\"center\">0.4</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr><td>Gamma-glutamyl transferase increased</td><td align=\"center\">42</td><td align=\"center\">7</td><td align=\"center\">42</td><td align=\"center\">9</td></tr><tr><td>Aspartate aminotransferase increased</td><td align=\"center\">37</td><td align=\"center\">4.8</td><td align=\"center\">35</td><td align=\"center\">1.6</td></tr><tr><td>Alanine aminotransferase increased</td><td align=\"center\">33</td><td align=\"center\">6</td><td align=\"center\">31</td><td align=\"center\">1.6</td></tr><tr><td>Phosphorous decreased</td><td align=\"center\">14</td><td align=\"center\">1.6</td><td align=\"center\">11</td><td align=\"center\">0.8</td></tr><tr><td>Potassium decreased</td><td align=\"center\">11</td><td align=\"center\">1.2</td><td align=\"center\">14</td><td align=\"center\">1.2</td></tr><tr><td>Glucose serum decreased</td><td align=\"center\">10</td><td align=\"center\">0.4</td><td align=\"center\">10</td><td align=\"center\">0.4</td></tr><tr><td>Creatinine increased</td><td align=\"center\">8</td><td align=\"center\">0</td><td align=\"center\">2</td><td align=\"center\">0</td></tr></tbody></table>"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. ( 2.2, 7.1 ) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. ( 7.2 ) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. ( 7.3 ) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. ( 7.4 ) 7.1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure [see Clinical Pharmacology (12.3)] . Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation [see Warnings and Precautions (5.3)] . Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for CYP3A inhibition. In patients with early breast cancer, if coadministration of KISQALI with a strong CYP3A inhibitor cannot be avoided, reduce the dose of KISQALI to 200 mg once daily. In patients with advanced or metastatic breast cancer, if coadministration of KISQALI with a strong CYP3A inhibitor cannot be avoided, reduce the dose of KISQALI to 400 mg once daily [see Dosage and Administration (2.2)] . 7.2 Drugs That May Decrease Ribociclib Plasma Concentrations CYP3A4 Inducers Coadministration of a strong CYP3A4 inducers decreases the plasma exposure of ribociclib [see Clinical Pharmacology (12.3)] . Avoid concomitant use of strong CYP3A inducers and consider an alternate concomitant medication with no or minimal potential to induce CYP3A. 7.3 Effect of KISQALI on Other Drugs CYP3A Substrates Coadministration of sensitive CYP3A4 substrates with multiple doses of KISQALI increases the substrate exposure [see Clinical Pharmacology (12.3)] . For CYP3A substrates where minimal increases in the concentration may increase CYP3A substrate adverse reactions, monitor for increased adverse reactions of the CYP3A substrate during treatment with KISQALI. The dose of a sensitive CYP3A substrate may need to be reduced as KISQALI can increase its exposure. 7.4 Drugs That Prolong the QT Interval Avoid coadministration of KISQALI with products with a known potential to prolong QT interval, such as antiarrhythmic drugs that are known to prolong the QT interval. If concomitant use cannot be avoided, monitor ECG when initiating, during concomitant use, and as clinically indicated [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2)] ."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and the mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available human data informing the drug-associated risk. In animal reproduction studies, administration of ribociclib to pregnant animals during organogenesis resulted in increased incidences of post implantation loss and reduced fetal weights in rats and increased incidences of fetal abnormalities in rabbits at exposures 0.6 or 1.5 times the exposure in humans, respectively, at the highest recommended dose of 600 mg/day based on AUC (see Data) . Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of letrozole to pregnant animals during organogenesis resulted in increased post-implantation pregnancy loss and resorptions, fewer live fetuses, and fetal malformations affecting the renal and skeletal systems in rats and rabbits at doses approximately 0.1 times the daily MRHD on a mg/m 2 basis (see Data) . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects is 2% - 4% and of miscarriage is 15% - 20% of clinically recognized pregnancies in the U.S. general population. Data Animal Data - Ribociclib In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of ribociclib up to 1000 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis. In rats, 300 mg/kg/day resulted in reduced maternal body weight gain and reduced fetal weights accompanied by skeletal changes related to the lower fetal weights. There were no significant effects on embryo-fetal viability or fetal morphology at 50 or 300 mg/kg/day. In rabbits at doses \u2265 30 mg/kg/day, there were adverse effects on embryo-fetal development, including increased incidences of fetal abnormalities (malformations and external, visceral, and skeletal variants) and fetal growth (lower fetal weights). These findings included reduced/small lung lobes, additional vessel on the descending aorta, additional vessel on the aortic arch, small eyes, diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes, reduced/small accessory lung lobe, extra/rudimentary 13 th ribs, misshapen hyoid bone, bent hyoid bone alae and reduced number of phalanges in the pollex. There was no evidence of increased incidence of embryo-fetal mortality. There was no maternal toxicity observed at 30 mg/kg/day. At 300 mg/kg/day in rats and 30 mg/kg/day in rabbits, the maternal systemic exposures (AUC) were approximately 0.6 and 1.5 times, respectively, the exposure in patients at the highest recommended dose of 600 mg/day. Animal Data - Letrozole In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy day 6 resulted in an increase in pre-implantation loss at doses \u2265 0.003 mg/kg/day (approximately 0.01 times the MRHD on a mg/m 2 basis). In an embryo-fetal developmental toxicity study in rats, daily administration of oral letrozole during the period of organogenesis at doses \u2265 0.003 mg/kg (approximately 0.01 times the MRHD on a mg/m 2 basis) resulted in embryo-fetal toxicity, including intrauterine mortality, increased resorptions and postimplantation loss, decreased numbers of live fetuses and fetal anomalies, including absence and shortening of renal papilla, dilation of ureter, edema and incomplete ossification of frontal skull and metatarsals. Letrozole was teratogenic to rats at a dose of 0.03 mg/kg (approximately 0.1 times the MRHD on a mg/m 2 basis) and caused fetal domed head and cervical/centrum vertebral fusion. In an embryo-fetal developmental toxicity study in rabbits, daily administration of oral letrozole during the period of organogenesis at doses \u2265 0.002 mg/kg (approximately 0.01 the MRHD on a mg/m 2 basis) resulted in embryo-fetal toxicity, including increased resorptions, increased postimplantation loss and decreased numbers of live fetuses. Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs. 8.2 Lactation Risk Summary It is not known if ribociclib and letrozole are present in human milk. There are no data on the effects of ribociclib and/or letrozole on the breastfed infant or milk production. Ribociclib and its metabolites readily passed into the milk of lactating rats (see Data) . Exposure of lactating rats to letrozole was associated with an impaired reproductive performance of the male offspring (see Data) . Because of the potential for serious adverse reactions in breastfed infants from KISQALI FEMARA CO-PACK, advise lactating women not to breastfeed while taking KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose. Data Animal Data - Ribociclib In lactating rats administered a single dose of 50 mg/kg, exposure to ribociclib was 3.56-fold higher in milk compared to maternal plasma. Animal Data - Letrozole In a postnatal developmental toxicity study in lactating rats, letrozole was administered orally at doses of 1, 0.003, 0.03 or 0.3 mg/kg/day on Day 0 through Day 20 of lactation. The reproductive performance of the male offspring was impaired at a letrozole dose as low as 0.003 mg/kg/day (approximately 0.01 the MRHD on a mg/m 2 basis), as reflected by decreased mating and pregnancy ratios. There were no effects on the reproductive performance of female offspring. 8.3 Females and Males of Reproductive Potential Based on animal studies and mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)] . Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to starting treatment with KISQALI FEMARA CO-PACK. Contraception Females Advise females of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose. Infertility Females Based on studies with letrozole in female animals, KISQALI FEMARA CO-PACK may impair fertility in females of reproductive potential [see Nonclinical Toxicology (13.1)] . Males Based on animal studies in males, KISQALI FEMARA CO-PACK may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)] . 8.4 Pediatric Use The safety and efficacy of KISQALI FEMARA CO-PACK in pediatric patients have not been established. Letrozole administration to young (postnatal Day 7) rats for 12 weeks duration at 0.003, 0.03, 0.3 mg/kg/day by oral gavage resulted in adverse skeletal/growth effects (bone maturation, bone mineral density) and neuroendocrine and reproductive developmental perturbations of the hypothalamic-pituitary axis. Administration of 0.3 mg/kg/day resulted in AUC values that were similar to the AUC in adult patients receiving the recommended dose of 2.5 mg/day. Decreased fertility was accompanied by hypertrophy of the hypophysis and testicular changes that included degeneration of the seminiferous tubular epithelium and atrophy of the female reproductive tract. Young rats in this study were allowed to recover following discontinuation of letrozole treatment for 42 days. Histopathological changes were not reversible at clinically relevant exposures. 8.5 Geriatric Use Of the 2549 adults with early breast cancer who received KISQALI in NATALEE, 407 patients (16%) were \u2265 65 years of age and 123 patients (2.4%) were \u2265 75 years of age. No overall differences in safety or effectiveness of KISQALI were observed between older and younger adults with early breast cancer. Of 334 patients with advanced or metastatic breast cancer who received KISQALI plus letrozole in MONALEESA-2, 150 patients (45%) were \u2265 65 years of age and 35 patients (11%) were \u2265 75 years of age. No overall differences in safety or effectiveness of KISQALI plus letrozole were observed between older and younger adults with advanced or metastatic breast cancer. Of 248 patients with advanced or metastatic breast cancer who received KISQALI in MONALEESA-7, no patients were \u2265 65 years of age. 8.6 Hepatic Impairment No dose adjustment of KISQALI is necessary in patients with breast cancer who have mild hepatic impairment (Child-Pugh class A) [see Clinical Pharmacology (12.3)] . A reduced starting dose of 400 mg KISQALI is recommended in patients with advanced or metastatic breast cancer who have moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C) [see Dosage and Administration (2.2)] . No dose adjustment of FEMARA is necessary in patients with breast cancer who have mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment. The dose of FEMARA in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Clinical Pharmacology (12.3)] . The recommended dose of FEMARA for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined [see Clinical Pharmacology (12.3)] . 8.7 Renal Impairment No dose adjustment of KISQALI is necessary in patients breast cancer who have mild to moderate (30 mL/min to 89 mL/min/1.73 m 2 \u2264 estimated glomerular filtration rate (eGFR)) renal impairment. A reduced starting dose of 200 mg of KISQALI is recommended in patients with breast cancer who have severe renal impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)] . No dosage adjustment of FEMARA is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)] ."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary Based on findings from animal studies and the mechanisms of action, KISQALI FEMARA CO-PACK can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . There are no available human data informing the drug-associated risk. In animal reproduction studies, administration of ribociclib to pregnant animals during organogenesis resulted in increased incidences of post implantation loss and reduced fetal weights in rats and increased incidences of fetal abnormalities in rabbits at exposures 0.6 or 1.5 times the exposure in humans, respectively, at the highest recommended dose of 600 mg/day based on AUC (see Data) . Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of letrozole to pregnant animals during organogenesis resulted in increased post-implantation pregnancy loss and resorptions, fewer live fetuses, and fetal malformations affecting the renal and skeletal systems in rats and rabbits at doses approximately 0.1 times the daily MRHD on a mg/m 2 basis (see Data) . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects is 2% - 4% and of miscarriage is 15% - 20% of clinically recognized pregnancies in the U.S. general population. Data Animal Data - Ribociclib In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of ribociclib up to 1000 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis. In rats, 300 mg/kg/day resulted in reduced maternal body weight gain and reduced fetal weights accompanied by skeletal changes related to the lower fetal weights. There were no significant effects on embryo-fetal viability or fetal morphology at 50 or 300 mg/kg/day. In rabbits at doses \u2265 30 mg/kg/day, there were adverse effects on embryo-fetal development, including increased incidences of fetal abnormalities (malformations and external, visceral, and skeletal variants) and fetal growth (lower fetal weights). These findings included reduced/small lung lobes, additional vessel on the descending aorta, additional vessel on the aortic arch, small eyes, diaphragmatic hernia, absent accessory lobe or (partly) fused lung lobes, reduced/small accessory lung lobe, extra/rudimentary 13 th ribs, misshapen hyoid bone, bent hyoid bone alae and reduced number of phalanges in the pollex. There was no evidence of increased incidence of embryo-fetal mortality. There was no maternal toxicity observed at 30 mg/kg/day. At 300 mg/kg/day in rats and 30 mg/kg/day in rabbits, the maternal systemic exposures (AUC) were approximately 0.6 and 1.5 times, respectively, the exposure in patients at the highest recommended dose of 600 mg/day. Animal Data - Letrozole In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy day 6 resulted in an increase in pre-implantation loss at doses \u2265 0.003 mg/kg/day (approximately 0.01 times the MRHD on a mg/m 2 basis). In an embryo-fetal developmental toxicity study in rats, daily administration of oral letrozole during the period of organogenesis at doses \u2265 0.003 mg/kg (approximately 0.01 times the MRHD on a mg/m 2 basis) resulted in embryo-fetal toxicity, including intrauterine mortality, increased resorptions and postimplantation loss, decreased numbers of live fetuses and fetal anomalies, including absence and shortening of renal papilla, dilation of ureter, edema and incomplete ossification of frontal skull and metatarsals. Letrozole was teratogenic to rats at a dose of 0.03 mg/kg (approximately 0.1 times the MRHD on a mg/m 2 basis) and caused fetal domed head and cervical/centrum vertebral fusion. In an embryo-fetal developmental toxicity study in rabbits, daily administration of oral letrozole during the period of organogenesis at doses \u2265 0.002 mg/kg (approximately 0.01 the MRHD on a mg/m 2 basis) resulted in embryo-fetal toxicity, including increased resorptions, increased postimplantation loss and decreased numbers of live fetuses. Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use The safety and efficacy of KISQALI FEMARA CO-PACK in pediatric patients have not been established. Letrozole administration to young (postnatal Day 7) rats for 12 weeks duration at 0.003, 0.03, 0.3 mg/kg/day by oral gavage resulted in adverse skeletal/growth effects (bone maturation, bone mineral density) and neuroendocrine and reproductive developmental perturbations of the hypothalamic-pituitary axis. Administration of 0.3 mg/kg/day resulted in AUC values that were similar to the AUC in adult patients receiving the recommended dose of 2.5 mg/day. Decreased fertility was accompanied by hypertrophy of the hypophysis and testicular changes that included degeneration of the seminiferous tubular epithelium and atrophy of the female reproductive tract. Young rats in this study were allowed to recover following discontinuation of letrozole treatment for 42 days. Histopathological changes were not reversible at clinically relevant exposures."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use Of the 2549 adults with early breast cancer who received KISQALI in NATALEE, 407 patients (16%) were \u2265 65 years of age and 123 patients (2.4%) were \u2265 75 years of age. No overall differences in safety or effectiveness of KISQALI were observed between older and younger adults with early breast cancer. Of 334 patients with advanced or metastatic breast cancer who received KISQALI plus letrozole in MONALEESA-2, 150 patients (45%) were \u2265 65 years of age and 35 patients (11%) were \u2265 75 years of age. No overall differences in safety or effectiveness of KISQALI plus letrozole were observed between older and younger adults with advanced or metastatic breast cancer. Of 248 patients with advanced or metastatic breast cancer who received KISQALI in MONALEESA-7, no patients were \u2265 65 years of age."
    ],
    "description": [
      "11 DESCRIPTION KISQALI FEMARA CO-PACK consists of ribociclib 200 mg film-coated tablets co-packaged with letrozole 2.5 mg tablets. Ribociclib KISQALI (ribociclib) is a kinase inhibitor. Ribociclib succinate is a light yellow to yellowish brown crystalline powder. The chemical name of ribociclib succinate is: Butanedioic acid\u20147-cyclopentyl- N , N -dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7 H -pyrrolo[2,3- d ]pyrimidine-6-carboxamide (1/1). The molecular formula for ribociclib succinate is C 23 H 30 N 8 O.C 4 H 6 O 4 and the molecular weight is 552.64 g/mol [Free base: 434.55 g/mol] . The chemical structure of ribociclib is shown below: KISQALI film-coated tablets are supplied for oral use and contain 200 mg of ribociclib free base (equivalent to 254.40 mg ribociclib succinate). The tablets also contain colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate, and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum as inactive ingredients. Letrozole FEMARA (letrozole) is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31 g/mol, empirical formula C 17 H 11 N 5 , and a melting range of 184\u00b0C to 185\u00b0C. The chemical name of letrozole is 4,4'-(1H-1,2,4-Triazol-1ylmethylene) dibenzonitrile, and its structural formula is FEMARA is available as 2.5 mg tablets for oral administration. Inactive Ingredients: colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide. ribociclib structure letrozole structure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways, which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In vitro , ribociclib decreased pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced cell proliferation in breast cancer-derived lines. In vivo , treatment with single agent ribociclib in a rat xenograft model with human tumor cells led to decreased tumor volumes, which correlated with inhibition of pRb phosphorylation. Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. In studies, using patient-derived estrogen receptor positive breast cancer xenograft models, combination of ribociclib and antiestrogen (e.g., letrozole) therapies resulted in increased tumor growth inhibition compared to each drug alone. 12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of KISQALI have not been fully characterized in patients. Ribociclib Cardiac Electrophysiology A concentration-QT analysis of the data in patients with breast cancer treated with KISQALI at doses ranging from 50 to 1200 mg (0.083 to 2 times of the approved recommended high dose) suggested that ribociclib causes concentration-dependent increases in the QTcF interval. In patients with early breast cancer, the estimated mean QTcF interval change from baseline for the KISQALI 400 mg in combination with non-steroidal aromatase inhibitor (NSAI) was 10.0 ms (90% CI: 8.0, 11.9) at the mean steady-state C max [see Warnings and Precautions (5.3, 5.4)] . In patients with advanced or metastatic breast cancer the estimated mean QTcF interval change from baseline for KISQALI 600 mg in combination with aromatase inhibitors was 22.0 ms (90% CI: 22.0, 23.4), and was 34.7 ms (90% CI: 31.6, 37.8) in combination with tamoxifen at the mean C max at steady-state [see Warnings and Precautions (5.3)] . Letrozole In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg FEMARA (letrozole) suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays. Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher. Letrozole is highly specific in inhibiting aromatase activity. There is no impairment of adrenal steroidogenesis. No clinically relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, adrenocorticotropic hormone (ACTH) or in plasma renin activity among postmenopausal patients treated with a daily dose of FEMARA 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary. No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of FEMARA or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg. This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were not affected by letrozole in patients, nor was thyroid function as evaluated by thyroid stimulating hormone (TSH) levels, T3 uptake, and T4 levels. 12.3 Pharmacokinetics Ribociclib exhibited over-proportional increases in exposure (C max and AUC) across the dose range of 50 mg to 1200 mg (0.083 to 2 times of the approved recommended high dose) following both single dose and repeated doses of KISQALI. Following repeated 600 mg once daily administration, steady-state was generally achieved after 8 days and ribociclib accumulated with a mean accumulation ratio of 2.5 (range, 0.97 to 6.4) and mean (coefficient of variation (CV%)) steady-state ribociclib C max was 1820 (62%) ng/mL and AUC was 23800 (66%) ng*h/mL. Letrozole\u2019s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks. Plasma concentrations at steady state are 1.5 to 2 times higher than predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. These steady-state levels are maintained over extended periods, however, and continuous accumulation of letrozole does not occur. Absorption Ribociclib The T max following KISQALI administration was between 1 and 4 hours. The mean absolute bioavailability of ribociclib after a single oral dose of 600 mg was 65.8%. Food Effect: Compared to the fasted state, oral administration of a single 600 mg dose of KISQALI tablet with a high-fat, high-calorie meal (approximately 800 to 1000 calories with ~50% calories from fat, ~35% calories from carbohydrates, and ~15% calories from protein) had no clinically meaningful differences in ribociclib C max or AUC inf . Letrozole Letrozole is rapidly and completely absorbed from the gastrointestinal tract and absorption is not affected by food. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway. About 90% of radiolabeled letrozole is recovered in urine. Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg). Metabolism and Elimination/Excretion Ribociclib Ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of radio-labeled ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Ribociclib was the major circulating drug-derived entity in plasma (44%). The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9%, 9%, and 8% of total radioactivity, and 22%, 20%, and 18% of ribociclib exposure. Clinical activity of ribociclib was due primarily to parent drug, with negligible contribution from circulating metabolites. Ribociclib was extensively metabolized with unchanged drug accounting for 17% and 12% in feces and urine, respectively. Metabolite LEQ803 represented approximately 14% and 4% of the administered dose in feces and urine, respectively. Elimination The mean plasma effective half-life (CV%) was 32.0 hours (63%) and the mean apparent oral clearance (CL/F) was 25.5 L/hr (66%) at steady-state following 600 mg dose of KISQALI in patients with advanced cancer. The steady state mean CL/F was 38.4 L/hr following the 400 mg dose of KISQALI in patients with early breast cancer. The mean apparent plasma terminal half-life of ribociclib ranged from 29.7 to 54.7 hours and mean CL/F of ribociclib ranged from 39.9 to 77.5 L/hr at 600 mg across studies in healthy adults. Following a single oral dose of radio-labeled ribociclib in healthy adults, 92% of the total administered radioactive dose was recovered within 22 days; 69% in feces and 23% in urine. Letrozole Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole inhibited CYP2A6 and inhibited CYP2C19, however, the clinical significance of these findings is unknown. Specific Populations Patients with Hepatic Impairment Ribociclib Compared to adults with normal hepatic impairment, mild (Child-Pugh class A) hepatic impairment had no effect on the exposure of ribociclib; while in adults with moderate (Child-Pugh class B) hepatic impairment, the mean ratio was 1.44 for C max and 1.28 for AUC inf ; and with adults with severe (Child-Pugh class C) hepatic impairment, the mean ratio was 1.32 for C max and 1.29 for AUC inf . Letrozole The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined. In a study of subjects with mild to moderate non-metastatic hepatic dysfunction (e.g., cirrhosis, Child-Pugh class A and B), the mean AUC values of the volunteers with moderate hepatic impairment were 37% higher than in normal subjects, but still within the range seen in subjects without impaired function. In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh class C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had 2-fold increase in exposure (AUC) and 47% reduction in systemic clearance. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients with normal liver function receiving similar doses of this drug [see Clinical Pharmacology (12.3)]. Patients with Renal Impairment Ribociclib In adults with severe renal impairment and end stage renal disease, ribociclib AUC inf increased 2.4-fold and 3.8-fold, and C max increased 2.1-fold and 2.7-fold relative to the exposure in adults with normal renal function. Mild or moderate renal impairment had no effect on the exposure of ribociclib. In a subgroup analysis of data from studies following oral administration of KISQALI in patients with advanced cancer or early breast cancer who have mild to moderate renal impairment, AUC and C max were comparable to those in patients with normal renal function, suggesting no clinically meaningful effect of mild or moderate renal impairment on ribociclib exposure. Letrozole In a study of volunteers with varying renal function (24-hour creatinine clearance: 9 to 116 mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5 mg of FEMARA was found. In addition, in a study of 347 patients with advanced breast cancer, about half of whom received 2.5 mg FEMARA and half 0.5 mg FEMARA, renal impairment (calculated creatinine clearance: 20 to 50 mL/min) did not affect steady-state plasma letrozole concentrations. Effect of Age, Weight, Gender, and Race No clinically relevant effects of age, body weight, gender, or race on the systemic exposure of ribociclib were identified. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Drugs That Affect Ribociclib Plasma Concentrations CYP3A Inhibitors: Following a single 400 mg dose of KISQALI with ritonavir (a strong CYP3A inhibitor), ritonavir (100 mg twice a day for 14 days) increased ribociclib C max and AUC inf by 1.7-fold and 3.2-fold, respectively, compared to ribociclib alone. C max and AUC for LEQ803 (a prominent metabolite of LEE011, accounting for less than 10% of parent exposure) decreased by 96% and 98%, respectively. A moderate CYP3A4 inhibitor (erythromycin) is predicted to increase ribociclib steady-state C max and AUC by 1.1-fold and 1.2-fold, respectively, following KISQALI 400 mg once daily, and 1.1-fold and 1.1-fold respectively, following KISQALI 600 mg once daily. CYP3A Inducers: Following a single 600 mg dose of KISQALI with rifampicin (a strong CYP3A4 inducer) at 600 mg daily for 14 days, ribociclib C max decreased by 81% and AUC inf decreased by 89%, while LEQ803 C max increased 1.7-fold and AUC inf decreased by 27% compared to ribociclib alone. A moderate CYP3A inducer (efavirenz) is predicted to decrease ribociclib steady-state C max by 55% and AUC by 74%, following KISQALI 400 mg once daily, and by 52% and 71% respectively, following KISQALI 600 mg once daily. Drugs That Are Affected by KISQALI CYP3A4 and CYP1A2 Substrates: In a cocktail study with midazolam (sensitive CYP3A4 substrate) multiple doses of ribociclib (400 mg once daily for 8 days) increased midazolam C max by 2.1-fold and increased AUC inf by 3.8-fold compared to midazolam alone. Administration of KISQALI 600 mg once daily is predicted to increase midazolam C max and AUC by 2.4-fold and 5.2-fold, respectively. The effect of multiple doses of 400 mg ribociclib on caffeine (sensitive CYP1A2 substrate) was minimal, with C max decreased by 10% and AUC inf increased slightly by 20%. Only weak inhibitory effects on CYP1A2 substrates are predicted at KISQALI 600 mg once daily dose. Gastric pH-Elevating Agents: Coadministration of ribociclib with drugs that elevate the gastric pH is not predicted to alter ribociclib absorption. Letrozole: Data from a clinical trial in patients with breast cancer indicated no drug interaction between ribociclib and letrozole following coadministration of the drugs. Anastrozole: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and anastrozole following coadministration of the drugs. Exemestane: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and exemestane following coadministration of the drugs. Fulvestrant: Data from a clinical trial in patients with breast cancer indicated no clinically relevant effect of fulvestrant on ribociclib exposure following coadministration of the drugs. Tamoxifen: KISQALI is not indicated for concomitant use with tamoxifen. Data from a clinical trial in patients with breast cancer indicated that tamoxifen C max and AUC increased approximately 2-fold following coadministration of KISQALI 600 mg. In Vitro Studies Effect of Ribociclib on CYP Enzymes: In vitro , ribociclib was a reversible inhibitor of CYP1A2, CYP2E1, and CYP3A4/5 and a time-dependent inhibitor of CYP3A4/5, at clinically relevant concentrations. In vitro evaluations indicated that ribociclib has no potential to inhibit the activities of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at clinically relevant concentrations. It has no potential for time-dependent inhibition of CYP1A2, CYP2C9, and CYP2D6, and no induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4 at clinically relevant concentrations. Effect of Ribociclib on Transporters: In vitro evaluations indicated that ribociclib has a low potential to inhibit the activities of drug transporters P-gp, OATP1B1/B3, OCT1, MATEK2 at clinically relevant concentrations. Ribociclib may inhibit BCRP, OCT2, MATE1, and human BSEP at clinically relevant concentrations. Effect of Transporters on Ribociclib: Based on in vitro data, P-gp, and BCRP mediated transport are unlikely to affect the extent of oral absorption of ribociclib at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1/1B3 or OCT-1 in vitro ."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and are downstream of signaling pathways, which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In vitro , ribociclib decreased pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced cell proliferation in breast cancer-derived lines. In vivo , treatment with single agent ribociclib in a rat xenograft model with human tumor cells led to decreased tumor volumes, which correlated with inhibition of pRb phosphorylation. Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. In studies, using patient-derived estrogen receptor positive breast cancer xenograft models, combination of ribociclib and antiestrogen (e.g., letrozole) therapies resulted in increased tumor growth inhibition compared to each drug alone."
    ],
    "pharmacodynamics": [
      "12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of KISQALI have not been fully characterized in patients. Ribociclib Cardiac Electrophysiology A concentration-QT analysis of the data in patients with breast cancer treated with KISQALI at doses ranging from 50 to 1200 mg (0.083 to 2 times of the approved recommended high dose) suggested that ribociclib causes concentration-dependent increases in the QTcF interval. In patients with early breast cancer, the estimated mean QTcF interval change from baseline for the KISQALI 400 mg in combination with non-steroidal aromatase inhibitor (NSAI) was 10.0 ms (90% CI: 8.0, 11.9) at the mean steady-state C max [see Warnings and Precautions (5.3, 5.4)] . In patients with advanced or metastatic breast cancer the estimated mean QTcF interval change from baseline for KISQALI 600 mg in combination with aromatase inhibitors was 22.0 ms (90% CI: 22.0, 23.4), and was 34.7 ms (90% CI: 31.6, 37.8) in combination with tamoxifen at the mean C max at steady-state [see Warnings and Precautions (5.3)] . Letrozole In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg FEMARA (letrozole) suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays. Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher. Letrozole is highly specific in inhibiting aromatase activity. There is no impairment of adrenal steroidogenesis. No clinically relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, adrenocorticotropic hormone (ACTH) or in plasma renin activity among postmenopausal patients treated with a daily dose of FEMARA 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary. No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of FEMARA or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg. This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were not affected by letrozole in patients, nor was thyroid function as evaluated by thyroid stimulating hormone (TSH) levels, T3 uptake, and T4 levels."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics Ribociclib exhibited over-proportional increases in exposure (C max and AUC) across the dose range of 50 mg to 1200 mg (0.083 to 2 times of the approved recommended high dose) following both single dose and repeated doses of KISQALI. Following repeated 600 mg once daily administration, steady-state was generally achieved after 8 days and ribociclib accumulated with a mean accumulation ratio of 2.5 (range, 0.97 to 6.4) and mean (coefficient of variation (CV%)) steady-state ribociclib C max was 1820 (62%) ng/mL and AUC was 23800 (66%) ng*h/mL. Letrozole\u2019s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks. Plasma concentrations at steady state are 1.5 to 2 times higher than predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. These steady-state levels are maintained over extended periods, however, and continuous accumulation of letrozole does not occur. Absorption Ribociclib The T max following KISQALI administration was between 1 and 4 hours. The mean absolute bioavailability of ribociclib after a single oral dose of 600 mg was 65.8%. Food Effect: Compared to the fasted state, oral administration of a single 600 mg dose of KISQALI tablet with a high-fat, high-calorie meal (approximately 800 to 1000 calories with ~50% calories from fat, ~35% calories from carbohydrates, and ~15% calories from protein) had no clinically meaningful differences in ribociclib C max or AUC inf . Letrozole Letrozole is rapidly and completely absorbed from the gastrointestinal tract and absorption is not affected by food. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway. About 90% of radiolabeled letrozole is recovered in urine. Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg). Metabolism and Elimination/Excretion Ribociclib Ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a single 600 mg dose of radio-labeled ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Ribociclib was the major circulating drug-derived entity in plasma (44%). The major circulating metabolites included metabolite M13 (CCI284, N-hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9%, 9%, and 8% of total radioactivity, and 22%, 20%, and 18% of ribociclib exposure. Clinical activity of ribociclib was due primarily to parent drug, with negligible contribution from circulating metabolites. Ribociclib was extensively metabolized with unchanged drug accounting for 17% and 12% in feces and urine, respectively. Metabolite LEQ803 represented approximately 14% and 4% of the administered dose in feces and urine, respectively. Elimination The mean plasma effective half-life (CV%) was 32.0 hours (63%) and the mean apparent oral clearance (CL/F) was 25.5 L/hr (66%) at steady-state following 600 mg dose of KISQALI in patients with advanced cancer. The steady state mean CL/F was 38.4 L/hr following the 400 mg dose of KISQALI in patients with early breast cancer. The mean apparent plasma terminal half-life of ribociclib ranged from 29.7 to 54.7 hours and mean CL/F of ribociclib ranged from 39.9 to 77.5 L/hr at 600 mg across studies in healthy adults. Following a single oral dose of radio-labeled ribociclib in healthy adults, 92% of the total administered radioactive dose was recovered within 22 days; 69% in feces and 23% in urine. Letrozole Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole inhibited CYP2A6 and inhibited CYP2C19, however, the clinical significance of these findings is unknown. Specific Populations Patients with Hepatic Impairment Ribociclib Compared to adults with normal hepatic impairment, mild (Child-Pugh class A) hepatic impairment had no effect on the exposure of ribociclib; while in adults with moderate (Child-Pugh class B) hepatic impairment, the mean ratio was 1.44 for C max and 1.28 for AUC inf ; and with adults with severe (Child-Pugh class C) hepatic impairment, the mean ratio was 1.32 for C max and 1.29 for AUC inf . Letrozole The effect of hepatic impairment on FEMARA exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined. In a study of subjects with mild to moderate non-metastatic hepatic dysfunction (e.g., cirrhosis, Child-Pugh class A and B), the mean AUC values of the volunteers with moderate hepatic impairment were 37% higher than in normal subjects, but still within the range seen in subjects without impaired function. In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh class C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had 2-fold increase in exposure (AUC) and 47% reduction in systemic clearance. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients with normal liver function receiving similar doses of this drug [see Clinical Pharmacology (12.3)]. Patients with Renal Impairment Ribociclib In adults with severe renal impairment and end stage renal disease, ribociclib AUC inf increased 2.4-fold and 3.8-fold, and C max increased 2.1-fold and 2.7-fold relative to the exposure in adults with normal renal function. Mild or moderate renal impairment had no effect on the exposure of ribociclib. In a subgroup analysis of data from studies following oral administration of KISQALI in patients with advanced cancer or early breast cancer who have mild to moderate renal impairment, AUC and C max were comparable to those in patients with normal renal function, suggesting no clinically meaningful effect of mild or moderate renal impairment on ribociclib exposure. Letrozole In a study of volunteers with varying renal function (24-hour creatinine clearance: 9 to 116 mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5 mg of FEMARA was found. In addition, in a study of 347 patients with advanced breast cancer, about half of whom received 2.5 mg FEMARA and half 0.5 mg FEMARA, renal impairment (calculated creatinine clearance: 20 to 50 mL/min) did not affect steady-state plasma letrozole concentrations. Effect of Age, Weight, Gender, and Race No clinically relevant effects of age, body weight, gender, or race on the systemic exposure of ribociclib were identified. Drug Interaction Studies Clinical Studies and Model-Informed Approaches Drugs That Affect Ribociclib Plasma Concentrations CYP3A Inhibitors: Following a single 400 mg dose of KISQALI with ritonavir (a strong CYP3A inhibitor), ritonavir (100 mg twice a day for 14 days) increased ribociclib C max and AUC inf by 1.7-fold and 3.2-fold, respectively, compared to ribociclib alone. C max and AUC for LEQ803 (a prominent metabolite of LEE011, accounting for less than 10% of parent exposure) decreased by 96% and 98%, respectively. A moderate CYP3A4 inhibitor (erythromycin) is predicted to increase ribociclib steady-state C max and AUC by 1.1-fold and 1.2-fold, respectively, following KISQALI 400 mg once daily, and 1.1-fold and 1.1-fold respectively, following KISQALI 600 mg once daily. CYP3A Inducers: Following a single 600 mg dose of KISQALI with rifampicin (a strong CYP3A4 inducer) at 600 mg daily for 14 days, ribociclib C max decreased by 81% and AUC inf decreased by 89%, while LEQ803 C max increased 1.7-fold and AUC inf decreased by 27% compared to ribociclib alone. A moderate CYP3A inducer (efavirenz) is predicted to decrease ribociclib steady-state C max by 55% and AUC by 74%, following KISQALI 400 mg once daily, and by 52% and 71% respectively, following KISQALI 600 mg once daily. Drugs That Are Affected by KISQALI CYP3A4 and CYP1A2 Substrates: In a cocktail study with midazolam (sensitive CYP3A4 substrate) multiple doses of ribociclib (400 mg once daily for 8 days) increased midazolam C max by 2.1-fold and increased AUC inf by 3.8-fold compared to midazolam alone. Administration of KISQALI 600 mg once daily is predicted to increase midazolam C max and AUC by 2.4-fold and 5.2-fold, respectively. The effect of multiple doses of 400 mg ribociclib on caffeine (sensitive CYP1A2 substrate) was minimal, with C max decreased by 10% and AUC inf increased slightly by 20%. Only weak inhibitory effects on CYP1A2 substrates are predicted at KISQALI 600 mg once daily dose. Gastric pH-Elevating Agents: Coadministration of ribociclib with drugs that elevate the gastric pH is not predicted to alter ribociclib absorption. Letrozole: Data from a clinical trial in patients with breast cancer indicated no drug interaction between ribociclib and letrozole following coadministration of the drugs. Anastrozole: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and anastrozole following coadministration of the drugs. Exemestane: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between ribociclib and exemestane following coadministration of the drugs. Fulvestrant: Data from a clinical trial in patients with breast cancer indicated no clinically relevant effect of fulvestrant on ribociclib exposure following coadministration of the drugs. Tamoxifen: KISQALI is not indicated for concomitant use with tamoxifen. Data from a clinical trial in patients with breast cancer indicated that tamoxifen C max and AUC increased approximately 2-fold following coadministration of KISQALI 600 mg. In Vitro Studies Effect of Ribociclib on CYP Enzymes: In vitro , ribociclib was a reversible inhibitor of CYP1A2, CYP2E1, and CYP3A4/5 and a time-dependent inhibitor of CYP3A4/5, at clinically relevant concentrations. In vitro evaluations indicated that ribociclib has no potential to inhibit the activities of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 at clinically relevant concentrations. It has no potential for time-dependent inhibition of CYP1A2, CYP2C9, and CYP2D6, and no induction of CYP1A2, CYP2B6, CYP2C9, and CYP3A4 at clinically relevant concentrations. Effect of Ribociclib on Transporters: In vitro evaluations indicated that ribociclib has a low potential to inhibit the activities of drug transporters P-gp, OATP1B1/B3, OCT1, MATEK2 at clinically relevant concentrations. Ribociclib may inhibit BCRP, OCT2, MATE1, and human BSEP at clinically relevant concentrations. Effect of Transporters on Ribociclib: Based on in vitro data, P-gp, and BCRP mediated transport are unlikely to affect the extent of oral absorption of ribociclib at therapeutic doses. Ribociclib is not a substrate for hepatic uptake transporters OATP1B1/1B3 or OCT-1 in vitro ."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Ribociclib In a 2-year carcinogenicity study with oral administration of ribociclib daily in cycles of 3 weeks on/1 week off, ribociclib was not carcinogenic at doses up to 50 mg/kg in male rats and 600 mg/kg in female rats. Systemic exposure in male and female rats were 1.3 and 1.8 times, respectively, the human exposure at the highest recommended dose of 600 mg/day based on AUC. Ribociclib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in an in vitro human lymphocyte chromosomal aberration assay or an in vivo rat bone marrow micronucleus assay. In a fertility and early embryonic development study, female rats received oral doses of ribociclib for 14 days prior to mating through the first week of pregnancy. Ribociclib did not affect reproductive function, fertility or early embryonic development at doses up to 300 mg/kg/day (approximately 0.6 times the clinical exposure in patients at the highest recommended dose of 600 mg/day based on AUC). A fertility study in male rats has not been performed with ribociclib. In repeat-dose toxicity studies with oral administration of ribociclib daily for 3 weeks on/1 week off in rats up to 26 weeks duration and dogs up to 39 weeks duration, atrophic changes in testes were reported. Findings included degeneration of seminiferous tubular epithelia in the testes and hypospermia and luminal cellular debris in the epididymides of rats and dogs and vacuolation of epithelia in the epididymides of rats. These findings were observed at doses \u2265 75 mg/kg in rats and \u2265 1 mg/kg in dogs which resulted in systemic exposures that were 1.4 and 0.03 times the human exposure at the highest recommended daily dose of 600 mg/day based on AUC, respectively. These effects can be linked to a direct anti-proliferative effect on the testicular germ cells resulting in atrophy of the seminiferous tubules and showed a trend towards reversibility in rats and dogs after a four-week, non-dosing period. Letrozole A conventional carcinogenesis study in mice at doses of 0.6 to 60 mg/kg/day (about 1 to 100 times the daily MRHD on a mg/m 2 basis) administered by oral gavage for up to 2 years revealed a dose-related increase in the incidence of benign ovarian stromal tumors. The incidence of combined hepatocellular adenoma and carcinoma showed a significant trend in females when the high dose group was excluded due to low survival. In a separate study, plasma AUC 0-12hr levels in mice at 60 mg/kg/day were 55 times higher than the AUC 0-24hr level in breast cancer patients at the recommended dose. The carcinogenicity study in rats at oral doses of 0.1 to 10 mg/kg/day (about 0.4 to 40 times the daily MRHD on a mg/m 2 basis) for up to 2 years also produced an increase in the incidence of benign ovarian stromal tumors at 10 mg/kg/day. Ovarian hyperplasia was observed in females at doses equal to or greater than 0.1 mg/kg/day. At 10 mg/kg/day, plasma AUC 0-24hr levels in rats were 80 times higher than the level in breast cancer patients at the recommended dose. The benign ovarian stromal tumors observed in mice and rats were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased luteinizing hormone resulting from the decrease in circulating estrogen. Letrozole was not mutagenic in in vitro tests (Ames and E.coli bacterial tests) but was observed to be a potential clastogen in in vitro assays [Chinese hamster ovary (CHO) K1 and CCL61 CHO cells]. Letrozole was not clastogenic in vivo (micronucleus test in rats). In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy Day 6 resulted in decreases in the incidence of successful mating and pregnancy at doses \u2265 0.03 mg/kg/day (approximately 0.1 times the recommended human dose on a mg/m 2 basis). In repeat-dose toxicity studies, administration of letrozole caused sexual inactivity in females and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1, and 0.03 mg/kg in mice, rats and dogs, respectively (approximately 1, 0.4, and 0.4 times the daily MRHD on a mg/m 2 basis, respectively). 13.2 Animal Toxicology and/or Pharmacology Ribociclib In vivo cardiac safety studies in dogs demonstrated dose and concentration related QTc interval prolongation at an exposure similar to patients receiving the recommended dose of 600 mg. There is a potential to induce incidences of premature ventricular contractions (PVCs) at elevated exposures (approximately 5-fold the anticipated clinical C max )."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Ribociclib In a 2-year carcinogenicity study with oral administration of ribociclib daily in cycles of 3 weeks on/1 week off, ribociclib was not carcinogenic at doses up to 50 mg/kg in male rats and 600 mg/kg in female rats. Systemic exposure in male and female rats were 1.3 and 1.8 times, respectively, the human exposure at the highest recommended dose of 600 mg/day based on AUC. Ribociclib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in an in vitro human lymphocyte chromosomal aberration assay or an in vivo rat bone marrow micronucleus assay. In a fertility and early embryonic development study, female rats received oral doses of ribociclib for 14 days prior to mating through the first week of pregnancy. Ribociclib did not affect reproductive function, fertility or early embryonic development at doses up to 300 mg/kg/day (approximately 0.6 times the clinical exposure in patients at the highest recommended dose of 600 mg/day based on AUC). A fertility study in male rats has not been performed with ribociclib. In repeat-dose toxicity studies with oral administration of ribociclib daily for 3 weeks on/1 week off in rats up to 26 weeks duration and dogs up to 39 weeks duration, atrophic changes in testes were reported. Findings included degeneration of seminiferous tubular epithelia in the testes and hypospermia and luminal cellular debris in the epididymides of rats and dogs and vacuolation of epithelia in the epididymides of rats. These findings were observed at doses \u2265 75 mg/kg in rats and \u2265 1 mg/kg in dogs which resulted in systemic exposures that were 1.4 and 0.03 times the human exposure at the highest recommended daily dose of 600 mg/day based on AUC, respectively. These effects can be linked to a direct anti-proliferative effect on the testicular germ cells resulting in atrophy of the seminiferous tubules and showed a trend towards reversibility in rats and dogs after a four-week, non-dosing period. Letrozole A conventional carcinogenesis study in mice at doses of 0.6 to 60 mg/kg/day (about 1 to 100 times the daily MRHD on a mg/m 2 basis) administered by oral gavage for up to 2 years revealed a dose-related increase in the incidence of benign ovarian stromal tumors. The incidence of combined hepatocellular adenoma and carcinoma showed a significant trend in females when the high dose group was excluded due to low survival. In a separate study, plasma AUC 0-12hr levels in mice at 60 mg/kg/day were 55 times higher than the AUC 0-24hr level in breast cancer patients at the recommended dose. The carcinogenicity study in rats at oral doses of 0.1 to 10 mg/kg/day (about 0.4 to 40 times the daily MRHD on a mg/m 2 basis) for up to 2 years also produced an increase in the incidence of benign ovarian stromal tumors at 10 mg/kg/day. Ovarian hyperplasia was observed in females at doses equal to or greater than 0.1 mg/kg/day. At 10 mg/kg/day, plasma AUC 0-24hr levels in rats were 80 times higher than the level in breast cancer patients at the recommended dose. The benign ovarian stromal tumors observed in mice and rats were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased luteinizing hormone resulting from the decrease in circulating estrogen. Letrozole was not mutagenic in in vitro tests (Ames and E.coli bacterial tests) but was observed to be a potential clastogen in in vitro assays [Chinese hamster ovary (CHO) K1 and CCL61 CHO cells]. Letrozole was not clastogenic in vivo (micronucleus test in rats). In a fertility and early embryonic developmental toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy Day 6 resulted in decreases in the incidence of successful mating and pregnancy at doses \u2265 0.03 mg/kg/day (approximately 0.1 times the recommended human dose on a mg/m 2 basis). In repeat-dose toxicity studies, administration of letrozole caused sexual inactivity in females and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1, and 0.03 mg/kg in mice, rats and dogs, respectively (approximately 1, 0.4, and 0.4 times the daily MRHD on a mg/m 2 basis, respectively)."
    ],
    "animal_pharmacology_and_or_toxicology": [
      "13.2 Animal Toxicology and/or Pharmacology Ribociclib In vivo cardiac safety studies in dogs demonstrated dose and concentration related QTc interval prolongation at an exposure similar to patients receiving the recommended dose of 600 mg. There is a potential to induce incidences of premature ventricular contractions (PVCs) at elevated exposures (approximately 5-fold the anticipated clinical C max )."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES 14.1 Early Breast Cancer NATALEE: KISQALI in Combination with a Non-steroidal Aromatase Inhibitor (NSAI) with or without Goserelin Adults with HR-positive, HER2-negative Stage II and III Early Breast Cancer at High Risk of Recurrence NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study in adults (N = 5101) with HR-positive, HER2-negative early breast cancer that was: Anatomic Stage Group IIB-III, or Anatomic Stage Group IIA that is either: Node positive or Node negative, with: Histologic Grade 3, or Histologic Grade 2, with any of the following criteria: Ki67 \u2265 20% High risk by gene signature testing Applying TNM criteria, NATALEE included patients with any lymph node involvement, or if no nodal involvement either tumor size > 5 cm, or tumor size 2 to 5 cm with either Grade 2 (and high genomic risk or Ki67 \u2265 20%) or Grade 3. Participants were randomized to receive KISQALI 400 mg plus a non-steroidal aromatase inhibitor (NSAI, letrozole or anastrozole) or NSAI only, and goserelin as indicated. Randomization was stratified by Anatomic Stage, prior treatment (neoadjuvant versus adjuvant chemotherapy), menopausal status (premenopausal and males versus postmenopausal) and region (North America/Western Europe/Oceania versus rest of the world). The main efficacy outcome measure was invasive disease-free survival (iDFS). iDFS was defined as the time from randomization to the first occurrence of: local invasive breast recurrence, regional invasive recurrence, distant recurrence, death (any cause), contralateral invasive breast cancer, or second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin). Overall survival (OS) was an additional outcome measure. KISQALI was given orally at a dose of 400 mg once daily for 21 consecutive days followed by 7 days off treatment in combination with letrozole 2.5 mg or anastrozole 1 mg orally once daily for 28 days; goserelin 3.6 mg was administered on Day 1 of each 28-day cycle. KISQALI was administered for up to 36 months in the absence of recurrence or unacceptable toxicity. NSAI was administered for at least 5 years. The median age was 52 years (range, 24 to 90); > 99% women (n = 19 men); 73% White, 13% Asian, 1.7% Black or African American, < 0.1% Native Hawaiian or other Pacific Islander, < 0.1% American Indian or Alaskan Native; 8.5% Hispanic or Latino; 99% ECOG 0-1; 88% node positive disease; 88% received prior (neo)adjuvant chemotherapy. A statistically significant improvement in iDFS was observed in the intent-to-treat (ITT) population at an interim analysis. The efficacy results at the time of the final iDFS analysis are summarized in Table 16 and Figure 1. At the time of the iDFS final analysis, OS was immature, and a total of 172 (3.5%) of patients had died across both study arms. Table 16: Efficacy Results \u2013 NATALEE (Investigator Assessment, Intent-to-Treat Population) KISQALI + NSAI +/- Goserelin NSAI +/- Goserelin Invasive Disease-Free Survival (iDFS) a N = 2549 N = 2552 Events (n, %) 226 (8.9%) 283 (11.1%) Hazard ratio (95% CI) 0.749 (0.628 to 0.892) iDFS at 36 months (%, 95% CI) 90.7 (89.3, 91.8) 87.6 (86.1, 88.9) Abbreviations: CI, confidence interval; iDFS, invasive disease-free survival. a iDFS was statistically significant at an interim analysis based on a one-sided stratified log-rank p-value of 0.0014. Figure 1: Kaplan-Meier Plot of iDFS \u2013 NATALEE (Investigator Assessment, Intent-to-Treat Population) 14.2 Advanced or Metastatic Breast Cancer MONALEESA-2: KISQALI in Combination with Letrozole Postmenopausal Women with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy MONALEESA-2 (NCT01958021) was a randomized (1:1), double-blind, placebo-controlled, multicenter clinical study of KISQALI plus letrozole vs. placebo plus letrozole conducted in postmenopausal women (N = 668) with HR-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease. Participants were randomized to receive either KISQALI and letrozole or placebo and letrozole, stratified according to the presence of liver and/or lung metastases. Letrozole 2.5 mg was given orally once daily for 28 days, with either KISQALI 600 mg or placebo orally once daily for 21 consecutive days followed by 7 days off until disease progression or unacceptable toxicity. The major efficacy outcome measure for the study was investigator-assessed progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The median age of 62 years (range, 23 to 91) and 45% of patients were older than 65. The majority of patients were White (82%), and all patients had an ECOG performance status of 0 or 1. A total of 47% of patients had received chemotherapy and 51% had received anti-hormonal therapy in the neoadjuvant or adjuvant setting. Thirty-four percent (34%) of patients had de novo metastatic disease, 21% had bone-only disease, and 59% had visceral disease. The efficacy results are summarized in Table 17, Figure 2, and Figure 3. The PFS assessment based on a blinded independent central radiological review was consistent with investigator assessment. Consistent results were observed across patient subgroups of prior adjuvant or neoadjuvant chemotherapy or hormonal therapies, liver and/or lung involvement, and bone-only metastatic disease. Table 17: Efficacy Results \u2013 MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population) Abbreviations: CI, confidence interval; NR, not reached. a p-value estimated from one-sided log-rank test. KISQALI + Letrozole Placebo + Letrozole Progression-Free Survival N = 334 N = 334 Events (n, %) 93 (27.8) 150 (44.9) Median (months, 95% CI) NR (19.3 \u2013 NR) 14.7 (13.0 \u2013 16.5) Hazard ratio (95% CI) 0.556 (0.429, 0.720) p-value a < 0.0001 a Overall Survival N = 334 N = 334 Events (n, %) 181 (54.2) 219 (65.6) Median (months, 95% CI) 63.9 (52.4, 71.0) 51.4 (47.2, 59.7) Hazard ratio (95% CI) 0.765 (0.628, 0.932) p-value 0.004 a Overall Response Rate for patients with measurable disease N = 256 N = 245 Overall Response Rate (95% CI) 52.7 (46.6, 58.9) 37.1 (31.1, 43.2) Figure 2 Kaplan-Meier Plot of Progression-Free Survival \u2013 MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population) Figure 3 Kaplan-Meier plot of Overall Survival Curves \u2013 MONALEESA-2 (Intent-to-Treat Population) MONALEESA-7: KISQALI in Combination with a Non-Steroidal Aromatase Inhibitor with or without Goserelin Pre/perimenopausal Patients with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy MONALEESA-7 (NCT02278120) was a randomized (1:1), double-blind, placebo-controlled study of KISQALI plus either NSAI or tamoxifen and goserelin vs. placebo plus either a NSAI or tamoxifen and goserelin conducted in pre/perimenopausal women (N = 672) with HR-positive, HER2-negative, advanced breast cancer who received no prior endocrine therapy for advanced disease. Participants were randomized to receive KISQALI plus NSAI or tamoxifen plus goserelin or placebo plus NSAI or tamoxifen plus goserelin, stratified according to the presence of liver and/or lung metastases, prior chemotherapy for advanced disease, and endocrine combination partner (tamoxifen and goserelin vs. NSAI and goserelin). NSAI (letrozole 2.5 mg or anastrozole 1 mg) or tamoxifen 20 mg were given orally once daily on a continuous daily schedule, goserelin was administered as a sub-cutaneous injection on Day 1 of each 28-day cycle, with either KISQALI 600 mg or placebo orally once daily for 21 consecutive days followed by 7 days off until disease progression or unacceptable toxicity. The major efficacy outcome measure for the study was investigator-assessed progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The median age was 44 years (range, 25 to 58). Patients were primarily White (58%), Asian (29%), or Black (3%). Nearly all patients (99%) had an ECOG performance status of 0 or 1. Of the 672 patients, 33% had received chemotherapy in the adjuvant vs. 18% in the neoadjuvant setting and 40% had received endocrine therapy in the adjuvant vs. 0.7% in the neoadjuvant setting prior to study entry. Forty percent (40%) of patients had de novo metastatic disease, 24% had bone-only disease, and 57% had visceral disease. Demographics and baseline disease characteristics were balanced and comparable between study arms, and endocrine combination partner. The efficacy results from a pre-specified subgroup analysis of 495 patients who had received KISQALI or placebo with NSAI plus goserelin are summarized in Table 18, Figure 4, and Figure 5. Consistent results were observed in the stratification factor subgroups of disease site and prior chemotherapy for advanced disease. Table 18: Efficacy Results \u2013 MONALEESA-7 (NSAI, Investigator Assessment) Abbreviations: CI, confidence interval; NR, not reached; NSAI, non-steroidal aromatase inhibitors. *Based on confirmed responses. 1 Investigator Assessment. KISQALI + NSAI + Goserelin Placebo + NSAI + Goserelin Progression-Free Survival 1 N = 248 N = 247 Events (n, %) 92 (37.1) 132 (53.4) Median (months, 95% CI) 27.5 (19.1, NR) 13.8 (12.6, 17.4) Hazard ratio (95% CI) 0.569 (0.436, 0.743) Overall Survival N = 248 N = 247 Events (n, %) 61 (24.6) 80 (32.4) Median (months, 95% CI) NR (NR, NR) 40.7 (37.4, NR) Hazard ratio (95% CI) 0.699 (0.501, 0.976) Overall Response Rate for patients with measurable disease *,1 N = 192 N = 199 Overall Response Rate (95% CI) 50.5 (43.4, 57.6) 36.2 (29.5, 42.9) Figure 4 Kaplan-Meier Plot of Progression-Free Survival Curves \u2013 MONALEESA-7 (NSAI, Investigator Assessment) Figure 5 Kaplan-Meier Plot of Overall Survival - MONALEESA-7 (NSAI, Investigator Assessment) COMPLEEMENT-1: KISQALI in combination with Letrozole and Goserelin or Leuprolide Men with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer for Initial Endocrine-Based Therapy COMPLEEMENT-1 (NCT 02941926) was an open-label, multicenter clinical study of ribociclib in combination with letrozole and goserelin or leuprolide for the treatment of adults with HR-positive, HER2-negative, advanced breast cancer who received no prior hormonal therapy for advanced disease. The study included 39 male patients who received KISQALI 600 mg orally once daily for 21 consecutive days followed by 7 days off; and letrozole 2.5 mg orally once daily for 28 days; and goserelin 3.6 mg as injectable subcutaneous implant or leuprolide 7.5 mg as intramuscular injection administered on Day 1 of each 28-day cycle. Patients were treated until disease progression or unacceptable toxicity occurred. Male patients enrolled in this study had a median age of 62 years (range, 33 to 80). Of these patients, 39% were 65 years and older, including 10% aged 75 years and older. The male patients enrolled were White (72%), Asian (8%), and Black (3%), with 17% unknown. Nearly all male patients (97%) had an ECOG performance status of 0 or 1. The majority of male patients (97%) had 4 or less metastatic sites, which were primarily bone and visceral (69% each). Table 19 summarizes the efficacy results in male patients from COMPLEEMENT-1. Table 19: Efficacy Results in Male Patients 1 \u2013 COMPLEEMENT-1 (Investigator Assessment, Intent-to-Treat Population) Abbreviations: CI, confidence interval, NR, not reached. *Based on confirmed responses. 1 Patients with measurable disease. 2 Investigator Assessment. 3 Patients with complete response or partial response. KISQALI + Letrozole + Goserelin or Leuprolide Overall Response Rate for patients with measurable disease *,2 N = 32 Overall Response Rate (95% CI) 46.9 (29.1, 65.3) Duration of Response (DoR) 3 N = 15 Median (months, 95% CI) NR (21.3, NR) Patients with DoR \u226512 months, n (%) 12 (80.0) Figure 1: Kaplan-Meier Plot of iDFS \u2013 NATALEE (Investigator Assessment, Intent-to-Treat Population) Figure 2 Kaplan-Meier Plot of Progression-Free Survival \u2013 MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population) Figure 3 Kaplan-Meier Plot of Overall Survival \u2013 MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population) Figure 4 Kaplan-Meier Plot of Progression-Free Survival \u2013 MONALEESA-7 (NSAI, Investigator Assessment) Figure 5 Kaplan-Meier Plot of Overall Survival \u2013 MONALEESA-7 (NSAI, Investigator Assessment)"
    ],
    "clinical_studies_table": [
      "<table width=\"75%\"><caption>Table 16: Efficacy Results &#x2013; NATALEE (Investigator Assessment, Intent-to-Treat Population)</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Toprule Lrule Rrule\"/><td styleCode=\"Toprule Rrule\" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI +/- Goserelin</content></td><td styleCode=\"Toprule Rrule\" align=\"center\"><content styleCode=\"bold\">NSAI +/- Goserelin</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"><content styleCode=\"bold\">Invasive Disease-Free Survival (iDFS)<sup>a</sup></content></td><td styleCode=\"Toprule Rrule\" align=\"center\"><content styleCode=\"bold\">N = 2549</content></td><td styleCode=\"Toprule Rrule\" align=\"center\"><content styleCode=\"bold\">N = 2552</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> Events (n, %) </td><td styleCode=\"Toprule Rrule\" align=\"center\"> 226 (8.9%) </td><td styleCode=\"Toprule Rrule\" align=\"center\"> 283 (11.1%) </td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> Hazard ratio (95% CI) </td><td styleCode=\"Toprule Rrule\" align=\"center\" colspan=\"2\"> 0.749 (0.628 to 0.892) </td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> iDFS at 36 months (%, 95% CI) </td><td styleCode=\"Toprule Rrule\" align=\"center\"> 90.7 (89.3, 91.8) </td><td styleCode=\"Toprule Rrule\" align=\"center\"> 87.6 (86.1, 88.9) </td></tr><tr><td styleCode=\"Toprule Lrule Rrule\" colspan=\"3\"> Abbreviations: CI, confidence interval; iDFS, invasive disease-free survival. <sup>a</sup>iDFS was statistically significant at an interim analysis based on a one-sided stratified log-rank p-value of 0.0014.</td></tr></tbody></table>",
      "<table><caption>Table 17: Efficacy Results &#x2013; MONALEESA-2 (Investigator Assessment, Intent-to-Treat Population)</caption><col width=\"300\"/><col width=\"200\"/><col width=\"200\"/><tfoot><tr><td colspan=\"3\"> Abbreviations: CI, confidence interval; NR, not reached. <sup>a</sup>p-value estimated from one-sided log-rank test.</td></tr></tfoot><tbody><tr><td styleCode=\"Toprule Lrule Rrule \"/><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">KISQALI + Letrozole</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">Placebo + Letrozole</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Progression-Free Survival</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 334</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 334</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Events (n, %)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">93 (27.8)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">150 (44.9)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Median (months, 95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">NR (19.3 &#x2013; NR)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">14.7 (13.0 &#x2013; 16.5)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Hazard ratio (95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">0.556 (0.429, 0.720)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> p-value<sup>a</sup></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">&lt; 0.0001<sup>a</sup></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Overall Survival</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 334</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 334</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Events (n, %)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">181 (54.2)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">219 (65.6)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Median (months, 95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">63.9 (52.4, 71.0)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">51.4 (47.2, 59.7)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Hazard ratio (95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">0.765 (0.628, 0.932)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> p-value</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">0.004<sup>a</sup></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Overall Response Rate for patients with measurable disease</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 256</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 245</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Overall Response Rate (95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">52.7 (46.6, 58.9)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">37.1 (31.1, 43.2)</td></tr></tbody></table>",
      "<table><caption>Table 18: Efficacy Results &#x2013; MONALEESA-7 (NSAI, Investigator Assessment) </caption><col width=\"300\"/><col width=\"200\"/><col width=\"200\"/><tfoot><tr><td colspan=\"3\">Abbreviations: CI, confidence interval; NR, not reached; NSAI, non-steroidal aromatase inhibitors. *Based on confirmed responses. <sup>1</sup>Investigator Assessment.</td></tr></tfoot><tbody><tr><td styleCode=\"Toprule Lrule Rrule \"/><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">KISQALI + NSAI + Goserelin</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">Placebo + NSAI + Goserelin</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Progression-Free Survival<sup>1</sup></content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 248</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 247</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Events (n, %)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">92 (37.1)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">132 (53.4)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Median (months, 95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">27.5 (19.1, NR)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">13.8 (12.6, 17.4)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Hazard ratio (95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">0.569 (0.436, 0.743)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Overall Survival</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 248</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 247</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Events (n, %)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">61 (24.6)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">80 (32.4)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Median (months, 95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">NR (NR, NR)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">40.7 (37.4, NR)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Hazard ratio (95% CI)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\" colspan=\"2\">0.699 (0.501, 0.976)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"><content styleCode=\"bold\">Overall Response Rate for patients with measurable disease<sup>*,1</sup></content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 192</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">N = 199</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> Overall Response Rate (95% CI) </td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">50.5 (43.4, 57.6)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">36.2 (29.5, 42.9)</td></tr></tbody></table>",
      "<table width=\"50%\"><caption>Table 19: Efficacy Results in Male Patients<sup>1</sup> &#x2013; COMPLEEMENT-1 (Investigator Assessment, Intent-to-Treat Population)</caption><col width=\"40%\"/><col width=\"60%\"/><tfoot><tr><td colspan=\"2\">Abbreviations: CI, confidence interval, NR, not reached. *Based on confirmed responses. <sup>1</sup>Patients with measurable disease. <sup>2</sup>Investigator Assessment. <sup>3</sup>Patients with complete response or partial response.</td></tr></tfoot><tbody><tr><td styleCode=\"Toprule Lrule Rrule\"/><td styleCode=\"Toprule Lrule Rrule\"><content styleCode=\"bold\">KISQALI + Letrozole + Goserelin or Leuprolide</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"><content styleCode=\"bold\">Overall Response Rate for patients with measurable disease<sup>*,2</sup></content></td><td styleCode=\"Toprule Lrule Rrule\" align=\"center\"><content styleCode=\"bold\">N = 32</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> Overall Response Rate (95% CI)</td><td styleCode=\"Toprule Lrule Rrule\" align=\"center\">46.9 (29.1, 65.3)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"><content styleCode=\"bold\">Duration of Response (DoR)<sup>3</sup></content></td><td styleCode=\"Toprule Lrule Rrule\" align=\"center\"><content styleCode=\"bold\">N = 15</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> Median (months, 95% CI)</td><td styleCode=\"Toprule Lrule Rrule\" align=\"center\">NR (21.3, NR)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule\"> Patients with DoR &#x2265;12 months, n (%)</td><td styleCode=\"Toprule Lrule Rrule\" align=\"center\">12 (80.0)</td></tr></tbody></table>"
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING KISQALI FEMARA CO-PACK is dispensed in a carton for a total of 28 days of therapy. Each carton contains individual ribociclib and letrozole drug products as follows: KISQALI (ribociclib) Tablets: 200 mg tablets. Light greyish violet, round, curved with beveled edge, debossed with \u201cRIC\u201d on one side and \u201cNVR\u201d on the other side. FEMARA (letrozole) Tablets: 2.5 mg tablets. Dark yellow, round, slightly biconvex, with beveled edges, imprinted with the letters \u201cFV\u201d on one side and \u201cCG\u201d on the other side. KISQALI FEMARA CO-PACK Cartons: NDC 0078-0923-61 \u2013 Carton of 3 blister packs (63 tablets total) \u2013 each blister pack contains a 7-day supply of 21 tablets (200 mg per tablet) (600 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA NDC 0078-0916-61 \u2013 Carton of 3 blister packs (42 tablets total) \u2013 each blister pack contains a 7-day supply of 14 tablets (200 mg per tablet) (400 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA NDC 0078-0909-61 \u2013 Carton of 1 blister pack (21 tablets total) \u2013 each blister pack contains a 21-day supply of 21 tablets (200 mg per tablet) (200 mg daily dose) of KISQALI plus one 28-tablet count bottle of FEMARA Store at room temperature at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F). Store in the original blister package in order to protect from moisture."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). For additional information on KISQALI and FEMARA, refer to the full prescribing information for each product. Interstitial Lung Disease/Pneumonitis Advise patients to immediately report new or worsening respiratory symptoms [see Warnings and Precautions (5.1)] . Severe Cutaneous Adverse Reactions Inform patients of the signs and symptoms of severe cutaneous adverse reactions (e.g., skin pain/burning, rapidly-spreading skin rash, and/or mucosal lesions accompanied by fever or flu-like symptoms). Advise patients to contact their healthcare provider immediately if they develop signs and symptoms of severe cutaneous adverse reactions [see Warnings and Precautions (5.2)] . QT Prolongation Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation [see Warnings and Precautions (5.3)] . Hepatobiliary Toxicity Inform patients of the signs and symptoms of hepatobiliary toxicity. Advise patients to contact their healthcare provider immediately for signs or symptoms of hepatobiliary toxicity [see Warnings and Precautions (5.4)] . Neutropenia Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any suggestion of infection [see Warnings and Precautions (5.5)] . Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during KISQALI FEMARA CO-PACK therapy and for at least 3 weeks after the last dose. [see Warnings and Precautions (5.6), Use in Specific Populations (8.1, 8.3)] . Lactation Advise lactating women not to breastfeed during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose [see Use in Specific Populations (8.2)]. Drug Interactions Inform patients to avoid strong CYP3A inhibitors, strong CYP3A inducers, and drugs known to prolong the QT interval [see Drug Interactions (7.1, 7.2, 7.4)] . Infertility Inform males of reproductive potential that KISQALI may impair fertility [see Use in Specific Populations (8.3)] . Dosing Instruct patients to take the doses of KISQALI FEMARA CO-PACK at approximately the same time every day and to swallow tablets whole (do not chew, crush, or split them prior to swallowing) [see Dosage and Administration (2.1)] . If patient vomits or misses a dose, advise the patient to take the next prescribed dose at the usual time [see Dosage and Administration (2.1)] . Advise the patient that KISQALI FEMARA CO-PACK may be taken with or without food [see Dosage and Administration (2.1)] . Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 \u00a9 Novartis T2025-59"
    ],
    "spl_patient_package_insert": [
      "This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: September 2025 PATIENT INFORMATION KISQALI \u00ae FEMARA \u00ae CO-PACK (kis kah' lee fe ma' ra koe' pak) (ribociclib tablets; letrozole tablets) co-packaged for oral use What is the most important information I should know about KISQALI FEMARA CO-PACK? KISQALI FEMARA CO-PACK may cause serious side effects, including: Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: trouble breathing or shortness of breath cough with or without mucus chest pain Severe skin reactions. Tell your healthcare provider or get medical help right away if you get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, skin pain or burning, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, with or without fever. Heart rhythm problems (QT prolongation). KISQALI FEMARA CO-PACK can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. Your healthcare provider should check your heart and do blood tests before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint. Liver problems. KISQALI FEMARA CO-PACK can cause serious liver problems. Your healthcare provider will do blood tests to check your liver before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems: o yellowing of your skin or the whites of your eyes (jaundice) o dark or brown (tea-colored) urine o feeling very tired o loss of appetite o pain on the upper right side of your stomach area (abdomen) o bleeding or bruising more easily than normal Low white blood cell counts (neutropenia). Low white blood cell counts are very common during treatment with KISQALI FEMARA CO-PACK and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills. Your healthcare provider may tell you to decrease your dose, temporarily stop or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI. See \u201cWhat are the possible side effects of KISQALI FEMARA CO-PACK?\u201d for more information about side effects. What is KISQALI FEMARA CO-PACK? KISQALI FEMARA CO-PACK is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: in combination with aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back. That has gotten worse or has spread to other parts of the body (advanced or metastatic breast cancer) in combination with an aromatase inhibitor as the first endocrine-based therapy. KISQALI FEMARA CO-PACK contains 2 different types of medicines: The violet tablet contains the medicine KISQALI (ribociclib). The yellow tablet contains the medicine FEMARA (letrozole). It is not known if KISQALI FEMARA CO-PACK is safe and effective in children. Do not take KISQALI FEMARA CO-PACK if you are allergic to letrozole or any of the ingredients of FEMARA. See the end of this Patient Information for a list of the ingredients in KISQALI FEMARA CO-PACK. Before taking KISQALI FEMARA CO-PACK, tell your healthcare provider about all your medical conditions, including if you: have any heart problems, including heart failure, irregular heartbeats, and QT prolongation have ever had a heart attack have a slow heartbeat (bradycardia) have high blood pressure that is not controlled have decreased thyroid gland function (hypothyroidism) have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood have fever, chills, or any other signs or symptoms of infection have liver problems have kidney problems are pregnant, or plan to become pregnant. KISQALI FEMARA CO-PACK can harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with KISQALI FEMARA CO-PACK. Females who are able to become pregnant and who take KISQALI FEMARA CO-PACK should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK. Talk to your healthcare provider about birth control methods that may be right for you during this time. If you become pregnant or think you are pregnant, tell your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if KISQALI FEMARA CO-PACK passes into your breast milk. Do not breastfeed during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI FEMARA CO-PACK and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. How should I take KISQALI FEMARA CO-PACK? Take KISQALI FEMARA CO-PACK exactly as your healthcare provider tells you. Do not change your dose or stop taking KISQALI FEMARA CO-PACK without talking to your healthcare provider. KISQALI FEMARA CO-PACK comes in a carton that contains enough KISQALI tablets and FEMARA tablets for 28 days of treatment. Take KISQALI FEMARA CO-PACK each day at about the same time, preferably in the morning. Take KISQALI FEMARA CO-PACK with food or without food. Swallow KISQALI tablets and FEMARA tablets whole. Do not chew, crush or split tablets before swallowing them. Do not take any KISQALI tablets and FEMARA tablets that are broken, cracked, or that look damaged. If you miss a dose or vomit after taking a dose of KISQALI FEMARA CO-PACK, do not take another dose on that day. Take your next dose at your regular time. What are the possible side effects of KISQALI FEMARA CO-PACK? KISQALI FEMARA CO-PACK may cause serious side effects. See \"What is the most important information I should know about KISQALI FEMARA CO-PACK?\" The most common side effects of KISQALI in people with early breast cancer include: \u2022 decreased white blood cell counts \u2022 decreased red blood cell counts \u2022 increased liver function tests \u2022 infections \u2022 increased kidney function test \u2022 decreased platelet counts \u2022 nausea \u2022 headache \u2022 tiredness The most common side effects of KISQALI FEMARA CO-PACK in people with advanced or metastatic breast cancer include: \u2022 decreased white blood cell counts \u2022 decreased red blood cell counts \u2022 increased liver function tests \u2022 infections \u2022 nausea \u2022 tiredness \u2022 decreased platelet counts \u2022 diarrhea \u2022 headache \u2022 hair loss \u2022 vomiting \u2022 back pain \u2022 constipation \u2022 cough \u2022 rash \u2022 increased kidney function test \u2022 stomach-area (abdomen) pain KISQALI FEMARA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a problem for you. These are not all of the possible side effects of KISQALI FEMARA CO-PACK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store KISQALI FEMARA CO-PACK? Store KISQALI FEMARA CO-PACK at room temperature between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C). Store KISQALI FEMARA CO-PACK in the original blister package in order to protect from moisture. Keep KISQALI FEMARA CO-PACK and all medicines out of the reach of children. General information about the safe and effective use of KISQALI FEMARA CO-PACK. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KISQALI FEMARA CO-PACK for a condition for which it was not prescribed. Do not give KISQALI FEMARA CO-PACK to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about KISQALI FEMARA CO-PACK that is written for health professionals. What are the ingredients in KISQALI FEMARA CO-PACK? KISQALI (ribociclib) tablets: Active ingredient: ribociclib Inactive ingredients: colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum FEMARA (letrozole) tablets: Active ingredient: letrozole Inactive ingredients: colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 \u00a9 Novartis For more information, go to www.KISQALI.com or call 1-888-669-6682. T2025-60"
    ],
    "spl_patient_package_insert_table": [
      "<table width=\"100%\"><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><col width=\"25%\"/><tfoot><tr><td align=\"left\" colspan=\"3\">This Patient Information has been approved by the U.S. Food and Drug Administration.</td><td align=\"right\">Revised: September 2025</td></tr></tfoot><tbody><tr><td align=\"center\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><content styleCode=\"bold\">PATIENT INFORMATION  </content><content styleCode=\"bold\">KISQALI<sup>&#xAE;</sup> FEMARA<sup>&#xAE;</sup> CO-PACK (kis kah&apos; lee fe ma&apos; ra koe&apos; pak) </content><content styleCode=\"bold\">(ribociclib tablets; letrozole tablets)  </content><content styleCode=\"bold\">co-packaged for oral use</content></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Lrule Rrule Toprule\"><content styleCode=\"bold\">What is the most important information I should know about KISQALI FEMARA CO-PACK? </content><content styleCode=\"bold\">KISQALI FEMARA CO-PACK may cause serious side effects, including: </content><list><item><content styleCode=\"bold\">Lung problems.</content> KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your healthcare provider right away if you have any new or worsening symptoms, including: <list><item>trouble breathing or shortness of breath</item><item>cough with or without mucus</item><item>chest pain</item></list></item><item><content styleCode=\"bold\">Severe skin reactions.</content> Tell your healthcare provider or get medical help right away if you get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, skin pain or burning, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, with or without fever.</item><item><content styleCode=\"bold\">Heart rhythm problems (QT prolongation).</content> KISQALI FEMARA CO-PACK can cause a heart problem known as QT prolongation. This condition can cause an abnormal heartbeat and may lead to death. <list><item>Your healthcare provider should check your heart and do blood tests before and during treatment with KISQALI FEMARA CO-PACK.</item><item><content styleCode=\"bold\">Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you feel dizzy or faint.</content></item></list></item><item><content styleCode=\"bold\">Liver problems.</content> KISQALI FEMARA CO-PACK can cause serious liver problems. Your healthcare provider will do blood tests to check your liver before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you get any of the following signs and symptoms of liver problems:</item></list></td></tr><tr><td styleCode=\"Lrule\" colspan=\"2\"> o yellowing of your skin or the whites of your eyes (jaundice)  o dark or brown (tea-colored) urine  o feeling very tired</td><td colspan=\"2\" styleCode=\"Rrule\">o loss of appetite o pain on the upper right side of your stomach area (abdomen) o bleeding or bruising more easily than normal</td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Lrule Rrule Botrule\"><list><item><content styleCode=\"bold\">Low white blood cell counts (neutropenia).</content> Low white blood cell counts are very common during treatment with KISQALI FEMARA CO-PACK and may result in infections that may be severe. Your healthcare provider should check your white blood cell counts before and during treatment with KISQALI FEMARA CO-PACK. Tell your healthcare provider right away if you have signs and symptoms of low white blood cell counts or infections, such as fever and chills.</item></list>Your healthcare provider may tell you to decrease your dose, temporarily stop or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.  See <content styleCode=\"bold\">&#x201C;What are the possible side effects of KISQALI FEMARA CO-PACK?&#x201D;</content> for more information about side effects. </td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><content styleCode=\"bold\">What is KISQALI FEMARA CO-PACK?</content>  KISQALI FEMARA CO-PACK is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: <list><item>in combination with aromatase inhibitor for stage II and III early breast cancer with a high risk of coming back.</item><item>That has gotten worse or has spread to other parts of the body (advanced or metastatic breast cancer) in combination with an aromatase inhibitor as the first endocrine-based therapy.  KISQALI FEMARA CO-PACK contains 2 different types of medicines: <list listType=\"unordered\" styleCode=\"Circle\"><item>The violet tablet contains the medicine KISQALI (ribociclib).</item><item>The yellow tablet contains the medicine FEMARA (letrozole).</item></list>It is not known if KISQALI FEMARA CO-PACK is safe and effective in children. </item></list></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Do not take KISQALI FEMARA CO-PACK if you are allergic to letrozole or any of the ingredients of FEMARA.</content></paragraph><paragraph>See the end of this Patient Information for a list of the ingredients in KISQALI FEMARA CO-PACK.</paragraph></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">Before taking KISQALI FEMARA CO-PACK, tell your healthcare provider about all your medical conditions, including if you:</content> </paragraph><list><item>have any heart problems, including heart failure, irregular heartbeats, and QT prolongation</item><item>have ever had a heart attack</item><item>have a slow heartbeat (bradycardia)</item><item>have high blood pressure that is not controlled</item><item>have decreased thyroid gland function (hypothyroidism)</item><item>have problems with the amount of potassium, calcium, phosphorus, or magnesium in your blood</item><item>have fever, chills, or any other signs or symptoms of infection</item><item>have liver problems </item><item>have kidney problems</item><item>are pregnant, or plan to become pregnant. KISQALI FEMARA CO-PACK can harm your unborn baby. <list><item>If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with KISQALI FEMARA CO-PACK.</item><item>Females who are able to become pregnant and who take KISQALI FEMARA CO-PACK should use effective birth control during treatment and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK.</item><item>Talk to your healthcare provider about birth control methods that may be right for you during this time.</item><item>If you become pregnant or think you are pregnant, tell your healthcare provider right away.</item></list></item><item>are breastfeeding or plan to breastfeed. It is not known if KISQALI FEMARA CO-PACK passes into your breast milk. Do not breastfeed during treatment with KISQALI FEMARA CO-PACK and for at least 3 weeks after the last dose of KISQALI FEMARA CO-PACK.</item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI FEMARA CO-PACK and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</paragraph></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><content styleCode=\"bold\">How should I take KISQALI FEMARA CO-PACK? </content><list><item>Take KISQALI FEMARA CO-PACK exactly as your healthcare provider tells you.</item><item>Do not change your dose or stop taking KISQALI FEMARA CO-PACK without talking to your healthcare provider.</item><item>KISQALI FEMARA CO-PACK comes in a carton that contains enough KISQALI tablets and FEMARA tablets for 28 days of treatment.</item><item>Take KISQALI FEMARA CO-PACK each day at about the same time, preferably in the morning.</item><item>Take KISQALI FEMARA CO-PACK with food or without food.</item><item>Swallow KISQALI tablets and FEMARA tablets whole. Do not chew, crush or split tablets before swallowing them.</item><item>Do not take any KISQALI tablets and FEMARA tablets that are broken, cracked, or that look damaged.</item><item>If you miss a dose or vomit after taking a dose of KISQALI FEMARA CO-PACK, do not take another dose on that day. Take your next dose at your regular time.</item></list></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Lrule Rrule Toprule\"><content styleCode=\"bold\">What are the possible side effects of KISQALI FEMARA CO-PACK? KISQALI FEMARA CO-PACK may cause serious side effects.  </content><list><item>See <content styleCode=\"bold\">&quot;What is the most important information I should know about KISQALI FEMARA CO-PACK?&quot;</content></item></list><paragraph><content styleCode=\"bold\">The most common side effects of KISQALI in people with early breast cancer include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"> &#x2022; decreased white blood cell counts  &#x2022; decreased red blood cell counts  &#x2022; increased liver function tests  &#x2022; infections  &#x2022; increased kidney function test</td><td valign=\"top\">&#x2022; decreased platelet counts &#x2022; nausea &#x2022; headache &#x2022; tiredness</td><td/><td styleCode=\"Rrule\"/></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Lrule Rrule\"><paragraph><content styleCode=\"bold\">The most common side effects of KISQALI FEMARA CO-PACK in people with advanced or metastatic breast cancer include:</content></paragraph></td></tr><tr><td styleCode=\"Lrule\" valign=\"top\"> &#x2022; decreased white blood cell counts  &#x2022; decreased red blood cell counts  &#x2022; increased liver function tests</td><td valign=\"top\">&#x2022; infections &#x2022; nausea &#x2022; tiredness &#x2022; decreased platelet counts &#x2022; diarrhea</td><td valign=\"top\">&#x2022; headache &#x2022; hair loss &#x2022; vomiting &#x2022; back pain &#x2022; constipation &#x2022; cough</td><td styleCode=\"Rrule\" valign=\"top\">&#x2022; rash &#x2022; increased kidney function test  &#x2022; stomach-area (abdomen) pain</td></tr><tr><td styleCode=\"Rrule Lrule\" colspan=\"4\">KISQALI FEMARA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a problem for you. These are not all of the possible side effects of KISQALI FEMARA CO-PACK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><content styleCode=\"bold\">How should I store KISQALI FEMARA CO-PACK?</content><list><item>Store KISQALI FEMARA CO-PACK at room temperature between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item><item>Store KISQALI FEMARA CO-PACK in the original blister package in order to protect from moisture.</item></list><paragraph><content styleCode=\"bold\">Keep KISQALI FEMARA CO-PACK and all medicines out of the reach of children.</content></paragraph></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of KISQALI FEMARA CO-PACK.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KISQALI FEMARA CO-PACK for a condition for which it was not prescribed. Do not give KISQALI FEMARA CO-PACK to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about KISQALI FEMARA CO-PACK that is written for health professionals.</paragraph></td></tr><tr><td align=\"left\" colspan=\"4\" styleCode=\"Botrule Lrule Rrule Toprule\"><paragraph><content styleCode=\"bold\">What are the ingredients in KISQALI FEMARA CO-PACK?</content></paragraph><paragraph><content styleCode=\"bold\"> KISQALI (ribociclib) tablets: </content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> ribociclib</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolyzed), talc, titanium dioxide, and xanthan gum</paragraph><paragraph><content styleCode=\"bold\"> FEMARA (letrozole) tablets:</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> letrozole</paragraph><paragraph><content styleCode=\"bold\">Inactive ingredients:</content> colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide</paragraph><paragraph> Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 </paragraph><paragraph>&#xA9; Novartis</paragraph><paragraph>For more information, go to www.KISQALI.com or call 1-888-669-6682.</paragraph></td></tr></tbody></table>"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL NDC 0078-0909-61 Rx only 28-Day supply Kisqali \u00ae Femara \u00ae CO-PACK (ribociclib tablets; letrozole tablets) 200 mg daily dose (one 200 mg tablet) 21 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS PRINCIPAL DISPLAY PANEL NDC 0078-0909-61 Rx only 28-Day Supply Kisqali\u00ae Femara\u00ae CO-PACK (ribociclib tablets; letrozole tablets) 200 mg daily dose (one 200 mg tablet) 21 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS",
      "PRINCIPAL DISPLAY PANEL NDC 0078-0916-61 Rx only 28-Day supply Kisqali \u00ae Femara \u00ae CO-PACK (ribociclib tablets; letrozole tablets) 400 mg daily dose (two 200 mg tablets) 42 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS PRINCIPAL DISPLAY PANEL NDC 0078-0916-61 Rx only 28-Day Supply Kisqali\u00ae Femara\u00ae CO-PACK (ribociclib tablets; letrozole tablets) 400 mg daily dose (two 200 mg tablets) 42 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS",
      "PRINCIPAL DISPLAY PANEL NDC 0078-0923-61 Rx only 28-Day supply Kisqali \u00ae Femara \u00ae CO-PACK (ribociclib tablets; letrozole tablets) 600 mg daily dose (three 200 mg tablets) 63 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS PRINCIPAL DISPLAY PANEL NDC 0078-0923-61 Rx only 28-Day Supply Kisqali\u00ae Femara\u00ae CO-PACK (ribociclib tablets; letrozole tablets) 600 mg daily dose (three 200 mg tablets) 63 Film-coated tablets 2.5 mg per tablet 28 Film-coated tablets NOVARTIS"
    ],
    "set_id": "aa5e4446-19cd-4235-a382-5b48bf6c3b2f",
    "id": "774105bc-8258-481c-8883-f25f25166aea",
    "effective_time": "20250916",
    "version": "25",
    "openfda": {
      "application_number": [
        "NDA209935"
      ],
      "brand_name": [
        "KISQALI FEMARA CO-PACK"
      ],
      "generic_name": [
        "LETROZOLE AND RIBOCICLIB"
      ],
      "manufacturer_name": [
        "Novartis Pharmaceuticals Corporation"
      ],
      "product_ndc": [
        "0078-0909",
        "0078-0916",
        "0078-0923"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "rxcui": [
        "153124",
        "200064",
        "1873983",
        "1873989",
        "1923053",
        "1923054",
        "1923055",
        "1923056",
        "1923057",
        "1923058"
      ],
      "spl_id": [
        "774105bc-8258-481c-8883-f25f25166aea"
      ],
      "spl_set_id": [
        "aa5e4446-19cd-4235-a382-5b48bf6c3b2f"
      ],
      "package_ndc": [
        "0078-0909-61",
        "0078-0881-50",
        "0078-0888-21",
        "0078-0916-61",
        "0078-0895-14",
        "0078-0923-61",
        "0078-0902-21"
      ],
      "is_original_packager": [
        true
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Bio Co-Enzyme Phase Carduus Marianus, Ascorbicum Acidum, Cysteinum, Natrum Oxalaceticum, Nicotinamidum, Pulsatilla (Pratensis), Pyridoxinum Hydrochloricum, Riboflavinum, Thiaminum Hydrochloricum, Alpha-Ketoglutaricum Acidum, Alpha-Lipoicum Acidum, Cerium Oxalicum, Citricum Acidum, Fumaricum Acidum, Magnesium Oroticum Dihydricum, Malicum Acidum, Nadidum, Natrum Pyruvicum, Pantothenic Acid, Succinicum Acidum, Adrenalinum, Adenosinum Triphosphoricum Dinatrum, Hepar Sulphuris Calcareum, Sulphur, Aconiticum Acidum, Cis-, MILK THISTLE MILK THISTLE ASCORBIC ACID ASCORBIC ACID CYSTEINE CYSTEINE SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE NIACINAMIDE NIACINAMIDE PULSATILLA PRATENSIS WHOLE PULSATILLA PRATENSIS WHOLE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE RIBOFLAVIN RIBOFLAVIN THIAMINE HYDROCHLORIDE THIAMINE ION OXOGLURIC ACID .ALPHA.-KETOGLUTARIC ACID ALPHA LIPOIC ACID .ALPHA.-LIPOIC ACID CEROUS OXALATE NONAHYDRATE CEROUS CATION ANHYDROUS CITRIC ACID ANHYDROUS CITRIC ACID FUMARIC ACID FUMARIC ACID MAGNESIUM OROTATE DIHYDRATE OROTIC ACID MALIC ACID MALIC ACID NADIDE NADIDE SODIUM PYRUVATE PYRUVIC ACID PANTOTHENIC ACID PANTOTHENIC ACID SUCCINIC ACID SUCCINIC ACID EPINEPHRINE EPINEPHRINE ADENOSINE TRIPHOSPHATE DISODIUM ADENOSINE TRIPHOSPHATE CALCIUM SULFIDE CALCIUM SULFIDE SULFUR SULFUR ACONITIC ACID ACONITIC ACID MANGANESE PHOSPHATE, DIBASIC MANGANOUS CATION PROTEUS MORGANII PROTEUS MORGANII BARIUM OXALOSUCCINATE BARIUM CATION WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENTS: Aconiticum Acidum, Cis 16X, Adenosinum Triphosphoricum Dinatrum 10X, Adrenalinum 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Alpha-Ketoglutaricum Acidum 8X, Alpha-Lipoicum Acidum 8X, Ascorbicum Acidum 6X, Barium Oxalsuccinicum 34C, Carduus Marianus 4X, Cerium Oxalicum 8X, Citricum Acidum 8X, Cysteinum 6X, Fumaricum Acidum 8X, Hepar Sulphuris Calcareum 10X, Magnesium Oroticum Dihydricum 8X, Malicum Acidum 8X, Manganum Phosphoricum 16X, Nadidum 8X, Natrum Oxalaceticum 6X, Natrum Pyruvicum 8X, Nicotinamidum 6X, Pantothenic Acid 8X, Proteus (Morgani) 30C, Pulsatilla (Pratensis) 6X, Pyridoxinum Hydrochloricum 6X, Riboflavinum 6X, Succinicum Acidum 8X, Sulphur 10X, Thiaminum Hydrochloricum 6X."
    ],
    "purpose": [
      "PURPOSE: Aconiticum Acidum, Cis - Fatigue, Adenosinum Triphosphoricum Dinatrum - Weakness, Adrenalinum - Exhaustion, Alpha-Ketoglutaricum Acidum - Weakness, Alpha-Lipoicum Acidum - Fatigue, Ascorbicum Acidum - Exhaustion, Barium Oxalsuccinicum - Fatigue, Carduus Marianus - Exhaustion, Cerium Oxalicum - Fatigue, Citricum Acidum - Weakness, Cysteinum - Exhaustion, Fumaricum Acidum - Fatigue, Hepar Sulphuris Calcareum - Fatigue, Magnesium Oroticum Dihydricum - Weakness, Malicum Acidum - Exhaustion, Manganum Phosphoricum - Weakness, Nadidum - Exhaustion, Natrum Oxalaceticum - Fatigue, Natrum Pyruvicum - Exhaustion, Nicotinamidum - Fatigue, Pantothenic Acid - Fatigue, Proteus (Morgani) - Weakness, Pulsatilla (Pratensis) \u2013 Exhaustion, Pyridoxinum Hydrochloricum - Weakness, Riboflavinum - Fatigue, Succinicum Acidum - Weakness, Sulphur - Weakness, Thiaminum Hydrochloricum - Fatigue"
    ],
    "indications_and_usage": [
      "USES: \u2022 For the temporary relief of symptoms including: \u2022 exhaustion \u2022 fatigue \u2022 weakness These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."
    ],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. Tamper Evident: Sealed for your protection. Do not use if seal is broken or missing."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: In case of overdose, contact a physician or Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: 1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized water, 25% ethanol"
    ],
    "questions": [
      "QUESTIONS: Dist. By: Deseret Biologicals, Inc. 469 W. Parkland Drive Sandy, UT 84070 www.desbio.com 800-827-8204"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: Des Bio Bio Co-Enzyme Phase Homeopathic NDC 43742-2054-1 1 FL OZ (30 ml) Bio Co-Enzyme Phase"
    ],
    "set_id": "afad858e-064f-454d-be78-da1501ffe853",
    "id": "40071048-e931-4ec6-b3df-b46c1898888b",
    "effective_time": "20241004",
    "version": "4",
    "openfda": {
      "brand_name": [
        "Bio Co-Enzyme Phase"
      ],
      "generic_name": [
        "CARDUUS MARIANUS, ASCORBICUM ACIDUM, CYSTEINUM, NATRUM OXALACETICUM, NICOTINAMIDUM, PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, THIAMINUM HYDROCHLORICUM, ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CERIUM OXALICUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, NADIDUM, NATRUM PYRUVICUM, PANTOTHENIC ACID, SUCCINICUM ACIDUM, ADRENALINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, HEPAR SULPHURIS CALCAREUM, SULPHUR, ACONITICUM ACIDUM, CIS-,"
      ],
      "manufacturer_name": [
        "Deseret Biologicals, Inc."
      ],
      "product_ndc": [
        "43742-2054"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ACONITIC ACID",
        "ADENOSINE TRIPHOSPHATE DISODIUM",
        "ALPHA LIPOIC ACID",
        "ANHYDROUS CITRIC ACID",
        "ASCORBIC ACID",
        "BARIUM OXALOSUCCINATE",
        "CALCIUM SULFIDE",
        "CEROUS OXALATE NONAHYDRATE",
        "CYSTEINE",
        "EPINEPHRINE",
        "FUMARIC ACID",
        "MAGNESIUM OROTATE DIHYDRATE",
        "MALIC ACID",
        "MANGANESE PHOSPHATE, DIBASIC",
        "MILK THISTLE",
        "NADIDE",
        "NIACINAMIDE",
        "OXOGLURIC ACID",
        "PANTOTHENIC ACID",
        "PROTEUS MORGANII",
        "PULSATILLA PRATENSIS WHOLE",
        "PYRIDOXINE HYDROCHLORIDE",
        "RIBOFLAVIN",
        "SODIUM DIETHYL OXALACETATE",
        "SODIUM PYRUVATE",
        "SUCCINIC ACID",
        "SULFUR",
        "THIAMINE HYDROCHLORIDE"
      ],
      "spl_id": [
        "40071048-e931-4ec6-b3df-b46c1898888b"
      ],
      "spl_set_id": [
        "afad858e-064f-454d-be78-da1501ffe853"
      ],
      "package_ndc": [
        "43742-2054-1"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0810151881652"
      ],
      "nui": [
        "N0000175833",
        "N0000175835",
        "N0000175980",
        "N0000008556",
        "N0000175089",
        "N0000193618",
        "M0001797",
        "N0000000209",
        "N0000000245",
        "N0000175552",
        "N0000175555",
        "N0000175570",
        "M0003647"
      ],
      "pharm_class_moa": [
        "Acidifying Activity [MoA]",
        "Calcium Chelating Activity [MoA]",
        "Adrenergic alpha-Agonists [MoA]",
        "Adrenergic beta-Agonists [MoA]"
      ],
      "pharm_class_epc": [
        "Calculi Dissolution Agent [EPC]",
        "Anti-coagulant [EPC]",
        "Vitamin C [EPC]",
        "alpha-Adrenergic Agonist [EPC]",
        "beta-Adrenergic Agonist [EPC]",
        "Catecholamine [EPC]"
      ],
      "pharm_class_pe": [
        "Decreased Coagulation Factor Activity [PE]"
      ],
      "pharm_class_cs": [
        "Ascorbic Acid [CS]",
        "Catecholamines [CS]"
      ],
      "unii": [
        "93371T1BXP",
        "5L51B4DR1G",
        "73Y7P0K73Y",
        "XF417D3PSL",
        "PQ6CK8PD0R",
        "L7A49804ZQ",
        "1MBW07J51Q",
        "0UV74P3R0J",
        "K848JZ4886",
        "YKH834O4BH",
        "88XHZ13131",
        "VQ922CRY87",
        "817L1N4CKP",
        "VZ3U1H7Q5B",
        "U946SH95EE",
        "0U46U6E8UK",
        "25X51I8RD4",
        "8ID597Z82X",
        "19F5HK2737",
        "56X6LID5ZY",
        "8E272251DI",
        "68Y4CF58BV",
        "TLM2976OFR",
        "6CA025Y4FG",
        "POD38AIF08",
        "AB6MNQ6J6L",
        "70FD1KFU70",
        "M572600E5P"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO. Clear Moisture Mineral SPF-30 ZINC OXIDE ALLANTOIN ALOE VERA LEAF ARGAN OIL CALENDULA OFFICINALIS FLOWER GREEN TEA LEAF MEDIUM-CHAIN TRIGLYCERIDES CAPRYLYL GLYCOL CHAMOMILE CITRIC ACID MONOHYDRATE WATERMELON COCONUT OIL DECYL GLUCOSIDE DODECANE FUCUS VESICULOSUS GLYCERIN GLYCERYL LAURATE GLYCERYL MONOSTEARATE GLYCERYL STEARATE CITRATE HELIANTHUS ANNUUS FLOWERING TOP HYALURONIC ACID AVOCADO OIL SACCHARIDE ISOMERATE JOJOBA OIL SORBITAN MONOSTEARATE TOCOPHEROL TRIDECYL SALICYLATE WATER XANTHAN GUM ZINC OXIDE ZINC CATION"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Oxide 12.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses \u2022 Helps prevent sunburn \u2022 If used as directed with other sun protection measures (see ), decreases the risk of skin cancer and early skin aging caused by the sun. Directions"
    ],
    "warnings": [
      "Warnings Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120\u00b0F (49\u00b0C). For external use only. Flammable: Do not use \u2022 on damaged or broken skin. When using this product \u2022 keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use \u2022 on damaged or broken skin."
    ],
    "when_using": [
      "When using this product \u2022 keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions \u2022 Apply liberally 15 minutes before sun exposure and as needed. \u2022 Children under 6 months: ask a doctor. \u2022 Reapply: \u2022 After 80 minutes of swimming or sweating \u2022 Immediately after towel drying \u2022 At least every two hours. \u2022 Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: \u2022 limit time in the sun, especially from 10 a.m. - 2 p.m. \u2022 wear long-sleeved shirts, pants, hats and sunglasses. Sun Protection Measures:"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients Algae Extract, Allantoin, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Argania Spinosa (Argan) Oil, Calendula Officinalis Extract, Camellia Sinensis (Green Tea) Extract, Caprylic/Capric Triglyceride, Caprylyl Glycol, Cereus Grandiflorus (Cactus) Extract, Chamomilla Matricaria (Chamomile) Extract, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Decyl Glucoside, Dodecane, Fucus Vesiculosus (Seaweed) Extract, Glycerin, Glyceryl Laurate, Glyceryl Stearate, Glyceryl Stearate Citrate, Glyceryl Undecylenate, Helianthus Annuus (Sunflower) Oil, Hyaluronic Acid, Natural Fragrance, Persea Gratissima (Avocado) Oil, Polyhydroxystearic Acid, Saccharide Isomerate, Simmondsia Chinensis (Jojoba) Oil, Sorbitan Stearate, Tocopherol (Vitamin E), Tridecyl Salicylate, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Label"
    ],
    "set_id": "c241261c-d887-4ac2-89ce-93dcc0fce267",
    "id": "09762c8e-b9b8-ccc3-e063-6294a90aa7a3",
    "effective_time": "20231106",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO. Clear Moisture Mineral SPF-30"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-393"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "09762c8e-b9b8-ccc3-e063-6294a90aa7a3"
      ],
      "spl_set_id": [
        "c241261c-d887-4ac2-89ce-93dcc0fce267"
      ],
      "package_ndc": [
        "81159-393-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007668"
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO SPF 40 SPORT AVOBENZONE, OCTISALATE, OCTOCRYLENE TRIDECYL SALICYLATE AVOBENZONE AVOBENZONE OCTISALATE OCTISALATE OCTOCRYLENE OCTOCRYLENE ALOE VERA LEAF GREEN TEA LEAF CARROT COCONUT OIL FUCUS VESICULOSUS METHYL ABIETATE AVOCADO OIL ARTHROSPIRA PLATENSIS .ALPHA.-TOCOPHEROL ACETATE"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information: Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Avobenzone 3.0% Octisalate 5.0% Octocrylene 10.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses: \u2022 Helps prevent sunburn. \u2022 Higher SPF gives more sunburn protection. \u2022 Retains SPF after 80 minutes of swimming or sweating."
    ],
    "warnings": [
      "Warnings: Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120\u00b0F (49\u00b0C). For external use only. Flammable: Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions: \u2022 Apply liberally 15 minutes before sun exposure and as needed. \u2022 Children under 6 months: ask a doctor. \u2022 Reapply: \u2022 After 80 minutes of swimming or sweating \u2022 Immediately after towel drying \u2022 A t least every two hours. \u2022 Sun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: \u2022 Limit time in the sun, especially from 10 a.m. \u2013 2 p.m. \u2022 Wear long-sleeve shirts, pants, hats and sunglasses."
    ],
    "inactive_ingredient": [
      "Inactive Ingredients: Algae Ex tract, Aloe Barbadensis Leaf (Aloe Vera Gel) Juic e, Camell ia Si nensis (Green Tea) E xtr act, Daucus Ca rota S ativa (Car rot) Extrac t, Cocos Nucifer a (Coconut) Oil, Fucus Vesiculosus (Bladderwrack Seaweed ) Extract, Methyl Abietate, Natural Fragrance, Persea Gratissima (Avocado) Oil, SD -Alcohol 40B, Spirulina Platensis Extract, Tocopheryl Acetate ( Vitamin E), Tridecyl Salicylate."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: SSNew6oz"
    ],
    "set_id": "d64d4a52-0bea-4bbc-8d34-e16c1b4efe8c",
    "id": "1bca04d9-d2a2-5f33-e063-6294a90ae6fd",
    "effective_time": "20240626",
    "version": "3",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO SPF 40 SPORT"
      ],
      "generic_name": [
        "AVOBENZONE, OCTISALATE, OCTOCRYLENE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-132"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "AVOBENZONE",
        "OCTISALATE",
        "OCTOCRYLENE"
      ],
      "spl_id": [
        "1bca04d9-d2a2-5f33-e063-6294a90ae6fd"
      ],
      "spl_set_id": [
        "d64d4a52-0bea-4bbc-8d34-e16c1b4efe8c"
      ],
      "package_ndc": [
        "81159-132-00"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "G63QQF2NOX",
        "4X49Y0596W",
        "5A68WGF6WM"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Bio Co-Enzyme Phase Beta Vulgaris, Ascorbicum Acidum, Cysteinum, Natrum Oxalaceticum, Nicotinamidum, Pulsatilla (Pratensis), Pyridoxinum Hydrochloricum, Riboflavinum, Thiaminum Hydrochloricum, Alpha-Ketoglutaricum Acidum, Alpha-Lipoicum Acidum, Cerium Oxalicum, Citricum Acidum, Fumaricum Acidum, Magnesium Oroticum Dihydricum, Malicum Acidum, Nadidum, Natrum Pyruvicum, Pantothenic Acid, Succinicum Acidum, Adrenalinum, Adenosinum Triphosphoricum Dinatrum, Hepar Sulphuris Calcareum, Sulphur, Aconiticum Acidum, Cis-, BETA VULGARIS WHOLE BETA VULGARIS WHOLE ASCORBIC ACID ASCORBIC ACID CYSTEINE CYSTEINE SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE NIACINAMIDE NIACINAMIDE PULSATILLA PRATENSIS WHOLE PULSATILLA PRATENSIS WHOLE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE RIBOFLAVIN RIBOFLAVIN THIAMINE HYDROCHLORIDE THIAMINE ION OXOGLURIC ACID .ALPHA.-KETOGLUTARIC ACID ALPHA LIPOIC ACID .ALPHA.-LIPOIC ACID CEROUS OXALATE NONAHYDRATE CEROUS CATION ANHYDROUS CITRIC ACID ANHYDROUS CITRIC ACID FUMARIC ACID FUMARIC ACID MAGNESIUM OROTATE DIHYDRATE OROTIC ACID MALIC ACID MALIC ACID NADIDE NADIDE SODIUM PYRUVATE PYRUVIC ACID PANTOTHENIC ACID PANTOTHENIC ACID SUCCINIC ACID SUCCINIC ACID EPINEPHRINE EPINEPHRINE ADENOSINE TRIPHOSPHATE DISODIUM ADENOSINE TRIPHOSPHATE CALCIUM SULFIDE CALCIUM SULFIDE SULFUR SULFUR ACETIC ACID ACETIC ACID MANGANESE PHOSPHATE, DIBASIC MANGANESE CATION (2+) PROTEUS MORGANII PROTEUS MORGANII BARIUM OXALOSUCCINATE BARIUM CATION WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENTS: Beta Vulgaris 4X, Ascorbicum Acidum 6X, Cysteinum 6X, Natrum Oxalaceticum 6X, Nicotinamidum 6X, Pulsatilla (Pratensis) 6X, Pyridoxinum Hydrochloricum 6X, Riboflavinum 6X, Thiaminum Hydrochloricum 6X, Alpha-Ketoglutaricum Acidum 8X, Alpha-Lipoicum Acidum 8X, Cerium Oxalicum 8X, Citricum Acidum 8X, Fumaricum Acidum 8X, Magnesium Oroticum Dihydricum 8X, Malicum Acidum 8X, Nadidum 8X, Natrum Pyruvicum 8X, Pantothenic Acid 8X, Succinicum Acidum 8X, Adrenalinum 8X, 12X, 30X, 200X, 12C, 30C, 60C, 200C, Adenosinum Triphosphoricum Dinatrum 10X, Hepar Sulphuris Calcareum 10X, Sulphur 10X, Aconiticum Acidum, Cis 16X, Manganum Phosphoricum 16X, Proteus (Morgani) 30C, Barium Oxalsuccinicum 34C."
    ],
    "purpose": [
      "HOMEOPATHIC INDICATIONS: For the temporary relief of exhaustion, fatigue, and feelings of low energy.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."
    ],
    "warnings": [
      "WARNINGS: Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away. If pregnant or breast-feeding, ask a health professional before use. Tamper seal: \"Sealed for Your Protection.\" Do not use if seal is broken or missing."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: Keep out of reach of children. In case of overdose, contact a physician or Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: 1-10 drops under the tongue, 2 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age."
    ],
    "indications_and_usage": [
      "HOMEOPATHIC INDICATIONS: For the temporary relief of exhaustion, fatigue, and feelings of low energy.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized Water, 25% Ethanol"
    ],
    "questions": [
      "QUESTIONS: Dist. By: Deseret Biologicals, Inc. 469 W. Parkland Drive Sandy, UT 84070 www.desbio.com"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: DES BIO NDC 43742-1661-1 HOMEOPATHIC BIO CO-ENZYME PHASE 1 FL OZ (30 ml) Bio Co-Enzyme Phase"
    ],
    "set_id": "e8f6e2ec-ae2e-4bee-b9d3-5f3a2e3daf65",
    "id": "37f9d039-404c-4c9d-b8cd-3cc4e34d9b66",
    "effective_time": "20220509",
    "version": "3",
    "openfda": {
      "brand_name": [
        "Bio Co-Enzyme Phase"
      ],
      "generic_name": [
        "BETA VULGARIS, ASCORBICUM ACIDUM, CYSTEINUM, NATRUM OXALACETICUM, NICOTINAMIDUM, PULSATILLA (PRATENSIS), PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, THIAMINUM HYDROCHLORICUM, ALPHA-KETOGLUTARICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CERIUM OXALICUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MAGNESIUM OROTICUM DIHYDRICUM, MALICUM ACIDUM, NADIDUM, NATRUM PYRUVICUM, PANTOTHENIC ACID, SUCCINICUM ACIDUM, ADRENALINUM, ADENOSINUM TRIPHOSPHORICUM DINATRUM, HEPAR SULPHURIS CALCAREUM, SULPHUR, ACONITICUM ACIDUM, CIS-,"
      ],
      "manufacturer_name": [
        "Deseret Biologicals, Inc."
      ],
      "product_ndc": [
        "43742-1661"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ACETIC ACID",
        "ADENOSINE TRIPHOSPHATE DISODIUM",
        "ALPHA LIPOIC ACID",
        "ANHYDROUS CITRIC ACID",
        "ASCORBIC ACID",
        "BARIUM OXALOSUCCINATE",
        "BETA VULGARIS WHOLE",
        "CALCIUM SULFIDE",
        "CEROUS OXALATE NONAHYDRATE",
        "CYSTEINE",
        "EPINEPHRINE",
        "FUMARIC ACID",
        "MAGNESIUM OROTATE DIHYDRATE",
        "MALIC ACID",
        "MANGANESE PHOSPHATE, DIBASIC",
        "NADIDE",
        "NIACINAMIDE",
        "OXOGLURIC ACID",
        "PANTOTHENIC ACID",
        "PROTEUS MORGANII",
        "PULSATILLA PRATENSIS WHOLE",
        "PYRIDOXINE HYDROCHLORIDE",
        "RIBOFLAVIN",
        "SODIUM DIETHYL OXALACETATE",
        "SODIUM PYRUVATE",
        "SUCCINIC ACID",
        "SULFUR",
        "THIAMINE HYDROCHLORIDE"
      ],
      "spl_id": [
        "37f9d039-404c-4c9d-b8cd-3cc4e34d9b66"
      ],
      "spl_set_id": [
        "e8f6e2ec-ae2e-4bee-b9d3-5f3a2e3daf65"
      ],
      "package_ndc": [
        "43742-1661-1"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175833",
        "N0000175835",
        "N0000175980",
        "N0000008556",
        "N0000175089",
        "N0000193618",
        "M0001797",
        "N0000000209",
        "N0000000245",
        "N0000175552",
        "N0000175555",
        "N0000175570",
        "M0003647"
      ],
      "pharm_class_moa": [
        "Acidifying Activity [MoA]",
        "Calcium Chelating Activity [MoA]",
        "Adrenergic alpha-Agonists [MoA]",
        "Adrenergic beta-Agonists [MoA]"
      ],
      "pharm_class_epc": [
        "Calculi Dissolution Agent [EPC]",
        "Anti-coagulant [EPC]",
        "Vitamin C [EPC]",
        "alpha-Adrenergic Agonist [EPC]",
        "beta-Adrenergic Agonist [EPC]",
        "Catecholamine [EPC]"
      ],
      "pharm_class_pe": [
        "Decreased Coagulation Factor Activity [PE]"
      ],
      "pharm_class_cs": [
        "Ascorbic Acid [CS]",
        "Catecholamines [CS]"
      ],
      "unii": [
        "Q40Q9N063P",
        "5L51B4DR1G",
        "73Y7P0K73Y",
        "XF417D3PSL",
        "PQ6CK8PD0R",
        "L7A49804ZQ",
        "4G174V5051",
        "1MBW07J51Q",
        "0UV74P3R0J",
        "K848JZ4886",
        "YKH834O4BH",
        "88XHZ13131",
        "VQ922CRY87",
        "817L1N4CKP",
        "VZ3U1H7Q5B",
        "0U46U6E8UK",
        "25X51I8RD4",
        "8ID597Z82X",
        "19F5HK2737",
        "56X6LID5ZY",
        "8E272251DI",
        "68Y4CF58BV",
        "TLM2976OFR",
        "6CA025Y4FG",
        "POD38AIF08",
        "AB6MNQ6J6L",
        "70FD1KFU70",
        "M572600E5P"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO. SPF 50 SPORT OCTOCRYLENE, ZINC OXIDE, OCTISALATE ALOE VERA LEAF BENZYL ALCOHOL SHEA BUTTER CALENDULA OFFICINALIS FLOWER GREEN TEA LEAF MEDIUM-CHAIN TRIGLYCERIDES CETOSTEARYL ALCOHOL CITRIC ACID MONOHYDRATE WATERMELON COCONUT OIL DECYL GLUCOSIDE DEHYDROACETIC ACID FUCUS VESICULOSUS GLYCERIN GLYCERYL MONOSTEARATE HELIANTHUS ANNUUS FLOWERING TOP HYDROXYETHYL CELLULOSE, UNSPECIFIED AVOCADO OIL JOJOBA OIL COCOA .ALPHA.-TOCOPHEROL ACETATE TRIDECYL SALICYLATE WATER XANTHAN GUM OCTOCRYLENE OCTOCRYLENE ZINC OXIDE ZINC CATION OCTISALATE OCTISALATE"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information: Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Octocrylene 10.0% Zinc Oxide 8.5% Octisalate 5.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses: \u2022 Helps prevent sunburn. \u2022 Higher SPF gives more sunburn protection. \u2022 Retains SPF after 80 minutes of swimming or sweating."
    ],
    "warnings": [
      "Warnings: For external use only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use on damaged or broken skin."
    ],
    "when_using": [
      "When using this product keep out of eyes. Rinse with water to remove."
    ],
    "stop_use": [
      "Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. \u2022 If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions: \u2022 Apply liberally 15 minutes before sun exposure and as needed. \u2022 Children under 6 months: ask a doctor. \u2022 Reapply: \u2022 After 80 minutes of swimming or sweating \u2022 Immediately after towel drying \u2022 A t least every two hours. \u2022 Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: \u2022 Limit time in the sun, especially from 10 a.m. \u2013 2 p.m. \u2022 Wear long-sleeve shirts, pants, hats and sunglasses. Sun Protection Measures:"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients: Algae Extract, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Benzyl Alcohol, Butyrospermum Parkii (Shea) Butter), Calendula Officinalis Extract, Camellia Sinensis (Green Tea) Extract, Caprylic/Capric Triglyceride, Cetearyl Alcohol, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Decyl Glucoside, Dehydroacetic Acid, Fucus Vesiculosus (Bladderwrack Seaweed) Extract, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Hydroxyethylcellulose, Natural Fragrance, Persea Gratissima (Avocado) Oil, Polyhydroxystearic Acid, Simmondsia Chinensis (Jojoba) Oil, Theobroma Cacao (Cocoa) Butter, Tocopheryl Acetate (Vitamin E), Tridecyl Salicylate, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Bottle"
    ],
    "set_id": "f01516bf-8aed-4402-a3f9-ef11c54d46b3",
    "id": "09e25fad-8fe9-b0f7-e063-6294a90a20e8",
    "effective_time": "20231111",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO. SPF 50 SPORT"
      ],
      "generic_name": [
        "OCTOCRYLENE, ZINC OXIDE, OCTISALATE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-131"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "OCTISALATE",
        "OCTOCRYLENE",
        "ZINC OXIDE"
      ],
      "spl_id": [
        "09e25fad-8fe9-b0f7-e063-6294a90a20e8"
      ],
      "spl_set_id": [
        "f01516bf-8aed-4402-a3f9-ef11c54d46b3"
      ],
      "package_ndc": [
        "81159-131-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007378"
      ],
      "unii": [
        "4X49Y0596W",
        "5A68WGF6WM",
        "SOI2LOH54Z"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Lyme and Co-Infection Nosode Angelica Archangelica, Kali Muriaticum, Yucca Filamentosa, Cartilago Suis, Phytolacca Decandra, Hydrastis Canadensis, Rhus Tox, Causticum, Magnesia Phosphorica, Manganum Metallicum, Oxalicum Acidum, Arnica Montana, Babesia Microti, Borrelia Burgdorferi Nosode, Latrodectus Mactans, Citricum Acidum, Cytomegalovirus Nosode, Rickettsia Nosode (rickettsia prowazekii), Chlamydia Trachomatis, Ledum Palustre ANGELICA ARCHANGELICA ROOT ANGELICA ARCHANGELICA ROOT POTASSIUM CHLORIDE POTASSIUM CATION YUCCA FILAMENTOSA YUCCA FILAMENTOSA SUS SCROFA CARTILAGE SUS SCROFA CARTILAGE PHYTOLACCA AMERICANA ROOT PHYTOLACCA AMERICANA ROOT GOLDENSEAL GOLDENSEAL TOXICODENDRON PUBESCENS LEAF TOXICODENDRON PUBESCENS LEAF CAUSTICUM CAUSTICUM MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE MAGNESIUM CATION MANGANESE MANGANESE OXALIC ACID OXALIC ACID ARNICA MONTANA ARNICA MONTANA BABESIA MICROTI BABESIA MICROTI BORRELIA BURGDORFERI BORRELIA BURGDORFERI LATRODECTUS MACTANS LATRODECTUS MACTANS ANHYDROUS CITRIC ACID ANHYDROUS CITRIC ACID HUMAN HERPESVIRUS 5 HUMAN HERPESVIRUS 5 RICKETTSIA PROWAZEKII RICKETTSIA PROWAZEKII CHLAMYDIA TRACHOMATIS CHLAMYDIA TRACHOMATIS LEDUM PALUSTRE TWIG LEDUM PALUSTRE TWIG WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENTS: Angelica Archangelica 2X, Kali Muriaticum 3X, Yucca Filamentosa 3X, Cartilago Suis 4X, 6X, 12X, Phytolacca Decandra 4X, 12X, 30X, Hydrastis Canadensis 5X, Rhus Tox 6X, Causticum 6X, 12X, 30X, Magnesia Phosphorica 8X, Manganum Metallicum 8X, Oxalicum Acidum 8X, 12X, Arnica Montana 8X, 100X, 1000X, Babesia Microti 12X, 30X, 60X, Borrelia Burgdorferi Nosode 12X, 30X, 60X, Latrodectus Mactans 12X, 30X, 60X, Citricum Acidum 6C, Cytomegalovirus Nosode 6C, Rickettsia Nosode (Rickettsia prowazekii) 8C, Chlamydia Trachomatis 12C, Ledum Palustre 30C."
    ],
    "purpose": [
      "INDICATIONS: Supports the immune system for host resistance to Lyme disease and co-infections."
    ],
    "warnings": [
      "WARNINGS: If pregnant or nursing ask your health Care Practitioner before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use if tamper evident seal is broken or missing. Store in a cool, dry and dark place."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: Take 10 drops 1 to 3 times per day under the tongue 30 minutes before meal or as directed by a Health Care Practitioner. Consult your physician for use in children under 12 years of age."
    ],
    "indications_and_usage": [
      "INDICATIONS: Supports the immune system for host resistance to Lyme disease and co-infections."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized Water and Organic Alcohol (Ethanol) 20%."
    ],
    "questions": [
      "QUESTIONS: Manufactured for: BHP Holdings, Inc. Woodinville, WA 98072 Phone: 425-462-8414 www.biopureus.com info@biopureus.com Formulated and produced under the guidelines of the Homeopathic Pharmacopoeia of the United States."
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: 58048-0005-1 BioPure Lyme & Co-Infection NOSODE HOMEOPATHIC 2 fl.oz (60mL) Lyme & Co-Infection Nosode"
    ],
    "set_id": "f6186157-256f-4454-b122-f7665e3286f4",
    "id": "88e0c163-99e8-45bb-8911-8d29370dd909",
    "effective_time": "20230601",
    "version": "3",
    "openfda": {
      "brand_name": [
        "Lyme and Co-Infection Nosode"
      ],
      "generic_name": [
        "ANGELICA ARCHANGELICA, KALI MURIATICUM, YUCCA FILAMENTOSA, CARTILAGO SUIS, PHYTOLACCA DECANDRA, HYDRASTIS CANADENSIS, RHUS TOX, CAUSTICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, OXALICUM ACIDUM, ARNICA MONTANA, BABESIA MICROTI, BORRELIA BURGDORFERI NOSODE, LATRODECTUS MACTANS, CITRICUM ACIDUM, CYTOMEGALOVIRUS NOSODE, RICKETTSIA NOSODE (RICKETTSIA PROWAZEKII), CHLAMYDIA TRACHOMATIS, LEDUM PALUSTRE"
      ],
      "manufacturer_name": [
        "Bhp Holdings, Inc."
      ],
      "product_ndc": [
        "58048-0005"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "ANGELICA ARCHANGELICA ROOT",
        "ANHYDROUS CITRIC ACID",
        "ARNICA MONTANA",
        "BABESIA MICROTI",
        "BORRELIA BURGDORFERI",
        "CAUSTICUM",
        "CHLAMYDIA TRACHOMATIS",
        "GOLDENSEAL",
        "HUMAN HERPESVIRUS 5",
        "LATRODECTUS MACTANS",
        "LEDUM PALUSTRE TWIG",
        "MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE",
        "MANGANESE",
        "OXALIC ACID",
        "PHYTOLACCA AMERICANA ROOT",
        "POTASSIUM CHLORIDE",
        "RICKETTSIA PROWAZEKII",
        "SUS SCROFA CARTILAGE",
        "TOXICODENDRON PUBESCENS LEAF",
        "YUCCA FILAMENTOSA"
      ],
      "spl_id": [
        "88e0c163-99e8-45bb-8911-8d29370dd909"
      ],
      "spl_set_id": [
        "f6186157-256f-4454-b122-f7665e3286f4"
      ],
      "package_ndc": [
        "58048-0005-1"
      ],
      "is_original_packager": [
        true
      ],
      "nui": [
        "N0000175833",
        "N0000175835",
        "N0000175980",
        "N0000008556",
        "N0000175089"
      ],
      "pharm_class_moa": [
        "Acidifying Activity [MoA]",
        "Calcium Chelating Activity [MoA]"
      ],
      "pharm_class_epc": [
        "Calculi Dissolution Agent [EPC]",
        "Anti-coagulant [EPC]"
      ],
      "pharm_class_pe": [
        "Decreased Coagulation Factor Activity [PE]"
      ],
      "unii": [
        "DTN01M69SN",
        "XF417D3PSL",
        "O80TY208ZW",
        "1948X6KEG3",
        "0J8NV9V5Q8",
        "DD5FO1WKFU",
        "T6NI39QU44",
        "ZW3Z11D0JV",
        "7COI029E6K",
        "XJJ7QA858R",
        "877L01IZ0P",
        "HF539G9L3Q",
        "42Z2K6ZL8P",
        "9E7R5L6H31",
        "11E6VI8VEG",
        "660YQ98I10",
        "TVS414L9M5",
        "73ECW5WG2F",
        "6IO182RP7A",
        "T6VR38UJ9I"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Target Goodfellow and Co SPF 30 Face Scent No. 05 Kelp and Sea Mineral AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE TRIDECYL SALICYLATE LINOLEIC ACID OLEIC ACID POLYETHYLOXAZOLINE (5000 MW) SORBITOL .ALPHA.-TOCOPHEROL, DL- ALUMINUM STARCH OCTENYLSUCCINATE CAPRYLYL GLYCOL ETHYLHEXYLGLYCERIN STEARIC ACID PALMITIC ACID SORBITAN ISOSTEARATE WATER EDETATE DISODIUM AVOBENZONE AVOBENZONE OCTOCRYLENE OCTOCRYLENE PHENOXYETHANOL BENZYL ALCOHOL OCTISALATE OCTISALATE HOMOSALATE HOMOSALATE BENTONITE BETA VULGARIS ROOT FRUCTOOLIGOSACCHARIDES BEET POLYGLYCERYL-3 DISTEARATE SODIUM HYDROXIDE"
    ],
    "active_ingredient": [
      "Active ingredients Avobenzone 3.0%, Homosalate 15.0%, Octisalate 5.0%, Octocrylene 7.0%"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun"
    ],
    "warnings": [
      "Warnings For external use only"
    ],
    "do_not_use": [
      "Do not use \u2022 on damaged or broken skin."
    ],
    "when_using": [
      "When using this product \u2022 keep out of eyes. Rinse with water to remove."
    ],
    "ask_doctor": [
      "Stop use and ask a doctor if \u2022 rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions apply liberally 15 minutes before sun exposure reapply: after 80 minutes of swimming or sweating immediately after towel drying at least every 2 hours children under 6 months of age: Ask a doctor Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: \u2022 limit time in the sun, especially from 10 a.m. - 2 p.m. \u2022 wear long-sleeved shirts, pants, hats, and sunglasses"
    ],
    "other_safety_information": [
      "Other information protect the product in this container from excessive heat and direct sun may stain or damage some fabrics, materials or surfaces"
    ],
    "inactive_ingredient": [
      "Inactive ingredients water, TRIDECYL SALICYLATE, sorbitol, stearic acid, Aluminum Starch Octenylsuccinate, SODIUM HYDROXIDE, POLYETHYLOXAZOLINE, ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER, tocopherol, FRUCTOOLIGOSACCHARIDES, BETA VULGARIS (BEET) ROOT EXTRACT, disodium edta, polyglyceryl-3 distearate, LINOLEIC ACID, LINOLENIC ACID,CAPRYLYL GLYCOL, PHENOXYETHANOL, ETHYLHEXYLGLYCERIN, BENTONITE, Sorbitan isostearate, OILIC ACID, PALMITIC ACID BENZYL ALCOHOL, FRAGRANCE"
    ],
    "package_label_principal_display_panel": [
      "Label 82040A2"
    ],
    "set_id": "f98ee294-3ca5-18bd-e053-6394a90a9aa5",
    "id": "247633d1-82f3-2c46-e063-6394a90ac41b",
    "effective_time": "20241014",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "Target Goodfellow and Co SPF 30 Face Scent No. 05 Kelp and Sea Mineral"
      ],
      "generic_name": [
        "AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE"
      ],
      "manufacturer_name": [
        "TARGET CORPORATION"
      ],
      "product_ndc": [
        "11673-232"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "AVOBENZONE",
        "HOMOSALATE",
        "OCTISALATE",
        "OCTOCRYLENE"
      ],
      "spl_id": [
        "247633d1-82f3-2c46-e063-6394a90ac41b"
      ],
      "spl_set_id": [
        "f98ee294-3ca5-18bd-e053-6394a90a9aa5"
      ],
      "package_ndc": [
        "11673-232-04"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "G63QQF2NOX",
        "V06SV4M95S",
        "4X49Y0596W",
        "5A68WGF6WM"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "CO Q 10 Ubidecarenonum UBIDECARENONE UBIDECARENONE WATER ALCOHOL"
    ],
    "active_ingredient": [
      "ACTIVE INGREDIENT: (in each drop): Ubidecarenonum 30X 100%."
    ],
    "purpose": [
      "PURPOSE: Ubidecarenonum - forgetfulness** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
    ],
    "indications_and_usage": [
      "USES: May temporarily relieve poor memory.** **Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."
    ],
    "warnings": [
      "WARNINGS: Stop use and ask a doctor if symptoms persist for more than 7 days. If pregnant or breastfeeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. DO NOT USE IF TAMPER EVIDENT SEAL IS BROKEN OR MISSING Store in a cool, dry place."
    ],
    "keep_out_of_reach_of_children": [
      "KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or contact a Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "DIRECTIONS: \u2022 Adults and children 5 to 10 drops orally, 1 time daily or as otherwise directed by a health care professional. \u2022 Consult a physician for use in children under 12 years of age."
    ],
    "inactive_ingredient": [
      "INACTIVE INGREDIENTS: Demineralized water, 20% Ethanol."
    ],
    "questions": [
      "QUESTIONS: Dist. by Energique, Inc. 201 Apple Blvd. Woodbine, IA 51579 800.869.8078"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL DISPLAY: ENERGIQUE SINCE 1987 HOMEOPATHIC REMEDY CO Q 10 30X 1 fl. oz. (30 ml) CO Q 10 30X"
    ],
    "set_id": "fd5e45ae-403f-44a2-abc0-343b9f550bdf",
    "id": "53696b74-41c9-44a1-854d-da0afb748e03",
    "effective_time": "20240924",
    "version": "4",
    "openfda": {
      "brand_name": [
        "CO Q 10"
      ],
      "generic_name": [
        "UBIDECARENONUM"
      ],
      "manufacturer_name": [
        "Energique, Inc."
      ],
      "product_ndc": [
        "44911-0339"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "ORAL"
      ],
      "substance_name": [
        "UBIDECARENONE"
      ],
      "spl_id": [
        "53696b74-41c9-44a1-854d-da0afb748e03"
      ],
      "spl_set_id": [
        "fd5e45ae-403f-44a2-abc0-343b9f550bdf"
      ],
      "package_ndc": [
        "44911-0339-1"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0363113600445"
      ],
      "unii": [
        "EJ27X76M46"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "SEAWEED BATH CO. Sheer Mineral Sensitive SPF-50 ZINC OXIDE ALLANTOIN ALOE VERA LEAF BUTYLOCTYL SALICYLATE SHEA BUTTER CALENDULA OFFICINALIS FLOWER GREEN TEA LEAF MEDIUM-CHAIN TRIGLYCERIDES CAPRYLYL GLYCOL CARNOSINE CETOSTEARYL ALCOHOL CETEARYL GLUCOSIDE CHAMOMILE WATERMELON COCONUT OIL FUCUS VESICULOSUS GLYCERIN GLYCERYL LAURATE GLYCERYL OLEATE GLYCERYL MONOSTEARATE METHYL ABIETATE POLYSORBATE 20 SILICON DIOXIDE SORBITAN MONOSTEARATE SQUALANE TOCOPHEROL ULVA LACTUCA WATER XANTHAN GUM ZINC OXIDE ZINC CATION"
    ],
    "spl_unclassified_section": [
      "Drug Facts",
      "Other Information Protect this product from excessive heat and direct sun."
    ],
    "active_ingredient": [
      "Active Ingredient Zinc Oxide 17.0% Purpose Sunscreen"
    ],
    "purpose": [
      "Purpose Sunscreen"
    ],
    "indications_and_usage": [
      "Uses \u2022 Helps prevent sunburn \u2022 If used as directed with other sun protection measures (see ), decreases the risk of skin cancer and early skin aging caused by the sun. Directions"
    ],
    "warnings": [
      "Warnings Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120\u00b0F (49\u00b0C). For external use only. Flammable: Do not use \u2022 on damaged or broken skin. When using this product \u2022 keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs. Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "do_not_use": [
      "Do not use \u2022 on damaged or broken skin."
    ],
    "when_using": [
      "When using this product \u2022 keep out of eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs."
    ],
    "keep_out_of_reach_of_children": [
      "Keep out of reach of children. If swallowed, get medical help or contact Poison Control Center right away."
    ],
    "dosage_and_administration": [
      "Directions \u2022 Apply liberally 15 minutes before sun exposure and as needed. \u2022 Children under 6 months: ask a doctor. \u2022 Reapply: \u2022 After 80 minutes of swimming or sweating \u2022 Immediately after towel drying \u2022 At least every two hours. \u2022 Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: \u2022 limit time in the sun, especially from 10 a.m. - 2 p.m. \u2022 wear long-sleeved shirts, pants, hats and sunglasses. Sun Protection Measures:"
    ],
    "inactive_ingredient": [
      "Inactive Ingredients Algae Extract, Allantoin, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, a-Bisabalol, Butyloctyl Salicylate, Butyrospermum Parkii (Shea) Butter, Calendula Officinalis Extract, Camellia Sinensis (Green Tea) Extract, Caprylic/Capric Triglyceride, Caprylyl Glycol, l-Carnosine, Cetearyl Alcohol, Cetearyl Glucoside, Chamomilla Matricaria (Chamomile) Extract, Citric Acid, Citrullus Lanatus (Watermelon) Extract, Cocos Nucifera (Coconut) Oil, Fucus Vesiculosus (Seaweed) Extract, Glycerin, Glyceryl Laurate, Glyceryl Oleate, Glyceryl Stearate, Glyceryl Undecylenate, Methyl Abietate, Polyhydroxystearic Acid, Polysorbate-20, SD Alcohol, Silica, Sorbitan Stearate, Squalane, Tocopherol (Vitamin E), Ulva Lactuca (Sea Lettuce) Extract, Water, Xanthan Gum."
    ],
    "questions": [
      "Questions? Call toll free 1-877-317-3106"
    ],
    "package_label_principal_display_panel": [
      "Package Labeling: Label2"
    ],
    "set_id": "fdcfc7eb-da33-4461-a4f9-fe97ea6b873f",
    "id": "09764ab9-1a72-b42b-e063-6394a90a4a77",
    "effective_time": "20231106",
    "version": "2",
    "openfda": {
      "application_number": [
        "M020"
      ],
      "brand_name": [
        "SEAWEED BATH CO. Sheer Mineral Sensitive SPF-50"
      ],
      "generic_name": [
        "ZINC OXIDE"
      ],
      "manufacturer_name": [
        "The Seaweed Bath Co."
      ],
      "product_ndc": [
        "81159-394"
      ],
      "product_type": [
        "HUMAN OTC DRUG"
      ],
      "route": [
        "TOPICAL"
      ],
      "substance_name": [
        "ZINC OXIDE"
      ],
      "spl_id": [
        "09764ab9-1a72-b42b-e063-6394a90a4a77"
      ],
      "spl_set_id": [
        "fdcfc7eb-da33-4461-a4f9-fe97ea6b873f"
      ],
      "package_ndc": [
        "81159-394-00"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0857854007811"
      ],
      "unii": [
        "SOI2LOH54Z"
      ]
    }
  }
]